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Preface 
 
 
“To be alive at all involves some risk.”  
~Harold Macmillan (British politician, 1894-1986) 
Risk, the possibility of loss or injury, 
is indeed a fixture in all aspects of 
our lives, from investing in the stock 
market to crossing the street. This 
concept that we now take for 
granted is in fact relatively novel. 
Some have argued that the ability to 
describe, estimate and control risk is 
a key distinction between past and 
modern times.1 In early civilization, 
the future of human beings was 
largely thought to be at the whim of 
the gods.  The turning point came 
during the Renaissance when 
Chevalier de Méré, a French 
nobleman with an affinity for 
gambling and mathematics, 
challenged the famed French 
mathematician Blaise Pascal to 
solve an infamous puzzle: How to 
divide the stakes of an unfinished 
game of chance between two 
players when one of them is 
ahead.1,2 Collaboration between 
Pascal and Pierre de Fermat, a 
lawyer and a talented 
mathematician, resulted in a solution 
and consequently, the theory of 
probability was born. And it is this 
concept that is at the heart of 
modern cardiovascular medicine and 
research.  
 
In medicine, risk is characterised as 
the probability of morbidity or 
mortality as a result of a disease. 
Subsequent treatment of the disease 
may also bear some risks along with 
its benefits, and naturally the 
medical tradition seeks to mitigate 
these risks.  In part, this has been 
accomplished over the years 
through the sophistication of 
characterising and quantifying risk.  
Early approaches included case 
series and anecdotal observations 
based on physician/institution 
experience. These provided 
snapshots of the associations 
between signs/symptoms/conditions 
and subsequent events but could not 
easily be contextualised. The advent 
of the computer era, the subsequent 
evolution of statistical methods and 
the clinical trial movement (i.e., 
GUSTO-I trial3, the first mega-trial of 
over 40,000 AMI patients) are 
largely responsible for the 
transformation of risk assessment in 
cardiovascular medicine as we know 
it today.  
 
The product of risk assessment is 
information, which is valuable in 
guiding physicians, researchers, 
patients and their families, as well as 
those involved in resource allocation 
and health policy.  Risk models are 
designed to provide the probability of 
a diagnosis or of an outcome 
occurring in the future, which can 
then be used to inform medical 
decision making by identifying low-
risk patients for conservative therapy 
or reserving more aggressive 
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strategies for high-risk patients. 
Absolute risk reduction and the 
number needed to treat to prevent 
one event provide insights into the 
evaluation of risk on the larger scale, 
at the population level.  And net 
clinical benefit and cost-
effectiveness are measures 
commonly considered, especially by 
administrators, insurance providers 
and policy makers reviewing new 
therapies and allocating resources.  
 
Identifying novel risk factors has also 
enhanced our understanding of the 
pathophysiology, causal pathways 
and treatment mechanisms. For 
instance, the multiple biomarker era 
has recently been ushered into 
acute coronary syndromes (ACS) 
with recognition of markers of 
myocardial necrosis (e.g., troponin), 
hemodynamic stress (e.g., brain 
natriuretic peptide), vascular 
damage (e.g., creatinine clearance), 
inflammation (e.g., C-reactive 
protein (CRP)) and accelerated 
atherosclerosis (e.g., blood 
glucose).4 This information can be 
used in diagnostic and/or therapeutic 
development, in tailoring treatment 
and in the planning and design of 
future clinical trials by identifying 
specific risk levels appropriate for 
study enrolment.  
 
Clinical judgement and statistical 
methods support the art and science 
of putting the future in service of the 
present, and this is the common 
thread woven throughout this thesis. 
The following eleven chapters are 
based on various approaches to risk 
assessment in ACS (including 
unstable angina, non-ST-elevation 
myocardial infarction and ST-
elevation myocardial infarction) 
patients enrolled in selected 
contemporary clinical trials. In 
addition to the standard risk 
stratification techniques of logistic 
regression and survival analysis, 
several other methods and study 
designs are highlighted such as 
pooled/meta-analyses, dynamic risk 
modelling, multilevel modelling, 
nested case-control study design 
and non-inferiority trial design. 
 
Part 1: Approaches to risk 
prediction in acute coronary 
syndromes 
With the ever-increasing number of 
new treatments, risk prediction has 
become the focus of front-line 
assessment of these patients, and 
with that is the dominant principle to 
target more aggressive therapy in 
higher risk patients. Upon entry of a 
patient to the health care system, 
data are collected on their 
demographics, medical history and 
initial clinical indicators. In Chapter 
1, we examine the rich array of 
patient factors associated with short- 
and long-term outcomes in 7800 
non-ST-elevation ACS patients 
enrolled in the GUSTO IV ACS trial. 
Specifically, comprehensive risk 
models are developed to predict 
these outcomes and the relative 
strength of these factors are 
examined. Simplified risk scores are 
also presented to illustrate potential 
clinical applications in these 
patients.  
 
Typically, risk prediction takes into 
account the medical history and 
initial clinical indicators of a patient. 
However, patients are continually 
assessed from the first point of entry 
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into the health care system until 
discharge and throughout follow-up 
care. Chapter 2 introduces a novel 
approach to risk stratification, which 
accounts for this evolving nature of 
risk.  Dynamic risk modelling 
extends beyond the baseline 
approach by using accumulating 
information such as post-baseline 
ECG results, angiographic results, 
treatment and complications, 
thereby emulating how a patients 
risk can change over time with 
treatment and/or complications.  
 
In addition to patient factors, the 
story of risk can be impacted by 
higher-level factors such as the type 
of hospital in which a patient was 
treated or the country or region in 
which they live. While international 
differences in the treatment patterns 
and outcomes of ACS patients are 
well established, insights into “why” 
have not been clearly demonstrated. 
Thus, multilevel modelling is used in 
Chapter 3 to quantify the relative 
contribution of patient-, hospital- and 
country-level factors on clinical 
outcomes in patients enrolled in the 
GUSTO IV ACS trial. 
 
Part 2: Unravelling the 
pathophysiology of acute 
coronary syndromes 
This second section considers the 
associations of various co-morbid 
factors with short- and long-term 
outcomes in contemporary ACS 
patients. Insight into these 
relationships is important to our 
understanding of the mechanisms of 
the disease, which may then lead to 
development of novel therapies 
and/or improved care and outcomes.  
The richness of the data collected by 
large-scale clinical trials provides the 
ideal environment to pursue 
questions that were not among the 
primary objectives of the trial. The 
GUSTO IV ACS trial, for instance, 
systematically collected and 
centrally evaluated 
electrocardiograms and multiple 
biomarkers in 7800 non-ST-
elevation ACS patients. In Chapter 
4, these unique data were used to 
identify electrocardiographic left 
ventricular hypertrophy as well as to 
examine its association with long-
term mortality and the possible 
modulation of that relationship by N-
terminal pro-brain natriuretic peptide 
(NT-proBNP) and gender. 
 
While it may not be feasible to 
collect data on every factor of 
interest, a case-control study nested 
within a large clinical trial is an 
efficient means to this end. Such an 
approach was taken in Chapter 5, 
which examines the associations 
between chronic infection with 
Chlamydia pneumoniae and 30-day 
death or myocardial infarction (MI) 
and 1-year mortality.   
 
And finally, pooling data from similar 
clinical trials is an effective approach 
to examining infrequent but disabling 
events, such as stroke in ACS 
patients. By increasing the sample 
size and thus the power to do so, 
insights into modifiable (and non-
modifiable) factors may lead to 
improved care and outcomes. 
Chapter 6 identifies predictors of 
stroke within 30 days of an acute 
coronary event based on a pooled 
analysis of six major clinical trials 
testing glycoprotein IIb/IIIa inhibitors 
 12 
(GPIs) in non-ST-elevation ACS 
patients.  
 
Part 3: Glycoprotein IIb/IIIa 
inhibitors in the elderly 
Antiplatelet therapy has long been a 
cornerstone of the treatment of ACS. 
Advances in the understanding of 
the pathogenesis of ACS in recent 
decades have brought about further 
innovations, namely GPIs. GPIs are 
now well-established adjunctive 
agents for patients undergoing 
percutaneous coronary intervention 
(PCI), and substantial effort has 
gone into evaluating this class of 
agents in those who are not 
scheduled for early 
revascularisation.  Chapters 7 and 8 
provide a comprehensive review of 
this literature and an analysis of the 
risks and benefits associated with 
these agents, particularly in the 
elderly. Given that age is an 
established risk factor in ACS, both 
relative and absolute benefits (and 
risks) of GPI therapy across the 
spectrum of age are relevant. Thus, 
Chapter 9 examines this in detail 
using individual patient data from the 
six major GPI clinical trials in ACS 
patients not undergoing early 
revascularisation. 
 
Part 4: Therapeutic strategies in 
ST-elevation myocardial 
infarction 
Patients with the most severe of the 
acute coronary syndromes, that is, 
ST-elevation acute myocardial 
infarction (STEMI), present a 
formidable challenge to those who 
treat them. Although reperfusion of 
the occluded epicardial coronary 
artery is the primary goal, the 
optimal approach to do so remains 
quite controversial. Pharmacological 
and mechanical reperfusion 
strategies have been developed in 
parallel, each with their own set of 
strengths and weaknesses.  Given 
that “time is myocardium”, the time 
elapsed between symptom onset 
and treatment is one of the key 
factors in this discussion.  In 
Chapter 10, the relative and 
absolute influence of time to 
treatment on the efficacy of 
fibrinolytic therapy versus primary 
PCI is examined by pooling 
individual patient data from 22 
randomised clinical trials. Chapter 
11 introduces the next step in the 
evolution of reperfusion therapy 
through the WEST Study, a 
Canadian, randomized, feasibility 
study of 304 STEMI patients 
featuring a novel regimen of 
contemporary pharmacologic 
treatment delivered rapidly paired 
with a strategy of regimented rescue 
and routine coronary intervention 
within 24 hours of initial treatment. 
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Chapter One 
 
Short- and Long-Term Risk Stratification in 
Acute Coronary Syndromes 
The Added Value of Quantitative ST-Segment Depression 
and Multiple Biomarkers 
 
Cynthia M. Westerhout, Yuling Fu, Michael S. Lauer, Stefan James, Paul 
W. Armstrong, Eyad Al-Hattab, Robert M. Califf, Maarten L. Simoons, Lars 
Wallentin, Eric Boersma, on behalf of the GUSTO-IV ACS Trial 
Investigators 
 
 
OBJECTIVES The purpose of this study was to develop 30-day and 1-year risk 
stratification models for non–ST-segment elevation acute coronary syndrome (NSTE-ACS) 
patients that incorporate quantitative ST-segment depression and novel biomarkers. 
BACKGROUND Several novel biomarkers have changed the risk profile of ACS; thus, the 
reassessment of traditional indicators such as ST-segment depression in this new context 
is warranted. 
METHODS Multivariable logistic regression was used to identify significant predictors of 
30-day death 
and death/myocardial infarction (MI) and 1-year mortality in 7,800 NSTE-ACS patients 
enrolled in the GUSTO-IV (Global Utilization of Strategies to Open Occluded Arteries-IV 
ACS) trial between 1998 and 2000. 
RESULTS Among all other predictors, the degree of ST-segment depression had the 
highest prognostic value for 30-day death, 30-day death/MI, and 1-year death. Troponin T 
(TnT), creatinine clearance, N-terminal pro-brain natriuretic peptide (NT-proBNP), heart 
rate, and age were also highly influential on adverse outcomes. Unlike TnT and NT-
proBNP, C-reactive protein was only predictive of long-term death. In contrast to mortality, 
the contribution of TnT to predicting 30-day death/MI increased, whereas NT-proBNPs role 
was attenuated. The discriminatory power was excellent (c-index [adjusted for over-
optimism]: 0.82 [30-day death]; 0.72 [30-day death/MI]; 0.81 [1-year]). 
CONCLUSIONS In this large contemporary study of NSTE-ACS patients, novel insights 
into risk stratification were observed—in particular, the utility of quantitative ST-segment 
depression and multiple biomarkers. Collection of these indicators in future NSTE-ACS 
populations is recommended to evaluate generalizability and clinical application of these 
findings. 
 
Demographics, comorbidities, and 
other classic patient factors have 
long been the foundation of risk 
stratification in acute coronary 
syndromes (ACS)(1–4). More recently, 
several biomarkers have also been 
shown to be associated with the risk 
for subsequent coronary events, 
including indicators of myocardial 
necrosis (troponin), inflammation (C-
reactive protein), and hemodynamic 
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stress (brain natriuretic peptides). 
The electrocardiogram (ECG) has 
continually played an important role 
in prognosis of ACS patients. ST-
segment depression >0.5 mm at 
baseline, for instance, is associated 
with poorer prognosis than absence 
of ST-segment depression. The 
extent of ST-segment depression, 
however, is rarely measured or 
reported even though this refinement 
substantially improves risk 
stratification compared with 
conventional qualitative ECG data 
(5–8). The prognostic value of 
combining quantitative ECG data 
and the extended biomarker profile 
with classical patient risk factors is 
unclear. Thus, the systematic 
collection of quantitative ST-
segment depression, cardiac 
troponin T (TnT), C-reactive protein 
(CRP), and N-terminal pro-brain 
natriuretic peptide (NT-proBNP) in 
7,800 non–ST-segment elevation 
acute coronary syndrome (NSTE-
ACS) patients enrolled in the 
GUSTO-IV (Global Utilization of 
Strategies to Open Occluded 
Arteries-IV ACS) trial provided a 
unique opportunity to investigate the 
relative roles of factors influencing 
short- and long-term outcomes (9). 
Risk scores were also developed to 
illustrate potential clinical 
applications. 
 
METHODS 
Study population. The details of 
the GUSTO-IV-ACS trial have been 
previously described (9,10). Briefly, 
patients over the age of 21 years 
were eligible if they presented within 
24 h after an episode of ischemic 
chest pain lasting 5 min and had 
either elevated TnT/TnI above the 
upper limit of normal (ULN) 
according to the local quantitative or 
qualitative assays or 
transient/persistent ST-segment 
depression (0.5 mm) that was not 
known to be pre-existing and not 
attributable to a co-existing disorder 
or medication on the admission 
ECG. Patients were randomly 
assigned to abciximab (0.25 mg/kg 
bolus plus 0.125 μg/kg/min infusion 
for 24 or 48 h) or placebo. Because 
abciximab did not reduce the 
primary or secondary end points, 
patients from all 3 treatment arms 
were combined for this analysis. 
Coronary angiography was not to be 
performed during or within 12 h after 
the completion of the study agent 
infusion. Patients also received 
aspirin and either unfractionated or 
low-molecular weight heparin. Other 
clinically indicated medications were 
used at the discretion of the treating 
physician. 
ECG analysis. Standard 12-lead 
baseline ECG data obtained at 
baseline were centrally evaluated by 
2 experienced readers without 
knowledge of the clinical outcomes 
in 7,741 patients (99.2%) at the ECG 
core laboratory (Cleveland Clinic 
Foundation, Cleveland, Ohio) and 
were entered and analyzed at the 
Canadian VIGOUR Centre 
(University of Alberta, Edmonton, 
Canada). ST depression was 
prospectively defined and measured 
with the aid of a magnifying calliper 
to the nearest 0.5 mm in all leads 
except aVR. ST-segment depression 
was judged to be present if the J 
point was depressed by 0.5 mm and 
was followed by a horizontal or 
down-sloping ST-segment for at 
least 0.08 s. 
 15 
Patients were classified as having 
ST-segment depression if the ST-
segment was depressed by 0.5 mm 
in 2 of the limb leads or at least 2 
contiguous precordial leads. Patients 
were categorized into 5 mutually 
exclusive groups: no ST-segment 
depression, 0.5-mm, 1- to 1.5-mm, 
2-mm ST-segment depression, and 
“confounders.” Confounders 
included left bundle branch block, 
paced rhythm or ventricular rhythm 
in 225 patients, or ST-segment 
elevation on the baseline ECG in 
289 patients. 
Biomarker analysis. Blood samples 
were drawn at baseline and 
analyzed at a core laboratory 
(Department of Clinical Chemistry, 
University of Uppsala, Uppsala, 
Sweden). Details of the assays used 
have been previously published (11). 
Baseline levels of TnT, CRP, and 
NT-proBNP were determined per 
protocol in all but 685 (8.8%), 692 
(8.9%), and 991 (12.7%) patients, 
respectively. The loss of 500 
samples during transport accounts 
for much of these missing data. 
Complete data for all 3 biomarkers 
were available in 6,809 (87.3%) 
patients. Baseline serum creatinine 
concentration (mg/dl) was measured 
at local laboratories in 7,703 of 
7,800 patients. To assess renal 
function, creatinine clearance was 
calculated with the Cockcroft-Gault 
equation, which adjusts for age, 
gender, and weight (12). 
End point definitions. The end 
points of the current study included 
30-day death, 30-day death or MI, 
and 1-year death, as described 
previously (9). Double counting of 
patients with more than 1 event was 
avoided by classifying each patient 
according to the event with the 
greatest severity. Thus, a patient 
with MI who subsequently died was 
classified as experiencing death but 
not MI. At 1-year post-
randomization, follow-up data on 
vital status were obtained and were 
complete in 7,746 patients (99.3%). 
Possible cases of MI were 
adjudicated by a clinical end point 
committee that was not aware of 
biomarker levels evaluated in the 
core laboratory (i.e., TnT, CRP, NT-
proBNP) or the extent of ST-
segment depression on the baseline 
ECG (9). 
Statistical analysis. Baseline 
characteristics were summarized by 
frequency and percentage for 
categorical variables and by median 
and interquartile range for 
continuous variables. Creatinine 
clearance, TnT, CRP, and 
NTproBNP were categorized into 
quartiles of their distributions for 
ease of presentation (11). The 
choice of TnT over creatine kinase-
MB as the preferred marker of 
myocardial damage was based on 
established guidelines as well as by 
an independent analysis of their 
relative prognostic power (Appendix 
1) (13). 
 
Logistic regression evaluated the 
associations between baseline 
characteristics and adverse 
outcomes. Indicators were entered 
into the full multivariable model if the 
p value of the univariable 
association was <0.25. The final 
multivariable model was constructed 
by backward stepwise elimination of 
the least significant factors and the 
Akaike information criteria. Given 
that 1-year follow-up was complete 
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in 99.3% of patients, logistic 
regression was repeated to 
determine predictors of 1-year 
mortality. Unadjusted and adjusted 
odds ratios and their corresponding 
95% confidence intervals are 
reported. The Hosmer-Lemeshow 
goodness-of-fit test statistic and 
calibration of the predicted versus 
observed event rate according to 
deciles of predicted risk were 
calculated to assess model 
performance. The discriminatory 
power was estimated by the c-index 
(i.e., probability of concordance 
between observed and predicted 
survival on the basis of pairs of 
individuals). The models were 
developed in the entire study 
population and validated by 
bootstrapping techniques: 100 
bootstrap samples were drawn, with 
replacement, to estimate the amount 
of “over-optimism” in the models on 
the basis of the entire population 
and quantified by the decrease in 
the area under the receiver 
operating characteristic curve (14). 
Simplified risk scores were 
developed to demonstrate the 
potential for clinical application. The 
top 5 contributing factors in the 
model were assigned weights that 
were equivalent to the logistic 
regression coefficient multiplied by 
10. For patient “i”, a weighted risk 
score was estimated by summing 
the weighted risk for each variable 
(risk score= 10ßixi, where ß was 
the regression coefficient associated 
with the factor, and x was equal to 1 
when the factor was present and 0 
when absent). The discriminatory 
power of the simplified risk scores 
was also adjusted for over-optimism. 
 
RESULTS 
Overall, 301 (3.9%) of the 7,800 
enrolled patients died within 30 days 
after randomization, with an 
additional 348 patients (4.5%) dying 
between 30 days and 1 year (Table 
1). Of the 659 (8.4%) patients who 
had an MI or died within 30 days, 
358 had a non-fatal MI, 74 had an 
MI and died, and 227 died without 
an MI. Patients who experienced an 
end point were more often older and 
had a higher frequency of 
comorbidities and prior cardiac 
history. Baseline biomarkers (i.e., 
TnT, NT-proBNP, CRP), heart rate, 
and the extent of ST-segment 
depression were significantly higher 
in patients who died within 30 days 
or 1 year. 
Predictors of 30-day death 
Thirteen of 19 possible predictors of 
30-day mortality remained 
statistically significant in the final 
model. (Table 2) Compared with 
those without ST-segment 
depression, the likelihood of 30-day 
death was twice as high in patients 
with 1- to 1.5-mm and nearly 4-fold 
higher with 2-mm ST-segment 
depression, after baseline 
adjustment (p < 0.001). ST-segment 
depression contributed the most to 
the model, as indicated by the 
percentage of the total chi-square 
(Fig. 1). Creatinine clearance was 
also strongly associated with 30-day 
mortality: patients with creatinine 
clearance 58.4 ml/min had a 5-fold 
increase in the risk of 30-day death 
relative to >98.6 ml/min (p < 0.001). 
Patients with TnT >0.47 μg/l were 
more than 3 times as likely to die  
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within the first 30 days than those 
with TnT 0.01 μg/l (p < 0.001). 
Compared with NT-proBNP 237 
ng/l, the odds of 30-day mortality 
steadily rose with increasing levels 
of NT-proBNP, particularly in those 
>1,896 ng/l, who had nearly a 3-fold 
increase in the risk of death (p = 
0.012). Strong prognostic 
associations were also observed for 
heart rate and age and, to a lesser 
extent, histories of MI and heart 
failure; weight; current smoker; and 
histories of hyperlipidemic therapy, 
percutaneous coronary intervention 
(PCI), and stroke. 
Predictors of 30-day death/MI. 
Among the 8 independent predictors 
of 30-day death/MI, ST-segment 
depression and TnT made the 
greatest contributions. (Table 2, Fig. 
1). Compared with patients without 
ST-segment depression, the odds 
ratio of 30-day death/MI ranged from 
1.2 to 3 as the extent of ST-segment 
depression increased (p < 0.001). 
Also, patients with TnT >0.47 μg/l 
were over 2.5 times more likely to 
experience the composite within 30 
days compared with those 0.01 μg/l 
(p < 0.001). Creatinine clearance, 
age, and NT-proBNP were important 
risk factors, similar to the 30-day 
mortality model. However, the 
relative contribution of NT-proBNP 
was attenuated compared with the 
mortality models (Fig. 1). Unlike the 
mortality model, heart rate was not a 
significant independent predictor of 
30-day death/MI. 
Predictors of 1-year death. ST-
segment depression was the 
strongest contributor to the model 
predicting 1-year mortality, similar to 
the 30-day mortality model (Table 2, 
Fig. 1). A marked gradient in risk 
Table 1. Baseline Characteristics According to Survival Status at 30 Days and 1 Year After Randomization
30-Day Death 30-Day Death/MI 1-Yr Death
Survived Died No Yes Survived Died
n 7,499 301 7,141 659 7,151 649
Age, yrs* 66 (57–73) 74 (69–79)† 66 (56–73) 72 (65–77)† 65 (56–73) 74 (68–79)†
Men, % 62.6 59.5 62.4 63.1 62.7 59.3
Caucasian, % 96.8 96.3 96.8 97.0 96.8 96.5
Hypertension, % 51.8 62.8† 51.5 59.2† 51.3 62.6†
History of hyperlipidemic
therapy, %
35.0 39.2 35.1 36.0 34.9 37.3
Diabetes mellitus, % 21.1 33.6† 21.3 27.6† 20.3 35.2†
Current smoker, % 22.9 17.3‡ 23.1 18.5† 23.2 16.8†
History of angina pectoris, % 45.4 60.1† 45.2 54.8† 44.5 62.9†
History of MI, % 30.9 50.5† 30.6 43.7† 29.8 52.4†
History of heart failure, % 7.7 23.3† 7.7 14.9† 6.9 23.1†
History of PCI, % 9.9 6.6 9.8 8.6 9.8 8.8
History of CABG, % 9.2 8.6 9.3 8.2 9.1 10.5
History of stroke, % 2.4 7.3† 2.4 5.3† 2.2 6.6†
Body weight, kg* 76 (68–86) 74 (64–83)† 76 (68–86) 75 (66–85)† 76 (68–86) 74 (64–83)†
Heart rate, beats/min 68 (60–79) 75 (65–93)† 68 (60–79) 71 (62–84)† 68 (60–78) 75 (64–90)†
Creatinine clearance, ml/min* 78 (59–99) 55 (39–72)† 78 (60–100) 62 (45–83)† 79 (61–100) 56 (40–73)†
ST-segment depression, mm † † †
None 34.0 13.7 34.5 19.3 34.7 16.6
0.5 27.3 15.3 27.4 20.0 27.6 18.5
1.0–1.5 27.4 35.3 27.1 34.9 27.1 35.1
2 5.0 20.3 4.8 13.9 4.7 15.2
Confounders§ 6.3 15.3 6.2 11.9 5.9 14.6
Troponin T, g/l* 0.11 (0.01–0.44) 0.41 (0.08–1.10)† 0.10 (0.01–0.44) 0.23 (0.06–0.68)† 0.10 (0.01–0.43) 0.30 (0.06–0.84)†
NT-proBNP, ng/l* 635 (228–1,724) 2,926 (1,193–7,683)† 622 (223–1,702) 1,560 (529–4,288)† 635 (228–1,723) 2,926 (1,202–7,667)†
CRP, mg/l* 3.90 (1.81–9.40) 6.76 (2.74–24.3)† 3.91 (1.82–9.42) 4.91 (2.15–13.0)† 3.80 (1.78–8.96) 6.97 (2.73–20.3)†
*Median (interquartile range). †p  0.001 (died vs. survived). ‡p  0.05 (died vs. survived). §Confounders include left bundle branch block, paced rhythm, ventricular rhythm,
or ST-segment elevation on the baseline electrocardiogram (ECG).
CABG coronary artery bypass graft; CRPC-reactive protein; MImyocardial infarction; NT-proBNPN-terminal pro-brain natriuretic peptide; PCI percutaneous
coronary intervention.
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relative to ST-segment depression 
was observed, even after baseline 
adjustment: patients with 2 mm 
were 2.4 times more likely to die 
within the first year compared with 
those without ST-segment 
depression (p < 0.001). Other 
important predictors included 
creatinine clearance, NT-proBNP, 
age, heart rate, and TnT. For 
instance, patients who had 58 
ml/min creatinine clearance were 
nearly 4 times more likely to die 
within the first year compared with 
>98.6 ml/min. In contrast to 30-day 
mortality, CRP, diabetes, and prior 
angina were significant prognostic 
factors, whereas past use of 
hyperlipidemic therapy and PCI were 
no longer significant factors to long-
term prognosis. There was also a 
significant interaction between NT-
proBNP and age (p = 0.006). In 30-
day survivors, the risk profile 
changed to some extent (Appendix 
2, Table A2.1). Whereas TnT was no 
longer a significant factor, 30-day 
post-randomization PCI reduced the 
likelihood of death by 50% (p = 
0.001). 
Model performance. The Hosmer-
Lemeshow goodness-of-fit test 
statistic indicated adequate fit of all 
models (30-day mortality: chi-square 
= 4.72 [p = 0.787]; 30-day death/MI: 
chi-square = 11.84 [p = 0.158]; 1-
year mortality: chi-square = 5.72 [p = 
0.679]), and calibration was 
Table 2. Adjusted OR and 95% CI of Baseline Characteristics Predicting 30-Day Mortality, 30-Day Death/MI, and 1-Year Mortality
30-Day Mortality 30-Day Death/MI 1-Yr Mortality
Adjusted OR
(95% CI) p Value
Chi-
Square
Adjusted OR
(95% CI) p Value
Chi-
Square
Adjusted OR
(95% CI) p Value
Chi-
Square
Age, yrs 1.03 (1.01–1.05) 0.001 10.7 1.02 (1.01–1.03) 0.001 10.9 1.04 (1.02–1.05) 0.001 29.6
Current smoker 1.60 (1.1–2.3) 0.008 6.7 1.70 (1.3–2.2) 0.001 15.9
Diabetes mellitus 1.38 (1.1–1.7) 0.001 10.7
History of hyperlipidemic therapy 1.41 (1.1–1.8) 0.009 6.6
History of angina 1.45 (1.2–1.8) 0.001 14.7
History of MI 1.46 (1.1–1.8) 0.005 7.9 1.39 (1.16–1.65) 0.001 10.6 1.59 (1.3–1.9) 0.001 23.4
History of heart failure 1.56 (1.1–2.1) 0.006 7.1 1.64 (1.3–2.1) 0.001 16.2
History of stroke 1.80 (1.1–3.0) 0.021 4.8 1.58 (1.07–2.34) 0.023 4.5 1.67 (1.1–2.5) 0.010 6.3
No history of PCI 1.70 (1.05–2.76) 0.034 5.1
No history of CABG 1.55 (1.14–2.11) 0.006 8.0
Heart rate, beats/min 1.02 (1.0–1.02) 0.001 17.1 1.01 (1.0–1.02) 0.001 24.3
Body weight, kg 1.01 (1.0–1.03) 0.009 6.8 1.01 (1.01–1.02) 0.001 12.0 1.01 (1.0–1.01) 0.007 7.3
Creatinine clearance, ml/min
98.6 1 0.001 39.8 1 0.001 25.0 1 0.001 42.9
76.9–98.6 2.17 (1.1–4.1) 1.36 (0.99–1.86) 1.89 (1.3–2.8)
58.4–76.9 3.61 (1.9–6.8) 1.71 (1.22–2.39) 2.54 (1.7–3.8)
58.4 5.39 (1.1–4.1) 2.39 (1.64–3.49) 3.85 (2.5–6.02)
ST-segment depression, mm
No 1 0.001 45.1 1 0.001 69.7 1 0.001 41.0
0.5 1.10 (0.7–1.7) 1.18 (0.91–1.53) 1.05 (0.8–1.4)
1.0–1.5 1.73 (1.2–2.5) 1.74 (1.38–2.21) 1.37 (1.1–1.8)
2 3.73 (2.4–5.8) 3.14 (2.31–4.26) 2.42 (1.7–3.4)
Confounders 2.42 (1.5–3.8) 2.27 (1.66–3.11) 2.03 (1.5–2.8)
Troponin-T, ug/l
0.01 1 0.001 33.7 1 0.001 42.2 1 0.001 23.5
0.01–0.12 2.06 (1.2–3.4) 2.20 (1.61–3.01) 1.31 (0.95–1.8)
0.12–0.47 2.09 (1.2–3.5) 2.38 (1.74–3.26) 1.60 (1.2–2.2)
0.47 3.54 (2.1–5.8) 2.52 (1.83–3.46) 1.99 (1.5–2.7)
NT-proBNP, ng/l
237 1 0.012 13.7 1 0.041 10.3 1 0.001 30.0
237–669 1.60 (0.8–3.2) 1.46 (1.04–2.06) 1.33 (0.9–2.1)
669–1,896 2.00 (1.0–3.9) 1.30 (0.92–1.83) 1.80 (1.2–2.8)
1,896 2.72 (1.4–5.3) 1.66 (1.17–2.36) 2.58 (1.7–4.0)
CRP, mg/l
1.84 1 0.05 8.8
1.84–3.96 1.10 (0.8–1.5)
3.96–9.62 1.06 (0.8–1.4)
9.62 1.38 (1.0–1.8)
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
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excellent (Fig. 2). The c-index was 
0.83 for the 30-day mortality model, 
which reflected excellent 
discriminatory power. The level of 
over-optimism determined by 
bootstrapping was 0.01, which 
reduced the c-indexadjusted to 0.82. 
The model predicting 1-year 
mortality had comparable 
discriminatory power of c-indexadjusted 
= 0.81 (over-optimism = 0.01), 
whereas it was lower for 30-day 
death/MI (0.72 [over-optimism = 
0.01]).  
Incremental value of novel risk 
factors. The incremental value of 
quantitative ST-segment depression 
and these biomarkers over 
“traditional” patient characteristics 
(e.g., age, comorbidities, history of 
cardiovascular disease, heart rate) 
was assessed with 2 approaches. 
First, the relative contribution of 
each independent predictor in the 
model was estimated (Fig. 1). 
Second, as each of these novel risk 
factors was added to the model of 
traditional baseline characteristics, a 
noticeable increase in the c-
indexadjusted was observed (Fig. 3). 
Simplified risk scores. As shown 
in Figure 4, the 5-factor risk score 
ranged from 0 in patients with no risk 
factors to 51 in those with all (and 
the most severe degree) of the risk 
factors for 30-day mortality, from 0 to 
39 for 30-day death/MI, and from 0 
to 48 for 1-year mortality. The 
accompanying nomogram translates 
the risk score into the likelihood of 
the outcome. The discriminatory 
power of the risk scores was slightly 
attenuated but remained reasonably 
strong (c-indexadjusted = 0.78, 0.67, 
and 0.77, respectively). 
 
DISCUSSION 
This large study of contemporary 
NSTE-ACS patients highlights the 
striking prognostic value of 
quantitative ST-segment depression 
even in the context of an expanded 
biomarker profile including creatinine 
clearance, NTproBNP, TnT, and 
CRP as well as other more 
traditional baseline risk factors such 
as creatinine clearance and age. 
Electrocardiography has long been 
Figure 1. Relative contribution of significant, independent factors to the prediction of 30-day death, 30-day death/myocardial infarction (MI), and 1-year
death. Creat. Cl. creatinine clearance; CRP C-reactive protein; Curr. Smok. current smoker; HR heart rate; Hx Ang history of angina pectoris;
Hx CABG  history of coronary artery bypass graft; Hx CHF  history of congestive heart failure; Hx MI  history of MI; Hx lipidRx  history of
hyperlipidemic therapy; Hx PCI  history of percutaneous coronary intervention; Hx strk  history of stroke; NT-proBNP  N-terminal pro-brain
natriuretic peptide; ST-dep  ST-segment depression; TnT  troponin T; Wgt  weight.
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an essential clinical tool in the 
evaluation of ACS as it is 
inexpensive, readily available, and 
non-invasive. Numerous studies on 
the basis of clinical trial and registry 
samples have also demonstrated 
that ST-segment depression on the 
admission ECG is highly influential 
on short- and long-term outcomes 
(6,15,16). Although the binary 
indicator (i.e., presence vs. absence 
of ST-segment depression) is often 
used in risk stratification, an 
increasing body of evidence, 
including this study, has 
demonstrated that quantitative ST-
segment depression is a substantial 
refinement (7,8). The PARAGON-A 
(Platelet IIb/IIIa Antagonism for the 
Reduction of Acute Global 
Organization Network) investigators 
(7) noted a steady increase in 30-
day and 1-year mortality as the 
extent of ST-segment depression 
rose (30-day mortality: 0.7% [no ST-
segment depression], 2.8%[1-mm], 
and 6.3% [2-mm ST-segment 
depression]; 1-year mortality: 2.0%, 
7.8%, and 13.4%, respectively). 
After baseline adjustment, ST-
segment depression made the 
highest relative contribution to the 
prediction of 1-year mortality, which 
was similarly observed in this study. 
 
The quantitative collection of 
indicators of renal function, 
myocardial necrosis, hemodynamic 
stress, and inflammation offered a 
unique opportunity to explore the 
pathophysiology of ACS. Abnormal 
renal function is a well-documented 
predictor of morbidity and mortality 
in a wide variety of patients (17). In 
concert with other ACS studies, 
lower levels of creatinine clearance 
were significantly associated with 
poorer short- and long-term 
prognosis, even though patients with 
advanced renal dysfunction were 
excluded from this trial (9). Impaired 
renal function might also alter the 
prognostic value of other serum 
biomarkers, because their clearance 
might be inhibited; however, 
previously published findings dispel 
Figure 2. Calibration of risk models: (A) 30-day death; (B) 30-day
death/myocardial infarction (MI); (C) 1-year death. Dots represent deciles
of predicted risk; the solid line represents perfect calibration.
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this concern (11,18). 
 
In the past, creatine kinase-MB was 
the reference standard in MI 
diagnosis, but troponins have 
replaced creatine kinase-MB with 
improved sensitivity and specificity 
(13). In the current study, TnT was 
ranked second and third among the 
predictors of 30-day death/MI and 
30-day death, respectively, which 
reflects its role as a highly sensitive 
marker of myocardial necrosis in the 
acute phase. Although TnT 
remained a significant predictor of 1-
year mortality (in all-comers), its 
influence declined over time after the 
index coronary event. 
 
Elevated levels of BNP have been 
linked with left ventricular 
dysfunction and poorer prognosis in 
patients with heart failure and other 
associated disorders. Recently, 
these observations have been 
extended to ACS patients in whom 
elevated BNP levels also might be 
the result of transient ischemia (19–
21). As demonstrated previously, 
increasing quartiles of NT-proBNP 
were strongly related to an increase 
in the odds of 30-day and 1-year 
mortality but not of 30-day MI, after 
multivariable adjustment (21). 
Although this relationship remained 
robust in the current study, it was no 
longer the top contributor of 
prognostic information after 
introducing the extent of ST-
segment depression. 
 
The role of inflammation in the 
pathophysiology of ACS is 
increasingly important, with CRP as 
one of the best recognized markers. 
Although once thought to have a 
passive role in vascular 
inflammation, CRP might be an 
active contributor to atherogenesis, 
as suggested by recent evidence 
Figure 3. Increase in adjusted C-index as biomarkers and quantitative ST-segment depression are added to the models predicting (A) 30-day (open dots)
and 1-year death (closed dots) and (B) 30-day death or MI (closed diamonds). Abbreviations as in Figure 1.
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 (22). Similar to the current study, 
others observed that the prognostic 
impact of elevated CRP was not 
evident early after the coronary 
event but emerged later as an index 
of the ongoing evolution of coronary 
artery disease (23–25). 
 
Classical risk factors such as age 
and heart rate played a significant 
role in risk prediction; however, 
compared with previously published 
risk models, these factors lost 
considerable prognostic value in the 
current study with the inclusion of 
quantitative ST-segment depression 
and biomarkers(1,2,26). Heart rate 
was not an independent predictor of 
30-day death/MI, a finding similar to 
those of other studies, (2). 
 
Clinical implications. Whether risk 
stratification that defines the optimal 
management strategy should be 
driven by non-invasive determinants 
of ischemia or knowledge of the 
coronary anatomy remains 
controversial. Although there is 
general consensus that patients at 
highest baseline risk tend to benefit 
most from early invasive therapy, 
others have argued that despite risk, 
invasive angiography and/or 
revascularization should become the 
standard of care in virtually all such 
patients. Higher rates of early 
invasive treatment, however, do not 
necessarily translate into improved 
outcomes in all patients, especially 
in those without ST-segment 
changes (27–29). International 
practice patterns revealed that the 
use of angiography and angioplasty 
in NSTE-ACS patients was inversely 
related to the extent of ST-segment 
depression (30). Thus, improved risk 
Figure 4. Simplified risk score and nomogram to estimate risk of mortality at 30 days (open dots) and 1 year (closed dots) and of death or myocardial
infarction (MI) at 30 days (solid x’s).
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assessment as proposed in the 
current study would better identify 
patients at increased risk, in whom 
coronary intervention should be 
considered, and its implementation 
might result in the increased 
efficiency of care. It seems clear that 
application of this approach 
depends, to some extent, on what 
risk one aims to predict and when. 
As evident in Figure 1, the shorter-
term risk of death is strongly 
influenced by ST-segment 
depression, renal function, cardiac 
troponin, and NT-proBNP in addition 
to traditional risk factors. The relative 
contribution of ST-segment 
depression and troponin is actually 
enhanced as it relates to 30-day 
death/MI. By 1 year some 
repositioning occurs such that age, 
diabetes, prior angina, and CRP 
appear as factors associated with 
mortality: whereas the influence of 
ST-segment depression remains 
strong, NT-proBNP is strengthened, 
and troponin is attenuated. 
 
Identifying appropriate treatment 
strategies might be facilitated 
through the use of simplified risk 
models in clinical practice. Several 
user-friendly risk scores have been 
developed from clinical trial and 
registry populations, such as the 
Thrombolysis In Myocardial 
Infarction (TIMI) risk score in NSTE-
ACS and the recently published risk 
score from the GRACE (Global 
Registry of Acute Coronary Events) 
registry (3,4). However, there are 
notable limitations. 
Although the TIMI risk score 
contains few factors, its 
discriminatory power is modest (c 
index = 0.65), which limits its clinical 
application. And although the 
GRACE registry risk score extends 
beyond the TIMI risk score to include 
serum creatinine, heart rate, and 
systolic blood pressure, it is lacking 
quantitative ST-segment depression, 
NT-proBNP, and CRP, which were 
shown to have significant prognostic 
value in the current study and other 
studies. 
 
Some limitations of our study should 
be addressed. First, baseline 
systolic blood pressure was not 
available and could have influenced 
our findings. However, this seems 
unlikely. An ad hoc analysis of the 
PURSUIT (Platelet Glycoprotein 
IIb/IIIa in Unstable Angina: Receptor 
Suppression Using Integrilin 
Therapy) 30-day death model 
revealed that if systolic blood 
pressure was not included, the top 5 
predictors (as measured by percent 
Sigma chi-square) to the model—
heart rate(interaction with AMI/UA), 
age, rales, ST-segment depression 
(yes/no), and region of enrolment— 
essentially remained unchanged 
from the model that included systolic 
blood pressure (2). Notably, if one of 
the top indicators, such as heart 
rate, was not included in the model, 
the structure of the overall model 
changed significantly. Second, the 
extrapolation of these findings to the 
general ACS population might be in 
question. According to the protocol, 
coronary angiography was restricted 
at least 12 h after the completion of 
the study drug infusion. Although 
this might not be routine procedure 
in many tertiary facilities, it likely is 
representative of the sizeable 
proportion of the overall ACS 
population who do not present 
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directly to these facilities. And finally, 
the external validation of these risk 
models was not provided. To our 
knowledge, no other clinical trial or 
population-based cohort possesses 
the requisite ECG and/or biomarker 
data required for this task. Validation 
of clinically meaningful cut points will 
also be important. Future 
investigations should incorporate 
these indicators into their design to 
achieve this. 
 
In conclusion, the degree of ST-
segment depression was the highest 
contributor to the prediction of 30-
day and 1-year mortality and 30-day 
death/MI in a contemporary sample 
of 7,800 NSTE-ACS patients. 
Creatinine clearance, TnT, and NT-
proBNP also were significant 
independent prognostic indicators of 
adverse outcomes, whereas CRP 
was only significant in the long-term 
prediction. The current study 
provides novel contemporary 
insights into the risk stratification of 
NSTE-ACS patients, which might be 
of particular value in identifying 
strategies for risk reduction and the 
planning of future studies. 
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APPENDIX 
For an independent analysis of the 
relative prognostic power of TnT 
over creatine kinase-MB as the 
preferred marker of myocardial 
damage and adjusted odds ratios 
and 95% confidence intervals of 
baseline characteristics in predicting 
1-year mortality in 30-day survivors, 
please see the online version of this 
article.
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Chapter Two 
 
Forecasting mortality: dynamic 
assessment of risk in ST-segment 
elevation acute myocardial infarction 
Wei-Ching Chang, Padma Kaul, Yuling Fu, Cynthia M. Westerhout, 
Christopher B. Granger, Kenneth W. Mahaffey, Lars Wallentin, Frans Van 
de Werf, and Paul W. Armstrong for the ASSENT-3 Investigators 
 
AIMS  To demonstrate the feasibility and clinical utility of developing dynamic risk assessment 
models for ST-segment elevation myocardial infarction (STEMI) patients. 
METHODS AND RESULTS  In 6066 STEMI patients enrolled in the Assessment of the Safety 
and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial with complete electrocardiographic data, 
we assessed the probability of 30-day mortality over the following forecasting periods beginning 
at day 0 (baseline), 3 h, day 2, and day 5 using multiple-logistic regression. These models were 
validated and simplified in independent samples of 1622 similar fibrinolytic-treated patients from 
the ASSENT-3 PLUS trial and in 814 STEMI patients undergoing primary percutaneous coronary 
intervention in the COMplement inhibition in Myocardial infarction treated with Angioplasty 
(COMMA) trial. The discriminatory power of these predictive models, from baseline to day 5, 
was excellent (c-statistics 0.80 to 0.87); and their predictive ability was supported by strong 
gradients in mortality outcomes as the risk score increased. Dynamic modelling also provided 
information on the change in prognosis over time which may be used to advise more appropriate 
therapeutic decisions, e.g. the identification of high-risk patients for possible co-interventions. 
CONCLUSION  Dynamic modelling for STEMI patients enhances the risk assessment and 
stratification and should provide valuable ongoing guidance for their management. 
By virtue of its nature and the 
demands of the health care system, 
medical decision-making in acute 
coronary syndromes (ACS) is a 
dynamic process. Patients are 
continually assessed from the time 
of entry into the health care system 
until discharge and throughout the 
follow-up care. Critical decisions, 
based in part on the expected 
outcomes, must be promptly made 
on admission and over the next 
several hours and days, as well as 
at the time of hospital discharge. To 
help guide patient management and 
reflect the rapid transition of patient 
status during hospital stay, we 
previously introduced the concept of 
dynamic risk modelling in non-ST-
segment elevation ACS patients 
enrolled in the Global Utilization of 
Strategies to Open Occluded 
Arteries- IIb (GUSTO-IIb) trial.1 
Because the short-term morbidity 
and mortality for ST-segment 
elevation myocardial infarction 
(STEMI) patients exceed that of 
patients without ST-segment 
elevation, we now extend this 
concept to provide relevant and 
timely prognostic information at key 
decision points for this important 
population. 
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As prognostic indices derived from 
complex models are rarely used in 
clinical practice,2 our aim is to further 
develop simplified and valid risk 
scores for this dynamic process that 
can be used at the bedside for risk 
assessment and clinical 
management. More specifically, we 
undertook to: (1) develop a series of 
prognostic models (dynamic risk 
models) incorporating clinically 
relevant information unfolding during 
the hospital stay; (2) validate these 
models in independent STEMI 
patient populations; and (3) generate 
simplified risk scores and explore 
their clinical utility. 
 
METHODS 
Data sources 
Data from the Assessment of the 
Safety and Efficacy of a New 
Thrombolytic-3 (ASSENT-3) trial 
were used to develop a series of 
dynamic models, which were 
validated in two independent 
samples: one with fibrinolytic therapy 
and the other with primary 
percutaneous coronary intervention 
(PCI). The details of these trials 
have been published previously.3–5 
Briefly, in the ASSENT-3 trial, 6095 
STEMI patients presenting 6 h of 
symptom onset were randomly 
assigned to one of the three 
treatment groups: full-dose 
tenecteplase and enoxaparin for a 
maximum of 7 days, full-dose 
tenecteplase with weight-adjusted 
unfractionated heparin for 48 h, or 
half-dose tenecteplase with weight-
adjusted low-dose unfractionated 
heparin and a 12-h infusion of 
abciximab. Our study sample 
consisted of 6066 patients after 
excluding 29 patients with missing 
baseline electrocardiographic data. 
Our first validation sample consisted 
of 1622 out of 1639 patients from the 
ASSENT-3 PLUS trial (after 
excluding 13 patients who died prior 
to hospital admission and four 
patients with missing 30-day 
mortality data), which enrolled 
STEMI patients presenting 6 h of 
symptom onset in the pre-hospital 
setting. Patients were randomly 
assigned to treatment with 
tenecteplase and either with 
enoxaparin or with weight-adjusted 
unfractionated heparin for 48 h as in 
the two arms of the ASSENT-3 trial 
common to ASSENT-3 PLUS. 
 
To broaden the applicability of this 
approach to patients with primary 
PCI, we used a second validation 
sample consisted of 814 STEMI 
patients enrolled in the COMplement 
inhibition in Myocardial infarction 
treated with Angioplasty (COMMA) 
trial between January 2000 and April 
2002, who arrived <6 h of symptom 
onset with ST-segment elevation 2 
mm in two contiguous leads or new 
left-bundle branch block (LBBB). 
The patients, who were to be treated 
with primary PCI, were randomly 
assigned to receive placebo bolus 
and placebo infusion, 2.0 mg/kg 
bolus of pexelizumab and placebo 
infusion for 20 h administered 4 h 
after the bolus, or 2.0 mg/kg bolus 
and 0.05 mg/kg/h of infusion of 
pexelizumab for 20 h. 
 
Categorization of data 
We categorized the continuous 
variables according to the 
conventions (e.g. age <65, 65–74, 
75+; and ST-segment resolution of 
<30, 30–70, 70+) or the quartiles of 
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these variables (heart rate, systolic 
BP, total ST-segment deviation, and 
QRS scores) as explained 
subsequently. Given the prognostic 
importance of the baseline 
electrocardiogram (ECG) and 
subsequent ST-segment resolution 
data in ACS patients,1,6,7 we 
incorporated serial ECG data 
collected after admission to assess 
the effect of the response to therapy. 
ECGs were collected in all patients 
at baseline and at 1 and 3 h after 
treatment in ASSENT-3 and 
ASSENT-3 PLUS6 and at baseline, 
30 min post-PCI, and 24 h after 
enrolment in COMMA.5 ECG data 
were incorporated using three 
measures: total baseline ST-
segment deviation categorized into 
<12, 12–17, >17 mm; baseline 
Selvester QRS score8 categorized 
into 0–1, 2–4, >4; and ST-segment 
resolution at 1 and 3 h categorized 
according to Schroeders method9 as 
complete resolution (70%), partial 
resolution (30–70%), and no ST-
segment resolution (<30%). In all 
trials, however, there were missing 
or incomplete ECG 
data/confounders (i.e. without the 
protocol-defined amount of ST-
segment elevation, had LBBB, 
paced rhythm, ventricular rhythm, or 
poor quality ECGs) that did not allow 
for an accurate assessment of ST-
segment resolution and QRS scores. 
Also excluded from the baseline 
QRS-score assessment were right-
bundle branch block (RBBB), Wolff 
Parkinson White pattern (WPW), left 
anterior fascicular block (LAHB), left 
posterior fascicular block (LPHB), 
left ventricular hypertrophy (LVH), 
and right ventricular hypertrophy 
(RVH). The proportion of technically 
suitable ECGs varied between the 
time of collection and among trials, 
as shown in Table 1. 
 
Model development 
Our primary endpoint was 30-day 
all-cause mortality. Four models 
were developed sequentially in our 
study (Figure 1), incorporating the 
information collected at baseline 
(day 0 model), at 3 h (3 h model), at 
day 2 (day 2 model), and at day 5 of 
the hospital stay (day 5 model). 
These time points were selected to 
coincide with conventional clinical 
practice: at baseline to devise an 
initial assessment/management 
plan; at 3 h to incorporate the ST-
resolution status relating to the 
success of reperfusion therapy; at 
the end of day 1 to reassess the 
early intervention strategies; and at 
day 4 to further adjust patient 
management strategies including 
possible early discharge. The 
following variables were included in 
the 30-day mortality models. Day 0 
model: Baseline patient data such as 
demographics (e.g. age, sex, and 
race), medical histories (e.g. prior 
MI, hypertension), and presenting 
characteristics (e.g. Killip class, 
systolic blood pressure, total ST-
deviation, and QRS score). 3 h 
model: The baseline data plus 
ST-segment resolution status at 1 
and 3 h. Day 2 model: The baseline 
and 3 h data plus data on 
revascularization procedures and 
adverse events that occurred during 
day 0–1. Day 5 model: The baseline 
and 3 h data plus data on 
revascularization procedures and 
adverse events that occurred prior to 
day 5. 
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Multiple-logistic regression 
procedures for patients who survived 
to the start of the forecasting period, 
based on the stepwise, backward 
variable selection method, were 
used to develop these models. We 
assessed the relative contribution of 
a prognostic factor in the logistic 
regression model as the proportion 
of the chi-square value associated 
with that factor out of the sum of all 
chi-square values associated with all 
significant factors. In developing 
these models, we monitored the use 
of revascularization [i.e. PCI and 
coronary artery bypass grafting 
(CABG)] procedures and the 
occurrence of serious in-hospital 
adverse events, defining a broad 
clinical category of heart failure as a 
composite of cardiogenic shock, 
pulmonary edema, or right heart 
failure and an electrical disorder as a 
composite of asystole, electro-
mechanical dissociation, or 
ventricular fibrillation after day 1. 
Missing data were treated either as 
separate categories or imputed as 
non-events when they were shown 
to be associated with the lower 30-
day mortality. 
 
Table 1 Baseline patient characteristics in the ASSENT-3 trial and the validation samples from the
ASSENT-3 PLUS and COMMA trials
ASSENT-3 ASSENT-3þ COMMA
n 6066 1622 814
Age (years), median (IQR) 61 (52, 70) 62 (53, 72) 60 (51, 71)
75 years 14 20 19
Female (%) 24 23 25
Caucasian (%) 85 62 85
Diabetes mellitus (%) 18 15 19
Hypertension (%) 41 36 52
Killip class (%)
I 89 93a 84
II 10 5 13
III–V 2 2 3
Anterior MI (%) 39 42 79
Systolic blood pressure (mmHg),
median (IQR)
132 (119, 150) 133 (120, 150) 135 (118, 155)
Heart rate (b.p.m.), median (IQR) 73 (62, 85) 74 (60, 85) 78 (66, 90)
QRS score (%)
0–1 25 23 26
2–4 28 22 30
.4 22 18 27
Confoundersb/missing 25 36 17
Total ST-segment deviation (mm) (%)
,12 46 38 44
12–17 22 26 20
.17 21 24 20
Confoundersb/missing 11 13 16
ST-segment resolution at 3 h (%)
No resolution 14 16 10
Partial 25 26 26
Complete 42 39 49
Confoundersb/missing 20 19 15
b.p.m., beats per minute; MI, myocardial infarction; IQR, interquartile range.
a21% of Killip class data were missing in ASSENT-3 PLUS and were excluded in these calculations.
bECG confounders were those without the protocol-defined amount of ST-segment elevation, had LBBB, paced rhythm,
ventricular rhythm, or poor quality ECGs that did not allow for an accurate assessment of ST-segment resolution and QRS
scores. Also excluded from the baseline QRS-score assessment were RBBB, WPW, LAHB, LPHB, LVH, and RVH.
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Model validation 
We evaluated our models based on 
the discriminatory capacity (i.e. c-
statistic) and the model calibration 
(i.e. concordance between the 
predicted and the observed 
outcomes).10,11 Bootstrapping was 
performed to estimate the degree of 
over-optimism associated with c-
statistics.12 The validation was 
performed internally on ASSENT-3 
and externally on ASSENT-3 PLUS 
and COMMA, as noted earlier. In 
validating these models, we checked 
the correlation matrices, performed 
backward stepwise regression, and 
examined the standard errors of 
coefficients and interactions among 
these variables to assess any 
collinearity and confounding factors. 
 
Simplified risk scores and clinical 
applications 
To illustrate the potential of dynamic 
risk modelling for bedside use, we 
further developed and validated 
simplified risk scores from the day 0, 
3 h, day 2, and day 5 models. This 
was done by assigning points to the 
coefficients of the most significant 
(i.e. x2  10 in Supplementary 
material online, Table S1) predictors 
in the models in a 0.5 increment as 
follows: one point for the coefficient 
ß = 0.5±0.25, two points for ß = 
1.0±0.25, three points for ß = 
1.5±0.25, and so on.13 We then 
calculated the total risk score for 
each patient at each period as the 
sum of the points assigned to the 
patients applicable risk factors in 
the model. These simplified risk 
scores were validated as for the full 
models, in terms of both model 
discrimination and calibration. 
 
To compare our approach with a 
conventional risk assessment tool, 
 34 
we also calculated for each patient a 
simple Thrombolysis In Myocardial 
Infarction (TIMI) risk index as 
follows: (heart rate x [age/10]2) 
/(systolic blood pressure).14 This 
composite index was then used in 
lieu of the three separate factors of 
age, heart rate, and systolic blood 
pressure in our four full models in 
ASSENT-3 to evaluate the relative 
contributions of this index to 
mortality prediction over time. All 
analyses were performed using 
SPSS version 13.0 (Chicago, IL, 
USA) except for bootstrapping, 
which was performed using STATA 
version 7 (College Station, TX, 
USA). 
 
RESULTS 
Our ASSENT-3 study sample 
consisted of 6066 patients whose 
median age was 61, 24% were 
women, and 85% were Caucasians. 
There were some differences in 
baseline patient characteristics 
between ASSENT-3 and the 
validation datasets: patients in 
ASSENT-3 PLUS were slightly older 
with fewer Caucasians in the 
sample, and more patients in 
COMMA had hypertension and 
anterior MI as well as higher heart 
rates (Table 1). Serious in-hospital 
adverse events among patients in 
ASSENT-3 were as follows: 3.0% for 
recurrent ischaemia and also for re-
infarction, 3.6% for electrical 
disorders, 5.5% for heart failure, 
1.5% for stroke, 3.1% for major 
bleeding, and 5.1% for death. Most 
of these complications occurred 
within the first few days. In-hospital 
PCI and CABG procedures were 
performed on 28.6 and 4.5% of the 
patients, respectively, with a median 
of 3 and 6 days to these procedures 
(Table 2). 
 
Model development 
A series of predictive models 
forecasting 30-day mortality from 
baseline, 3 h, day 2, and day 5 were 
developed on the basis of patient 
characteristics, complications, and 
procedures acquired up until the 
beginning of each forecasting period 
(Tables 1 and 2) and are hereafter 
referred to as the full ASSENT-3 
models (Supplementary material 
online). As shown in Figure 2A, the 
three most influential factors in the 
baseline model were age, systolic 
blood pressure, and heart rate, 
Table 2 Events and procedures during hospitalization
Day 0–1
(n ¼ 6066)
Day 2
(n ¼ 5968)
Day 3–4
(n ¼ 5879)
Day 5/disch
(n ¼ 5839)
Day 0–disch
(n ¼ 6066)
Median days
to event
In-hospital events
Serious recurrent ischaemia 84 (1.4) 39 (0.5) 29 (0.5) 53 (0.9) 180 (3.0) 2.0
Re-infarction 104 (1.7) 12 (0.2) 27 (0.5) 38 (0.7) 180 (3.0) 1.0
Electrical disorder 132 (2.2) 132 (2.2) 21 (0.4) 46 (0.8) 220 (3.6) 0.0
Heart failure 223 (3.7) 40 (0.7) 28 (0.6) 44 (0.8) 335 (5.5) 1.0
Cardiogenic shock 143 (2.4) 27 (0.5) 14 (0.2) 27 (0.5) 210 (3.5) 1.0
Stroke 61 (1.0) 3 (0.1) 16 (0.3) 14 (0.2) 94 (1.5) 1.0
Major bleeding 51 (0.8) 13 (0.2) 21 (0.4) 106 (1.8) 191 (3.1) 2.0
Deatha 98 (1.6) 89 (1.5) 40 (0.7) 92 (1.5) 312 (5.1) 2.0
In-hospital procedures
Percutaneous coronary
intervention
662 (10.9) 182 (3.0) 280(4.8) 628 (10.8) 1737 (28.6) 3.0
Bypass surgery 27 (0.4) 17 (0.3) 60 (1.0) 170 (2.9) 274 (4.5) 6.0
Percentage of patients in parentheses. Both fatal and non-fatal events and procedures were included in these figures other than the row labelled as Death.
aThe number of deaths was 359 (5.9%) in 30 days: 312 (5.1%) in hospital, and 47 (0.8%) between discharge (disch) and 30 days.
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which accounted for 70% of the 
relative contribution to the mortality 
prediction. At 3 h, the relative 
contribution of these factors declined 
to 63%, and at both day 2 and day 5, 
it further dropped to 26%. The ECG 
measures, including the total ST-
segment deviation and QRS score at 
baseline and the ST-segment 
resolution status at 3 h, accounted 
Figure 2 Changing influences of prognostic factors from baseline to day 5 (A),
and the proportions of patients whose risk of 30-day mortality were assessed as
low (1%), medium (1–5%), and high (.5%) from baseline to day 5 (B). (A) is
nearly replicated when age, heart rate, and systolic blood pressure were
replaced by the simple TIMI risk index composed of these three factors (C).
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for 13% of the relative contribution at 
baseline, 23% at 3 h, but attenuated 
to 11 and 15% at day 2 and day 5, 
respectively. The in-hospital events 
of heart failure and stroke were 
particularly influential and accounted 
for 45 and 32% of the relative 
contribution at day 2 and day 5, 
respectively. Figure 2B depicts the 
trends in prognosis over time 
according to low (1%), medium (1–
5%), and high risk (>5%) of 30-day 
mortality. Interestingly, the 
proportion of low-risk patients 
increased steadily from 18.7% at 
baseline to 52.2% at day 5, whereas 
that of high-risk patients declined 
steadily from 32.1 to 8.4% between 
baseline and day 5, with an 
additional 3.7% expiring during that 
period. 
Model validation 
As detailed in Supplementary 
material online, the c-statistics 
associated with the four full 
ASSENT-3 models ranged from 0.82 
to 0.87, and increased from 0.76 at 
baseline to 0.84 at day 5 when 
restricted only to those patients who 
survived the first four days of 
hospitalization. The amount of over-
optimism was minimal, ranging from 
0.004 to 0.005 for the baseline to 
day 2 models and 0.010 for the day 
5 model. None of the Hosmer–
Lemeshow statistics for these 
models was significant, and the 
Pearson correlation coefficients 
ranged from 0.997 to 0.999 between 
the predicted and the observed 30-
day mortality probabilities for all 
models based on the deciles of 
these probabilities. 
 
The full ASSENT-3 models were 
then externally validated in 
ASSENT-3 PLUS and COMMA 
(Supplementary material online). 
 
The c-statistics ranged from 0.78 to 
0.82 when the full ASSENT-3 
models were applied to the 
ASSENT-3 PLUS data, and none of 
the Hosmer–Lemeshow statistics for 
these four models was significant. 
The Pearson correlation coefficients 
ranged from 0.87 to 0.93 between 
the predicted and the observed 30-
day mortality probabilities for all 
models based on the deciles of 
these probabilities. When applied to 
the COMMA data, the c-statistics 
ranged from 0.83 to 0.86; and the 
Pearson correlation coefficients 
ranged from 0.93 to 0.97 between 
the predicted and the observed 30-
day mortality probabilities, with non-
significant Hosmer–Lemeshow 
statistics for all four models; thus 
showing the robustness of our 
ASSENT-3 models. Over-optimism 
was negligible (<0.001) for all these 
(full and their simplified) models, 
because only one predictor variable 
derived from the ASSENT-3 models 
was involved in each of these 
validation models. 
Simplified risk scores and clinical 
applications 
The simplified risk scores from the 
full ASSENT-3 models are detailed 
in Table 3, and the strong gradients 
of mortality rates associated with 
them are depicted in Figure 3. Their 
discriminatory capacity was also 
excellent, with the c-statistics 
ranging from 0.80 to 0.86 (Table 3). 
A more detailed account of the 
validation of the simplified models 
together with their applications to 
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individual patients is provided in 
Supplementary material online. 
 
Dynamic modelling can help identify 
high-risk patients who should be 
treated more aggressively. For 
instance, while the simplified risk 
score remained unchanged between 
baseline and 3 h for patients with 
either complete or partial ST-
segment resolution, 97.5% of 
patients without ST-segment 
resolution or with an ECG 
confounder had a higher risk score 
at 3 h. The rate of in-hospital 
revascularization in ASSENT-3 was 
33.2 and 30.8%, respectively, for 
those with no ST-segment resolution 
or an ECG confounder. This was 
virtually identical to the observed 
31.3 and 34.2% for those with partial 
or complete ST-segment resolution, 
respectively. The 30-day mortality 
for those with and without in-hospital 
revascularization was 5.2 and 10.0% 
(P = 0.041) among patients without 
ST-segment resolution and 4.6 and 
12.8% (P < 0.001) among those with 
an ECG confounder. The previous 
results were unchanged after 
adjusting for the propensity for in-
hospital revascularization. Hence, it 
is possible that a proportion of the 
177 patients who died without 
complete or partial ST-segment 
resolution by 3 h but were not 
revascularized may have been 
better served by more aggressive 
treatment. 
 
Our approach is flexible and may 
also be used to incorporate any 
traditional prognostic index for 
predicting clinical outcomes. For 
instance, when forecasting 30-day 
mortality in ASSENT-3 based on the 
simple TIMI risk index in place of 
individual baseline covariates of age, 
heart rate, and systolic blood 
pressure, a similar decline in its 
influence was also demonstrated 
(Figure 2C): while this index 
Table 3 Points assigned to selected factors for developing simplified risk scoresa
Factor Day 0 3 h Day 2 Day 5
Age (years)
65–74 2 2 2 1
75þ 4 4 3 3
Killip class
II 1 1
III–IV 3 3
Heart rate (b.p.m.)
63–85 1 1 1
.85 2 2 2
Systolic BP (mmHg)
,120 2 2 2 1
120–132 1 1 1 1
Total ST-segment deviation (mm)
12 1 1 1 1
ST-segment resolution
Partial 0 1 1
No 2 2 2
ECG confounders/missing 2 1 0
In-hospital event (,1 day or 4 days)
No PCI 2 2
Stroke 8 5
Heart failure 5 4
Electrical disorder 5 3
Maximum possible total score 11 13 32 22
C-index (95% confidence interval) 0.80 (0.77–0.82) 0.80 (0.78–0.82) 0.86 (0.83–0.88) 0.81 (0.77–0.85)
aThe reference groups are not shown, as the points assigned to them are all set to 0.
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accounted for 72% of the relative 
contribution to mortality prediction at 
baseline, that percentage was 
reduced to 63% at 3 h, and then to 
23 and 26% at day 2 and day 5, 
respectively. Conversely, other 
factors, such as the ECG measures 
and in-hospital events, assumed an 
increasingly greater role and 
became predominant in mortality 
prediction and risk stratification in 
day 2 and day 5 models.  
 
DISCUSSION 
Dynamic modelling attempts to 
capture the texture of clinical risk 
assessment from the time of first 
medical contact with acute coronary 
patients and thereafter, especially 
during the critical early phase of 
patient management. As the care of 
these patients requires prompt and 
timely adjustments, having 
implications for both risk-benefit and 
cost-effectiveness, developing a risk 
assessment process to reflect this 
evolutionary process is a worthwhile 
goal 1,15 and distinguishes our 
approach from the traditional 
baseline and discharge models.16,17 
 
Several key messages have 
emerged from our study. First, the 
dynamic modelling framework 
enables us to risk-stratify patients at 
any clinically important time point 
(e.g. at day 5 for early discharge) as 
well as over several time points. A 
Figure 3 The distribution of mortality rates associated with the risk scores for the day 0 (A), 3 h (B), day 2 (C), and day 5 (D) models, showing associations
between simplified risk scores and actual mortality rates.
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unique strength of dynamic 
modelling, therefore, is that it 
captures change in prognosis over 
time. An advantage of monitoring 
changes in prognosis is that it is 
feasible to devise decision rules for 
patient management, e.g. identifying 
candidates for early discharge based 
on the criterion of patients being 
stable and remaining at a low risk 
during the first few days of 
hospitalization.1 In this paper, we 
further demonstrated the feasibility 
of applying simplified risk scores to 
monitor change in prognosis 
between baseline and 3 h for 
identifying opportunities for more 
aggressive treatment. As factors not 
available at baseline, such as the 
ECG tracking of ST-segment 
evolution and in-hospital events, 
convey significant prognostic 
information in addition to baseline 
values, the performance of these 
models improved over the traditional 
baseline model as a result of their 
inclusion. To illustrate this point, we 
have used vital signs (i.e. systolic 
blood pressure, heart rate) collected 
at both baseline and 24 h in the 
COMMA trial to recalculate the 
simple TIMI risk index14 for each 
patient at these time points. Logistic 
regression based on this index alone 
was performed to predict day 0–30 
and day 2–30 mortality, resulting in 
the c-statistics of 0.85 and 0.92, 
respectively, when the sample was 
restricted in both models to those 
who survived to the start of day 2. A 
corollary, therefore, is that it is 
essential to test the optimal methods 
of collecting significant baseline and 
in-hospital predictors that can 
change over time, e.g. heart rate, 
blood pressure, ECG measures, and 
biomarkers.1 
Secondly, a spectrum of models, 
from very simple to very 
sophisticated, should be developed 
and utilized using the dynamic risk 
modelling framework. For scientific 
research at tertiary care institutions 
and academic centres, sophisticated 
full models should be further 
developed, tested, and used to 
provide most valid and reliable 
answers to clinical questions arising 
from various health care settings 
and systems. On the other hand, it is 
imperative to also develop simplified 
risk scores, because prognostic 
indices derived from complex 
models are rarely used in clinical 
practice.2 For rapid, user-friendly 
bedside use, we developed in this 
study highly reliable, simplified risk 
scores (c-statistics 0.80–0.86 after 
excluding the QRS score) to provide 
quick risk assessment. The 
implementation of dynamic risk 
modelling may be further facilitated 
through the use of centralized 
electronic medical records to 
automatically calculate these 
probabilities and reduce the burden 
of data entry to clinicians. Integrating 
computerized ECG analyses, which 
could generate standardized ECG 
measures, into this health 
information system should also be 
considered.18 
 
Thirdly, our dynamic models are 
applicable not only to fibrinolytic-
treated STEMI patients but also to 
those undergoing primary PCI. This 
is important, because an estimated 
25–50% of AMI patients currently 
undergo primary-PCI worldwide.19 
As shown in Supplementary material 
online, our dynamic models 
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performed extremely well in both 
fibrinolytic-treated and primary-PCI 
patients: the c-statistics for the 
simplified risk scores ranged from 
0.79 to 0.86 in ASSENT-3 PLUS and 
0.81 to 0.86 in COMMA; and these 
scores were strongly and positively 
associated with mortality rates in all 
models in both validation datasets. 
In comparison, the c-statistics for 
other baseline-risk models were 0.84 
for GUSTO-I full model,20 0.79 for 
the (simplified) TIMI risk score,11 and 
0.78 for a simple TIMI risk index 
(based only on age, heart rate, and 
systolic blood pressure).14 
 
Some limitations of our study should 
be noted. First, our risk models were 
developed and validated using 
specific clinical trials data, which 
may differ from the general STEMI 
patient population. It should be 
noted, however, that over 14% of 
them were 75 years or more. 
Although we have validated our 
models also on an independent 
sample of primary-PCI patients, 
further research is warranted to test 
the generalizability and 
reproducibility of our results in other 
settings. Secondly, unlike the 
probability measures derived from 
the full models, simplified risk scores 
are not consistently defined and 
standardized, and hence may not be 
strictly comparable, across the 
forecasting periods. For example, a 
score of 7 in our study was 
associated with an observed 30-day 
mortality rate that changed from 
19.8%, through 14.0, 2.9, and 5.9% 
as it was ascertained at baseline, 3 
h, day 2, and day 5, respectively 
(Figure 3). For tracking change in 
prognosis over time using simplified 
risk scores, it is crucial to always 
refer to the levels of risk associated 
with these scores (Figure 3) rather 
than comparing them directly across 
the periods. Thus, for comparing 
change in prognosis over time, a 
better approach may be to use 
programmable calculators or 
handheld computers, which can 
readily compute mortality 
probabilities for individuals or groups 
of patients directly from the full 
models.1,15 
 
In conclusion, we have extended the 
dynamic modelling methodology to 
STEMI patients receiving either 
fibrinolytic therapy or primary PCI 
and demonstrated that this strategy 
of continuous risk assessment and 
stratification is feasible and may 
sharpen evidence-based decision-
making in the management of 
STEMI patients within the critical 
days after hospital admission. 
 
Supplementary material 
Supplementary material is available 
at European Heart Journal online. 
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Chapter Three 
Are international differences in the 
outcomes of acute coronary syndromes 
apparent or real? A multilevel analysis 
Wei-Ching Chang, William K Midodzi, Cynthia M 
Westerhout, Eric Boersma, Judith Cooper, Elliot S 
Barnathan, Maarten L Simoons, Lars Wallentin, E Magnus 
Ohman, Paul W Armstrong for the GUSTO-IV ACS 
Investigators 
STUDY OBJECTIVE International variation in the outcomes of patients with acute coronary 
syndromes (ACS) has been well reported. The relative contributions of patient, hospital, and 
country level factors on clinical outcomes, however, remain unclear, and thus, was the objective 
of this study. 
DESIGN Multilevel logistic regression models were developed for death/(re)infarction (MI) at 30 
days and death in one year, with patients (1st level) nested in hospitals (2nd level) and hospitals 
in countries (3rd level). 
SETTINGS The GUSTO IV ACS clinical trial was carried out at 458 hospital sites in 24 countries 
in 7800 non-ST segment elevation (NSTE) ACS patients. 
MAIN RESULTS There were substantial variations among countries in the processes and 
outcomes of care at 30 days, ranging from 5.4% to 50.0% for percutaneous coronary 
intervention, 4.3% to 21.2% for coronary artery bypass graft surgery, 5.0% to 13.9% for 30 day 
death/(re)MI, and 4.9% to 14.8% for one-year mortality. However, the residual inter-country 
variations in 30 day death/(re)MI and one-year mortality became non-significant and nearly 
disappeared (p.0.500 for both) after adjusting for key baseline patient characteristics and 
hospital factors, which became significant (p,0.01 for both). Patient-level factors accounted for 
96%–99% of total variation in these end points, leaving the remaining 1% and 4% of variance 
attributable to hospital level factors. 
CONCLUSION The international differences in clinical outcomes in this study of NSTE ACS are 
primarily accounted for by the patient-level factors, with hospital level factors playing a minor 
part, and the country-level factors a negligible one. These findings have significant policy and 
research implications involving international collaboration and comparisons. 
Disparities in cardiovascular and 
other health outcomes across 
geographical regions are common, 
and yet not well understood.1 2 Even 
after adjustment for baseline patient 
characteristics, significant variations 
in clinical outcomes often persist in 
acute coronary syndrome (ACS) 
patients.3–9 Although some studies 
have not shown mortality differences 
in either ST segment elevation 
(STE)10–16 or non-ST segment 
elevation (NSTE) ACS patients,17 18 
others have reported better quality of 
life and mortality outcomes in 
countries with high revascularisation 
rates.3 12 19 Such disparities in 
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outcomes provide incentives to 
further investigate the underlying 
factors, including patient and 
provider characteristics, 
socioeconomic and cultural factors, 
healthcare practices, and other 
characteristics of healthcare 
systems. 
 
To our knowledge, however, no 
study has formally identified and 
quantified the sources of inter-
country variations in the ACS 
literature, although some have 
offered opinions on this.6 8 20 To 
gauge the amount of variation in 
outcomes among countries 
attributable to patient compared with 
non-patient level factors, we applied 
multilevel modelling techniques that 
took into account the hierarchical 
and correlated nature of healthcare 
data.21–24 In such data, findings are 
generally correlated among patients 
in the same subgroup, for instance, 
those cared for at the same hospital 
or in the same country. Thus, 
conventional, single level analyses 
that treat the data as if there were no 
hierarchical structures violate the 
assumption of independence of 
findings required for such methods, 
and result in suboptimal estimation 
of the effects of hospital and country 
level factors.21–24 Moreover, single 
level analyses are not designed to 
assess the components of variation 
attributable to individual (patient 
level) compared with contextual 
(hospital and country level) effects. 
Thus, our objectives were: (1) to 
assess the extent of international 
differences in patient characteristics, 
care processes, and clinical 
outcomes, and (2) to determine the 
extent to which the observed inter-
country variations in the composite 
of 30-day death or post-admission 
myocardial infarction (MI) and one 
year all cause mortality can be 
explained by patient, hospital, and 
country level factors. 
 
METHODS 
Patients and study design 
Data from the global utilisation of 
strategies to open occluded 
coronary arteries IV acute coronary 
syndromes (GUSTO IV ACS) were 
used. The details of this trial have 
been previously reported.25 26 Briefly, 
7800 patients from the 458 
participating hospitals in 24 
countries were enrolled between 
July 1998 and April 2000 (table 1). 
 
Eligible patients were 21 years or 
older, had at least one episode of 
angina lasting five minutes or more 
within the preceding 24 hours 
without persistent ST segment 
elevation, and a positive cardiac 
troponin T or I test (determined 
using a local qualitative or 
quantitative assay) or at least 0.5 
mm transient or persistent ST 
segment depression on admission. 
They were randomly assigned to 
one of the three treatment groups: 
abciximab therapy for 24 hours (0.25 
mg/kg bolus followed by a 0.125 
mg/kg per minute infusion up to 10 
mg/kg for 24 hours), abciximab 
therapy for 48 hours (same bolus 
and infusion for 48 hours), or 
matching placebo (bolus and 48 -
hour infusion). Coronary 
angiography was not to be 
performed during or within 12 hours 
after the completion of the study 
agent administration, unless the 
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patient had recurrent or continuing 
ischaemia at rest associated with 
ischaemic ST/T segment changes 
that were not responsive to medical 
treatment. A clinical end point 
committee, which was unaware of 
treatment assignment, adjudicated 
all possible incidences of MI and, 
when requested by the Safety and 
Efficacy Monitoring Committee, also, 
the cause of death within 30 days. 
An independent neurologist 
adjudicated all suspected 
occurrences of stroke and 
intracranial haemorrhage. The ethics 
committees of the participating 
hospitals approved the protocol, and 
patients gave informed consent. 
 
Statistical analysis 
The primary end point for the 
GUSTO IV ACS trial (and for this 
study) was 30-day death/(re)MI, and 
one-year mortality was a secondary 
end point. Because no treatment 
effect was found, the three treatment 
arms were combined. Biomarkers 
and renal function were grouped into 
tertiles to examine their relations 
with the primary end points: troponin 
T (TnT) (0.01, 0.01–0.5, and >0.5 
mg/l; and C reactive protein (CRP) 
(4, 4–10, and 10 mg/l; creatinine 
clearance (58.4, 58.4–76.9, and 
76.9 ml/min; and the extent of ST 
segment depression into <1 (or no 
ST segment depression), 1–1.5, and 
2 mm. For ease of presenting 
variation among countries, we 
further dichotomised these data after 
examining their relations with 
outcomes, and defined an increased 
value as follows: >0.01 mg/l for TnT, 
>1 mm for ST segment depression, 
>58.4 ml/min for creatinine 
clearance, and >10 mg/l for CRP. 
The results were presented in terms 
of percentages for categorical 
variables and medians (interquartile 
ranges) for continuous variables. 
Table 1 Number of study sites and patients and selected baseline patient level factors of each country* participating in the
GUSTO IV ACS trial
Country
Sites
(n)
Patients
(n)
Median
age
Female
(%)
Prior MI
(%)
Diabetes
(%)
TnT
(%)
ST depression
(%)
Creatinine
clearance (%)
CRP
(%)
Enrolment MI
(%)
North America
Canada 31 642 65 31 34 25 46 28 79 59 36
United States 48 462 66 42 33 33 39 36 71 68 34
Western Europe
Austria 8 78 66 33 30 35 81 32 66 36 13
Belgium 9 163 66 33 31 21 74 43 73 24 36
France 15 197 68 27 26 17 71 29 67 24 25
Germany 32 395 68 34 26 25 75 42 75 29 28
Greece 15 259 66 35 26 31 66 49 73 24 20
Ireland 5 40 64 15 40 10 83 23 78 43 23
Italy 29 486 66 34 30 21 76 42 71 27 27
Netherlands 27 570 66 33 26 11 71 43 83 25 31
Portugal 8 88 68 25 23 19 83 38 75 25 36
Spain 11 362 68 29 20 23 74 40 75 29 40
Switzerland 7 38 65 32 29 11 82 43 76 34 34
UK 15 124 64 30 36 16 77 32 76 29 35
Scandinavia
Denmark 12 149 66 28 29 10 80 38 80 35 31
Finland 2 79 66 32 34 18 80 42 79 22 28
Norway 10 91 64 42 23 21 84 26 78 23 31
Sweden 28 544 70 34 31 16 88 31 73 22 33
Eastern Europe
Czech 16 765 69 49 38 31 71 51 66 26 29
Poland 24 1657 65 49 34 17 50 44 81 19 26
Other
Australia 9 118 66 35 27 14 64 40 64 40 40
Israel 13 265 63 26 35 30 78 39 76 34 27
New Zealand 3 54 61 20 33 13 94 26 80 24 43
South Africa 10 144 60 22 17 19 76 34 80 33 41
All countries 387 7800 66 38 31 22 66 40 75 31 28
*The actual number of sites from 458 possible sites that had enrolled at least one patient. CRP, C reactive protein .1110 mg/l; creatinine clearance,58.4 ml/
min; MI, myocardial infarction; ST segment depression >1mm; TnT, troponin T .0.01 mg/l. All missing data were imputed as positive for these indicators.
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To assess the relative contributions 
of patient and non-patient level 
factors on outcomes, we began with 
two level null models (that is, 
without containing any independent 
variables), with patients at the first 
level and countries at the second. 
We then developed three level null 
models by including hospitals as an 
additional level to further identify the 
variance component attributable to 
the hospital effects, which has been 
distributed to both patient and 
country effects.28 Thereafter, we 
developed nested three level models 
by successively incorporating patient 
age, other patient baseline 
characteristics, and the country level 
percutaneous coronary intervention 
(PCI) and coronary artery bypass 
graft (CABG) rates (as estimated 
from our dataset). The amount of 
variance explained was calculated 
by the proportional change in 
variance (PCV), or the percentage 
reduction from the estimated 
variance in the null model as a result 
of incorporating a new factor(s) in 
the model—that is, PCV=(V0–V1)/V0, 
where V0 is the estimate of the initial 
(null) variance at the country or 
hospital level before adjusting for 
any compositional or contextual 
factor in the model, and V1 was the 
country or the hospital level residual 
variance after adjusting for 
covariates.23 The proportions of total 
variance related to hospital and 
country factors were estimated by 
the intraclass correlation coefficient 
(ICC) using the formula V/(V+2/3), 
where V=V0 or V1, and 2/3 is the 
fixed variance at the patient level as 
suggested by Snijders and Bosker.28 
Each model parameter was 
estimated using the restricted 
penalised quasilikelihood function in 
HLM version 6.0 (Lincolnwood, IL, 
USA) or MLwiN 2.1a (University of 
London, London, UK), which also 
Table 2 Use of evidence based drugs before and during hospitalisation according to country
Country
Aspirin (%) Clopidogrel (%) ACE inhibitors (%) b blockers (%) Nitrates (%)
Calcium channel
blockers (%)
Before During Before During Before During Before During Before During Before During
North America
Canada 90 98 1 11 27 43 57 86 37 63 29 32
United States 84 96 4 19 28 40 54 83 34 59 26 26
Western Europe
Austria 78 95 1 22 46 49 63 89 32 39 27 26
Belgium 79 94 0 0 17 25 66 87 25 52 23 22
France 52 96 3 10 18 22 66 81 82 82 41 43
Germany 80 99 4 12 44 72 55 81 35 66 24 15
Greece 69 96 0 0 41 51 49 73 41 85 40 36
Ireland 95 75 0 0 28 38 60 63 25 38 25 30
Italy 66 96 0 0 31 47 45 78 26 70 32 38
Netherlands 71 97 0 4 14 23 57 86 21 56 24 41
Portugal 90 100 0 1 38 63 53 89 50 81 30 18
Spain 89 96 1 4 17 32 34 66 44 74 32 50
Switzerland 87 97 0 37 24 40 68 84 24 37 21 21
UK 90 100 0 9 21 27 60 85 43 56 40 42
Scandinavia
Denmark 90 98 0 7 17 21 58 86 34 46 33 38
Finland 100 100 0 4 23 35 95 99 54 77 17 17
Norway 92 96 0 1 10 20 70 96 17 44 24 21
Sweden 87 97 1 15 17 28 81 93 34 51 20 24
Eastern Europe
Czech 81 98 0 0 35 48 53 78 58 79 20 16
Poland 91 98 0 0 48 63 63 84 65 90 25 28
Other
Australia 95 98 2 11 27 38 59 81 42 53 31 40
Israel 84 99 0 0 29 54 54 83 26 57 24 23
New Zealand 100 100 0 0 26 30 67 85 46 44 35 35
South Africa 71 98 0 0 24 30 31 63 28 44 13 23
All countries 84 97 1 5 31 43 58 83 46 61 26 29
ACE inhibitors, angiotension converting enzyme inhibitor.
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provides standard errors and t tests 
for fixed effects and chi-square tests 
for random effects. Each variance 
estimate was presented with a 
standard error and a p value based 
on the chi-square test. All other 
descriptive analyses were performed 
using SPSS version 11.0 (Chicago, 
IL, USA). 
 
RESULTS 
Variations among countries 
The baseline patient characteristics 
differed significantly among the 24 
countries participating in the study 
(table 1). Variation in other aspects 
of health care such as the use of 
evidence-based drugs was also 
noticeable, and except for calcium 
channel blockers, their use 
increased substantially during 
hospitalisation (table 2). 
 
The diversity was even greater for 
invasive procedures at 30 days, and 
there was a threefold variation in the 
median length of hospital stay (table 
3). 
 
Differences in outcomes across 
countries were also pronounced: 
5.0% to 13.9% in 30 day 
death/(re)MI, 2.5% to 8.0% in 30 day 
mortality, and 4.9% to 14.8% in one 
year mortality (table 3). 
 
 
Sources of variation in 30-day 
death/(re)MI and in one-year 
mortality 
Table 4 shows the results of our 
multilevel analyses for 30-day 
death/(re)MI. 
 
A small but significant intercountry 
variance of 0.036 (p=0.004) was first 
shown in the two level null model 
after factoring out the patient level 
Table 3 Median length of stay and rates of revascularisation (PCI or CABG) and of (re)-myocardial infarction, and/or death
at 30 days, and death at one year according to country
Country
Median LOS
(days)
30 day
One year
death (%)CABG (%) PCI (%)
Revasculation
(%) (re)MI (%) Death (%)
Death/(re)MI
(%)
North America
Canada 8 14 25 39 8.4 3.7 5.5 8.1
United States 7 21 27 47 12.6 4.5 9.1 10.6
Western Europe
Austria 14 5 10 15 8.5 4.2 5.9 11.9
Belgium 11 21 38 58 6.7 3.1 4.1 8.3
France 11 12 36 48 8.6 4.6 4.6 9.1
Germany 15 13 27 40 9.9 5.8 5.6 8.4
Greece 8 6 5 12 6.9 3.1 3.9 7.3
Ireland 15 10 13 20 5.0 5.0 0.0 10.0
Italy 11 16 25 40 9.9 4.5 6.4 8.6
Netherlands 9 12 21 33 6.7 3.7 3.7 7.0
Portugal 10 10 39 49 13.6 8.0 8.0 14.8
Spain 12 8 22 30 8.0 4.4 4.4 8.0
Switzerland 11 11 50 61 7.9 2.6 7.9 7.9
UK 9 7 19 25 8.1 4.8 4.8 10.5
Scandinavia
Denmark 8 15 18 32 8.7 4.0 5.4 8.1
Finland 9 18 19 35 13.9 2.5 12.7 8.9
Norway 7 10 15 25 6.6 4.4 3.3 7.7
Sweden 8 15 24 39 9.6 2.9 7.9 6.4
Eastern Europe
Czech 11 4 7 11 11.1 5.4 7.2 12.8
Poland 12 5 7 12 5.9 2.5 4.1 6.9
Other
Australia 6 8 40 47 10.3 5.1 6.4 6.4
Israel 9 19 40 58 7.5 3.0 5.7 4.9
New Zealand 5 15 11 26 9.3 7.4 1.9 9.3
South Africa 6 21 26 46 6.9 2.8 4.9 5.6
All countries 10 11 19 30 8.4 3.9 5.5 8.3
CABG, coronary artery bypass graft surgery; LOS, length of stay; PCI, percutaneous coronary intervention; (re)-MI, (re)-myocardial infarction.
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effects. To further exclude the 
hospital level effects that were 
distributed to both the patient level 
and country level effects in the two 
level model, we developed a series 
of three level models that also 
included the hospital level factors 
and showed, first of all, that the 
intercountry variance was reduced 
by 22.7% to 0.028 and became non-
significant (p=0.072) in the null 
model (model 1). This variance was 
further reduced and became 
negligible (p>0.500) after 
successively controlling for age, for 
all baseline patient characteristics, 
and then also for country level PCI 
and CABG rates (models 2–4), so 
that these factors explained nearly 
all (99.6%) the residual intercountry 
variation. In contrast, the estimated 
interhospital variance of 0.086 was 
significant (p=0.003) in the three 
level null model, but was only 
reduced to 0.046 (p=0.032) in the full 
model (model 4). The reduction in 
country level variance is depicted in 
caterpillar plots for shrunken 
residuals (logarithmic odds ratios) 
before and after adjusting for 
baseline patient factors (fig 1A). 
Similar plots for hospital level 
variance are given in figure 1B. 
 
The ICC further shows that 1.09% of 
the total variation was related to 
country factors (with the remaining 
98.91% related to patient factors) 
based on the two level null model 
(table 4). This proportion was 
reduced in the three level models to 
0.82%, 0.36%, 0.03%, and 0.00% in 
Table 4 Analysis of the hospital and country level effects on 30 day death/(re)MI and one year mortality
Variable
Hospital level effects Country level effects
Intrahospital
correlation (%)
Intracountry correlation
(%)Variance (SE, p)% Explained Variance (SE, p)% Explained
30 day death/(re)MI
Two level null model – 0.0361 1.09
(0.024;
p = 0.004)
Three level models
Model 1: null 0.0862 0.0279 22.7 2.53 0.82
(0.046; (0.023;
p = 0.003) p = 0.072)
Model 2: age only 0.0718 16.7 0.0122 56.3 2.13 0.36
(0.044; (0.017;
p = 0.010) p = 0.456)
Model 3: all baseline factors* 0.0419 51.4 0.0011 96.1 1.26 0.03
(0.041; (0.012;
p = 0.014) p.0.500)
Model 4: Baseline+country level
CABG-rate
0.0462 46.4 0.0001 99.6 1.38 0.00
0.039; (0.001;
(p = 0.032) p.0.500)
One year death
Two level null model – 0.0369 1.11
(0.024;
p = 0.005)
Three level models
Model 1: null 0.179 0.0172 46.6 5.13 0.49
(0.058; (0.022;
p = 0.001) p = 0.312)
Model 2: age only 0.170 4.9 0.0068 60.5 4.91 0.20
(0.059; (0.018;
p = 0.002) p.0.500)
Model 3: all baseline factors* 0.124 30.6 0.00002 99.7 3.64 0.00
(0.054; (0.015;
p = 0.014) p.0.500)
Model 4: Baseline+country level
CABG-rate
0.103 42.5 0.00023 99.4 3.03 0.01
(0.050; (0.001;
p = 0.008) p.0.500)
*Adjusted for age, prior myocardial infarction, prior transient ischaemic attacks, prior stroke, prior coronary artery bypass graft surgery, prior use of calcium
channel blockers and b blockers, ST segment depression, troponins T, creatinine clearance, and time to randomisation. Adjusted for country level coronary artery
bypass graft surgery (CABG) rate.
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models 1–4, respectively. By 
contrast, the intrahospital correlation 
coefficient was reduced from 2.53% 
in the three level null model to 
1.38% in the full, three level model 
(model 4). Thus, 3.4% 
((0.0279+0.0862)/(0.0279 
+0.0862+3.29)) of the total variance 
was situated at the hospital and 
country level in the null model 
(model 1), and as a proportion of the 
hospital and country variance, 
24.5% (0.0279/(0.0279+0.0862)) 
and 75.5% were at the country and 
the hospital level, respectively. After 
adjusting for baseline patient 
characteristics in model 3, however, 
such substantial country level effects 
were reduced from 24.5% to 2.6%. 
The patient factors, in contrast, 
accounted for 98.6% of the total 
variation. 
 
The same multilevel analyses 
performed for one-year mortality 
also confirmed that the country level 
factors, which was significant in the 
two level null model, played a 
negligible part (0%) in explaining the 
intercountry variation in one-year 
mortality according to the three level 
models: 97.0% was explained by the 
patient level factors and the 
remaining 3% by hospital level 
factors (model 4, table 4). 
 
DISCUSSION 
International comparisons of 
population health, the incidence and 
prevalence of disease, and the 
impact of healthcare organisations 
and interventions on health 
outcomes are of great interest.1 2 
The proliferation of large 
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Figure 1 Logarithmic odds ratio and
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30 day death/(re)MI (ranked in
ascending order) for each country (A)
and for each hospital (B) before and
after adjustment for baseline patient
level factors.
 50 
international clinical trials in 
cardiovascular and other areas of 
medicine in the past two decades 
further stimulated investigation into 
the variations in practice patterns 
and outcomes among countries and 
geographical regions. These 
variations in health status and 
treatment outcomes, if real, are of 
particular concern, as they raise a 
host of questions concerning the 
efficacy, effectiveness, efficiency, 
and equity of the social and 
healthcare systems as well as the 
diagnostic and therapeutic 
procedures used within and among 
these countries and geographical 
regions. Identifying the sources of 
variation in patient outcomes is 
important, as it may have enormous 
implications for the design, analysis, 
and interpretation of such studies. 
For example, abciximab was not 
shown to be beneficial in the overall 
GUSTO IV ACS sample except in 
North America, where a beneficial 
effect of a borderline significance 
was seen. Nevertheless, the Food 
and Drug Administration (FDA) in 
the USA has not approved 
abciximab for frontline medicinal 
treatment of ACS patients based on 
the conventional view that subgroup 
results are less reliable.27 Our 
findings of negligible country effects 
and of comparatively small hospital 
effects on outcomes in the GUSTO 
IV ACS trial lend support to the 
FDAs decision, although the 
reasons for better performance in 
North America deserve further 
investigations. To our knowledge, 
however, there has not been a 
rigorous study performed to quantify 
the sources of intercountry variations 
in treatment outcomes for ACS 
patients. In this paper we showed 
that patient level factors explained 
96%–99% of total NSTE ACS 
outcome variations. Similar findings 
were obtained in our previous 
studies of ST segment elevation 
myocardial infarction (STEMI)3,29 
where significant variations in 30 day 
and one-year mortality were related 
mainly to patient characteristics. 
However, variation in one-year 
mortality among countries remained 
highly significant for the STEMI 
sample even after adjusting for 
baseline patient characteristics, 
which was not the case for the 
NSTE-ACS cohort. Whereas the 
residual intercountry variation was 
explained primarily by the country 
level life expectancy among STEMI 
patients, the patient and hospital 
level factors explained that variation 
in NSTE ACS patients. Such 
differences may be related to the 
finding from these studies that 
variation was greater among 
countries but smaller among 
hospitals in STEMI than in NSTE 
ACS patients, and that life 
expectancy as a proxy for the state 
of the nations health and healthcare 
system had a greater impact on the 
outcomes of STEMI than of NSTE 
ACS. Further research is clearly 
required on this intriguing contrast. 
 
It is noteworthy that our results are 
in agreement with those in other 
NSTE ACS studies.7 17 18 Although 
significant international differences 
persisted in the efficacy and safety 
of subcutaneous enoxaparin in non-
Q wave coronary events 
(ESSENCE) trial,8 that study was 
based on very small samples from 
the outlier countries. Thus, our 
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results were aligned with those 
obtained from a Swedish study that 
used two level modelling of 30 day 
mortality after a heart failure,23 which 
confirmed that variation among 
hospitals in mortality after 
hospitalisation was mainly explained 
by the differences in baseline patient 
characteristics. A recent three level 
analysis of AMI patients in Ontario, 
Canada further showed that 96.6% 
of variation in one year mortality was 
related to patient level factors, 
leaving 2.8% and 0.6% to physician 
and hospital level factors, 
respectively.21  Similarly, another 
Ontario study showed that 
socioeconomic status, although a 
significant predictor of patient level 
mortality, had a minimal impact on 
hospital mortality rates after 
adjusting for age, sex, and illness 
severity30; as well, a study of social 
context on heart disease mortality in 
Texas, USA showed that 95% of the 
total variance was accounted for by 
variation at the individual level, 
leaving the rest to variations in 
socioeconomic and ethnic factors at 
the census tract and the county 
level.22 
 
It is also of interest to note that the 
country level revascularisation rates 
played a comparatively minor part in 
further reducing variations among 
hospitals and countries. Although we 
also found a negative relation 
between country level 
revascularisation and mortality rates, 
variation among countries remained 
significant after adjusting for the 
country level revascularisation rate. 
It should be noted here that these 
findings are contextual in nature, 
and they in no way imply that 
invasive procedures did not 
influence the outcomes of ACS at 
the patient level. To make such an 
inference is to commit a so-called 
ecological fallacy, to infer an 
individual level relation on the basis 
of group level associations.31 
As in other NSTE ACS studies,5 7–9 18 
32 we also found significant 
intercountry differences in drug and 
procedure use. In particular, in-
hospital aspirin use was mandated 
in the protocol and given at a high 
rate across all regions (except for 
Irish patients) as recommended by 
the 2002 ACC/AHA and ESC 
guidelines.33 34 The use of other 
efficacious drugs such as ACE 
inhibitors, ß blockers, and long 
acting nitrates also increased after 
hospital admission, and their rates 
were consistent with those found in 
other studies.7–9 18 Our finding of 
significant variations in practice 
patterns even within the context of 
rigorously designed clinical trials 
shows that opportunities exist to 
increase adherence to practice 
guidelines. 
 
Several limitations of our study 
should be noted. Firstly, despite the 
detailed clinical data that had been 
collected in the GUSTO IV ACS trial, 
specific characteristics of hospitals 
(for example, information of on-site 
interventional facilities) and 
physician level data were 
unavailable.27 35 Secondly, the 
GUSTO IV ACS sample may differ 
from the general population of 
patients with ACS, as it was not 
based on a representative sample in 
participating countries. In particular, 
coronary angiography was not 
performed within 12 hours of the 
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completion of study agent infusion, 
which is the common practice in 
most hospitals without interventional 
facilities in North America and 
Europe. However, this is unlikely to 
change the main findings of our 
study in view of other studies also 
showing the predominance of patient 
level factors accounting for clinical 
outcomes.21 23 Thirdly, we based our 
multilevel modelling on a latent 
variable approach, which assumed 
an underlying continuous dependent 
variable.36 It should be noted that 
there are other methods of 
calculating the intraclass correlations 
and of summarizing contextual level 
variances, for example, in terms of 
the median odds ratio.28 37 However, 
the use of measures such as the 
median odds ratios37 only confirms 
the findings of this study, and hence 
is not presented in this paper. 
Notwithstanding these limitations 
and considerations, our approach to 
the analysis of geographical 
variations has wider applications. 
 
In conclusion, we found that practice 
patterns as well as patient 
characteristics differ among 
countries in a large, contemporary 
sample of NSTE ACS patients, and 
that variations in outcomes were 
related primarily to patient level 
factors and only small but significant 
proportions were related to hospital 
and country level factors. The 
variation between countries, which 
was smaller than that between 
hospitals, became negligible after 
controlling for patient and hospital 
effects. Greater attention to 
collecting data on hospital and 
physician characteristics in future 
NSTE ACS international studies and 
clinical trials, in addition to further 
exploring and refining patient level 
data, should provide insights into 
patient outcomes and optimising 
care in all healthcare settings. 
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Chapter Four 
Electrocardiographic left ventricular 
hypertrophy in GUSTO IV ACS: an 
important risk marker of mortality in 
women 
Cynthia M. Westerhout, Michael S. Lauer, Stefan James, 
Yuling Fu, Lars Wallentin and Paul W. Armstrong for the 
GUSTO IV ACS Investigators 
 
AIM To examine the association of left ventricular hypertrophy (LVH) on admission 
electrocardiography with adverse outcomes in acute coronary syndrome (ACS) patients. 
METHODS AND RESULTS A total of 7443 non-ST-elevation ACS patients in Global Utilization 
of STrategies to Open occluded arteries (GUSTO) IV ACS trial had admission 
electrocardiograms analysed at a core laboratory. LVH [20 mm Cornell voltage (LV voltage) 
(women) or 28 mm (men) plus strain patterns] was observed in 586 (7.9%) patients, and 
women accounted for 74%. LVH patients were also older and had more co-morbidities, ST-
depression  0.5 mm, elevated C-reactive protein and N-terminal pro-brain natriuretic peptide 
(NT-proBNP), and lower troponin T. Invasive procedures occurred less often in LVH patients 
(cardiac catheterization: 31 vs. 38%, P = 0.001; percutaneous coronary intervention: 12 vs. 20%, 
P <0.001). Mortality was significantly higher in patients with LVH (30 day: 5 vs. 3%, P = 0.046; 1 
year: 14 vs. 7%, P <0.001), whereas 30-day myocardial infarction (MI) and death/MI did not 
differ. After baseline adjustment including NT-proBNP, LVH remained associated with increased 
hazard of 1-year mortality in women, but not in men [P-interaction = 0.033; women: adjusted 
hazard ratio (LVH vs. no LVH): 1.42 (1.04–1.94), P = 0.029]. 
CONCLUSION Electrocardiographic-LVH identifies an important subset of ACS patients with a 
higher risk of long-term mortality, particularly among women. These novel findings highlight 
opportunities to improve treatment and outcome among similar ACS patients. 
 
Although increases in left 
ventricular (LV) mass can 
accommodate an increased 
afterload stress, it may ultimately 
prove harmful. At that point, left 
ventricular hypertrophy (LVH) can 
lead to deleterious cardiovascular 
effects such as ventricular 
dysfunction, impaired coronary 
perfusion, and disturbances in 
cardiac rhythm.1 LVH is also a 
strong precursor of adverse 
outcomes in a variety of populations 
ranging from the general population 
to those with cardiovascular 
diseases.2–4 Women with LVH, in 
particular, have a higher risk of 
mortality than their male 
equivalents.5,6 
 
Despite recognized unfavourable 
influence of this condition across the 
spectrum of coronary artery disease 
(CAD), LVH is rarely discussed in 
the realm of acute coronary 
syndromes (ACS) or cited as a 
modulator of clinical outcomes in 
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these patients. In a large cohort of 
non-ST-elevation (NSTE)-ACS 
patients enrolled in the Global 
Utilization of STrategies to Open 
occluded arteries (GUSTO) IV ACS 
trial, we examined the prevalence of 
LVH [as diagnosed on the admission 
electrocardiogram (ECG)] and 
hypothesised that LVH would play a 
role in the likelihood of adverse 
outcomes. The extent to which 
gender and/or N-terminal pro-brain 
natriuretic peptide (NT-proBNP), a 
marker of haemodynamic stress, 
may modulate the relationship of 
LVH with outcomes was also 
explored. 
 
METHODS 
Patient population 
Details of the design and primary 
results of the GUSTO IV ACS trial 
have been previously described.7,8 In 
brief, patients over the age of 21 
years were eligible if they presented 
within 24 h after one or more 
episodes of ischaemic chest pain 
lasting at least 5 min. In addition, 
eligible patients had to have either 
elevated cardiac troponin T or I 
above the upper limit of normal 
according to the local quantitative or 
qualitative assays, or transient or 
persistent ST-segment depression 
(0.5 mm) on the admission ECG 
not known to be pre-existing or not 
attributable to coexisting disorders 
(e.g. LVH). Patients were excluded if 
they had evidence of an acute ST-
segment elevation myocardial 
infarction (MI) or new left bundle 
branch block, or if percutaneous 
coronary intervention (PCI) or 
coronary artery bypass graft (CABG) 
was planned within 30 days after 
enrolment. 
 
Eligible patients were randomly 
assigned to abciximab (0.25 mg/kg 
bolus plus 0.125 mg/kg/min 
continuous infusion for 24 or 48 h) or 
placebo. All patients were to receive 
aspirin and either unfractionated or 
low-molecular-weight heparin. Other 
clinically indicated medications were 
used at the discretion of the treating 
physician. 
The primary endpoint of the trial was 
all-cause death or MI at 30 days. All 
possible cases of MI were 
adjudicated by a clinical endpoint 
committee, which was unaware of 
the study treatment assignment. 
Secondary endpoints included 30- 
day and 1-year death.7 
 
Electrocardiogram measurements 
Admission ECGs were read 
independently at the core ECG 
laboratory at the Cleveland Clinic 
Foundation (Cleveland, OH, USA) 
by experienced readers blinded to 
clinical outcomes. ECG data were 
then managed and analysed at the 
University of Alberta (Edmonton, 
Alberta, Canada). Admission ECGs 
were available in 7443 (95.4%) of 
the 7800 patients enrolled in the 
trial. LVH was identified on the 
admission ECG defined according to 
two established criteria: (i) Cornell 
voltage criteria: the sum of the 
amplitude of the S-wave in V3 and R-
wave in the aVL lead, 28 mm for 
men and 20 mm for women,9 and 
(ii) the presence of repolarization 
abnormalities (strain patterns) 
classified as 1 mm ST-segment 
depression in lead I and aVL or in v5 
and v6, or T-wave inversion 
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in lead I and aVL or in v5 and v6.10 
 
Laboratory analyses 
Details of the central laboratory 
analyses have been published.11 
Briefly, venous blood samples were 
collected at the point of 
randomization, and centrifuged sera 
were stored at –20•C in aliquots and 
sent to a central laboratory at the 
University of Uppsala (Uppsala, 
Sweden) for the analysis of troponin 
T, C-reactive protein, and NT-
proBNP. A third-generation assay on 
an Elecsys (Roche Diagnostics) 
analyser was used to measure the 
levels of troponin T with a detection 
limit of 0.01 mg/L. C-reactive protein 
levels were ascertained using a 
chemiluminescent enzyme-labelled 
immunometric assay (Immulite CRP, 
Diagnostic Product Corp.) with a 
detection level of 0.1 mg/L. NT-
proBNP concentrations were 
measured with a sandwich 
immunoassay on an Elecsys 2010 
(Roche Diagnostics) analyser with 
an analytical range of 20–35 000 
ng/L and a coefficient of variation at 
3.3% at a level of 209 ng/L and 3.0% 
at a level of 7431 ng/L. Serum 
creatinine was also measured, and 
creatinine clearance rate was 
calculated using the gender-specific 
Cockcroft and Gault equation.12 
 
Statistical analysis 
Baseline patient characteristics were 
presented as numbers and 
percentages for discrete variables, 
whereas medians and 25th and 75th 
percentiles were given for 
continuous variables. Differences 
within these baseline characteristics 
Table 1 Patient characteristics according to the presence/absence of left ventricular hypertrophy
LVH status P-value
No LVH LVH
n 6857 586
Age, yearsa 66 (56–73) 71 (63–77) ,0.001
Female, n (%) 2362 (34.4) 430 (73.4) ,0.001
Caucasian, n (%) 6631 (96.7) 569 (97.1)
Hypertension, n (%) 3425 (49.9) 420 (71.7) ,0.001
History of hyperlipidaemic therapy, n (%) 2392 (34.9) 219 (37.4)
Diabetes mellitus, n (%) 1347 (19.7) 215 (36.8) ,0.001
Current smoker, n (%) 1649 (24.0) 77 (13.1) ,0.001
History of angina pectoris, n (%) 3040 (44.3) 348 (59.4) ,0.001
History of MI, n (%) 2101 (30.6) 217 (37.0) ,0.001
History of heart failure, n (%) 481 (7.0) 89 (15.2) ,0.001
History of stroke, n (%) 161 (2.3) 28 (4.8) ,0.001
History of PCI, n (%) 667 (9.7) 53 (9.0)
History of CABG, n (%) 604 (8.8) 55 (9.4)
ACE-inhibitors prior to randomization, n (%) 2002 (29.2) 270 (46.1) ,0.001
Beta-blockers prior to randomization, n (%) 3970 (57.9) 353 (60.2)
Aspirin prior to randomization, n (%) 5745 (83.8) 498 (85.0)
Ca channel blockers prior to randomization, n (%) 1743 (25.4) 186 (31.7) ,0.001
Factors available upon presentation
MI upon enrolment, n (%) 1952 (28.5) 124 (21.2) ,0.001
Trial entry criteria ,0.001
Positive local troponin I or T only, n (%) 1367 (22.7) 54 (10.4)
ST-segment depression 0.5 mm only, n (%) 2457 (40.8) 252 (48.6)
Both positive troponin and ST-segment depression, n (%) 2192 (36.4) 212 (40.9)
Body weight, kga 76 (68–86) 71 (63–77) ,0.001
Heart rate, b.p.m.a 68 (60–78) 73 (63–84) ,0.001
Creatinine clearance, mL/mina 79 (60–100) 64 (47–86) ,0.001
Central laboratory biomarkers
Troponin T, mg/La 0.11 (0.01–0.46) 0.07 (0.01–0.38)
C-reactive protein, mg/La 3.82 (1.81–9.20) 4.67 (2.15–11.6) ,0.001
NT-proBNP, ng/La 605 (219–1641) ,0.001
aMedian (25th–75th percentile).
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according to LVH were tested using 
the chi-square and Mann–Whitney U 
tests where appropriate. 
 
We examined the association of 
LVH status and 30 day PCI and then 
adjusted for other baseline 
characteristics using multivariable 
logistic regression (using stepwise 
selection). Baseline characteristics 
were considered if its univariable 
association with 30 day PCI had a P-
value < 0.25, and the final set of 
covariates included age, gender, 
histories of angina, MI, CHF, PCI 
and CABG, heart rate, troponin T 
(quartiles), and NT-proBNP 
(quartiles). Interactions among age, 
gender, and creatinine clearance 
were tested but did not achieve 
statistical significance. 
 
The association between LVH and 
clinical outcomes was examined 
using Kaplan–Meier estimates and 
multivariable Cox proportional 
hazard regression (using stepwise 
selection). In addition to LVH, other 
covariates predicting 1 year mortality 
included age, diabetes, histories of 
CHF and MI, current smoker, heart 
rate, ST-depression (none, 0.5 mm, 
1–1.5 mm, 2 mm), creatinine 
clearance (quartiles: 25th, 59.2; 
50th, 77.8; 75th, 99.1 mL/min), NT-
proBNP (quartiles: 25th, 230.5; 50th, 
643.7; 75th, 1763 ng/L), and 
troponin T (quartiles: 25th, 0.01; 
50th, 0.111; 75th, 0.452 μg/L).13 
Interactions among age, gender, and 
creatinine clearance did not achieve 
statistical significance. The likelihood 
of PCI within 30 days (quintiles) and 
plausible interaction terms with LVH 
were also tested (i.e. gender and 
NT-proBNP). The resulting 
discriminatory power (adjusted for 
over-optimism via bootstrapping) 
was a c-index of 0.805 and an over-
optimism factor of 0.01. All tests 
were two-tailed, and the 
conventional level of statistical 
significance (i.e. P < 0.05) was used. 
 
RESULTS 
Patient characteristics 
Of the 7443 patients with available 
baseline ECG data, LVH was 
diagnosed in 586 patients [7.9%, 
95% confidence interval (CI): 7.3–
8.5]. As shown in Table 1, patients 
with LVH were more often female 
and older than those without LVH. 
They were also more likely to have 
Figure 1 Rates of 7 day and 30 day invasive procedures [i.e. cardiac catheterization (Cath), percutaneous coronary intervention (PCI), coronary artery bypass
graft (CABG), and revascularization (Revasc)] according to left ventricular hypertrophy status.
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hypertension, diabetes mellitus, and 
a history of cardiovascular diseases 
including angina pectoris, MI, heart 
failure, and stroke, but less likely to 
be a current smoker. The use of 
medications such as ACE-inhibitors 
and calcium channel blockers within 
1 week prior to randomization was 
higher in LVH patients, a pattern 
which continued during the index 
hospitalization. 
 
Although LVH patients were less 
likely to present with MI and to have 
positive quantitative or qualitative 
troponin I or T, they were more likely 
to have at least 0.5 mm of ST-
segment depression, the second 
entry criterion of the GUSTO IV ACS 
trial, than those patients without 
LVH. This pattern was particularly 
evident in women with LVH (relative 
to those without LVH) (data not 
shown). Median heart rate was 
significantly higher in LVH patients, 
whereas renal function as indicated 
by creatinine clearance was 
significantly lower in LVH patients 
Figure 2 (A) Cumulative rates of mortality over 1 year according to left ven-
tricular hypertrophy status. (B) Cumulative rates of mortality over 1 year
according to left ventricular hypertrophy status and gender. Women with
left ventricular hypertrophy had significantly higher rates of 1 year mortality
relative to men with left ventricular hypertrophy (P-log rank ¼ 0.008) and
men and women without left ventricular hypertrophy (P-log rank , 0.001,
respectively).
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than in those without. Median values 
of C-reactive protein and NT-
proBNP assessed in core 
laboratories were also significantly 
higher in LVH patients. 
 
Invasive procedures 
According to the trial protocol, 
cardiac catheterization was 
discouraged during or within 12 h 
following the completion of the study 
drug infusion, and patients with PCI 
or CABG planned within 30 days of 
randomization were excluded from 
the trial. Overall, cardiac 
catheterization occurred in 22.5% of 
patients within the first 7 days and in 
37.0% by day 30. In both the short 
and long term, patients with LVH 
underwent fewer catheterizations 
than those without LVH [7 days: 
23.0% (no LVH) vs. 16.4% (LVH), P 
< 0.001; 30 days: 37.6 vs. 30.9%, P 
= 0.001] (Figure 1). Similarly, LVH 
patients were less likely to undergo 
PCI [7 days: 11.3% (no LVH) vs. 
4.8% (LVH), P < 0.001; 30 days: 
20.1 vs. 11.9%, P < 0.001]. The 
likelihood of PCI within 30 days was 
associated with LVH [adjusted odds 
ratio (OR): 0.78, 95% CI 0.57–0.98, 
P = 0.035]. Rates of CABG, 
however, were not statistically 
different [7 days: 3.2% (no LVH) vs. 
2.4% (LVH), P = 0.28; 30 days: 11.3 
vs. 9.9%, P = 0.31]. 
 
Clinical outcomes 
Rates of 30 day MI and death/MI 
were similar regardless of LVH [30 
day MI: 5.4% (no LVH) vs. 5.1% 
(LVH), P = 0.92; 30 day death/MI: 
8.0% (no LVH) vs. 8.0% (LVH), P = 
0.94]. Mortality, however, was 
significantly higher in LVH patients; 
31% higher in LVH patients at 30 
days and there was a two-fold 
increase at 1 year (Figure 2A). And 
higher rates of 1-year mortality were 
particularly evident in women with 
LVH (Figure 2B). After adjustment 
for various baseline characteristics 
and propensity for PCI, LVH did not 
remain a significant predictor of 30-
day death or 1-year mortality [30-day 
mortality: adjusted hazard ratio (HR): 
0.84 (0.56–1.26), P = 0.40; 1-year 
mortality: adjusted HR: 1.22 (0.95–
1.56), P = 0.119]. However, a 
significant interaction between 
gender and LVH was observed such 
that LVH remained strongly 
associated with increased long-term 
mortality in women, but not in men 
Figure 3 Adjusted hazard ratios (95% confidence interval) for left ventricular hypertrophy and N-terminal pro-brain naturetic peptide in the prediction of 1 year
mortality in women (left panel) and men (right panel). , baseline-adjusted hazard ratios.
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(P-interaction = 0.033). Women with 
LVH had a more than 40% increase 
compared with those without LVH 
[adjusted HR: 1.42 (1.04–1.94), P = 
0.029] (Figure 3). Notably, NT-
proBNP was independently 
associated with 1-year mortality in 
both genders. 
 
DISCUSSION 
Traditionally, LVH has not been 
considered in the list of established 
risk factors in ACS patients.14–17 A 
unique opportunity to examine this 
was possible through the 
assessment of LVH on the 
admission ECG in the GUSTO IV 
ACS trial. In terms of invasive 
treatment, we found that patients 
with LVH were less likely to undergo 
invasive procedures such as cardiac 
catheterization and PCI within the 
first week and through to 30 days. 
LVH was also associated with an 
increased risk of 1-year mortality, 
particularly in women, and notably, 
was independent of NT-proBNP. 
 
Comparisons with other studies 
Treatment following an acute 
coronary event in LVH patients has 
not been well studied. Similar to our 
study, however, East et al.6 showed 
in a cohort of CAD patients 
undergoing catheterization that 
patients with LVH subsequently 
underwent fewer PCI and CABG 
procedures. Whether there are 
opportunities to enhance outcomes 
of such patients through the 
utilization of these procedures or 
other strategies such as more 
intensive secondary preventative 
pharmacotherapy is unclear. In our 
study, an increased likelihood for 
PCI within 30 days of the initial acute 
event translated into improved 
survival in the first year, independent 
of LVH, which would suggest that 
increased use of PCI in those with 
co-existent epicardial coronary 
disease may also improve their 
outcomes. 
 
In contrast to its association with 
invasive therapy, the prognostic 
implications of LVH to the general 
population have received more 
attention. LVH was among the most 
significant predictors of 
cardiovascular morbidity and 
mortality in the general population, 
as demonstrated by the Framingham 
Heart Study.18 Not surprisingly, 
clinical trials of left ventricular 
dysfunction, hypertension, and heart 
failure patients also point to LVH as 
prominent contributor to adverse 
outcomes in long-term follow-up.5 To 
a lesser extent, the prognostic value 
of LVH has been recognized in CAD 
patients.6,19,20 For instance, East et 
al.s study demonstrated that 
echocardiographic LVH was a 
significant predictor of long-term 
mortality after adjustment for other 
baseline characteristics. There is a 
dearth, however, in our 
understanding of the role of LVH in 
NSTE-ACS patients who do not 
undergo invasive study. 
 
From the few studies conducted in 
ACS patients, the presence of LVH 
appears to confer significant risk of 
short- and long-term mortality. For 
instance, in angina patients 
presenting to the emergency 
department, a nearly seven-fold 
unadjusted relative risk of death 
within the first 48 h was observed in 
those with LVH.4 And in a cohort 
 64 
study of 4720 consecutive AMI 
patients treated in the coronary care 
unit in the early 1980s, the 1 year 
mortality rate was 19.7% in patients 
with LVH vs. 8.7% in those without 
(adjusted OR: 1.51, 95% CI 1.09–
2.10).3 
 
Elevation of brain natriuretic 
peptides, including NT-proBNP, is 
commonly observed in patients with 
heart failure, left ventricular 
dysfunction, and LVH.21,22 More 
recently, through our own work and 
others, the value of this biomarker 
has also been recognized in ACS 
patients.11,23,24 The novelty of the 
current study is the opportunity to 
examine the association between 
systematically collected NT-proBNP 
and ECG-diagnosed LVH in NSTE-
ACS patients. It seems likely that 
neurohormonal elevation provides 
additional indication of left 
ventricular overload and/or stretch, 
thereby signalling worse future 
outcomes in both men and women. 
 
Further interrogation of our findings, 
however, revealed a major and 
heretofore unreported difference in 
the role of gender, as it relates to the 
prognostic value of LVH in NSTE-
ACS. Several studies of CAD-free 
populations have observed that 
women have a substantially higher 
prevalence of LVH and poorer 
prognosis than men.18,20,25 These 
findings were confirmed in our study 
of ACS patients, with women 
constituting 38% of the overall 
GUSTO IV ACS population, yet over 
70% of LVH patients. These women 
had a 1-year mortality more than 
twice that of men with LVH [16.7% 
(women) vs. 7.7% (men), P = 0.006]. 
The underlying nature of their 
cardiac disease may help to explain, 
in part, this difference. Coronary 
perfusion and reserve are 
compromised in LVH patients, even 
in those with normal coronary 
arteries, owing to impaired dilation 
capacity as a result of structural 
changes and increased extrinsic 
coronary resistance.26,27 Women, in 
particular, tend to have greater 
increases in wall thickness and 
poorer dilation of the LV cavity, 
which compromises the ability to 
withstand wall stress and 
ischaemia.28 Conversely, the 
response to wall stress in men is not 
manifested in wall thickening or loss 
of dilation. The condition may be 
further exacerbated in women who 
have a higher likelihood for 
microvascular disease and normal 
coronary arteries, as previously 
suggested.7,29,30 Angiographic 
confirmation of microcirculatory 
disease in these female patients with 
LVH and elevated NT-proBNP in 
GUSTO IV ACS may have provided 
further insight into this issue. 
 
The current study also highlights that 
LVH was more prevalent in older 
patients. Data from the Framingham 
population and other studies have 
indicated that LV mass increased 
with age only in women,31 whereas 
more recent data from Olivetti et al.32 
suggested that with ageing, LV mass 
was preserved in women, but not in 
men. In particular, their work showed 
that as men aged, the number of 
ventricular cardiac myocytes and the 
proportion of mononucleated and 
binucleated cells decreased and the 
size of myocytes increased. 
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Limitations 
Some limitations of our study should 
be noted. First, the ECG was used in 
the current study to diagnose LVH, a 
method that has some inherent 
weaknesses. While the ECG is often 
used in large-scale screening 
programmes, it has established 
lower sensitive than 
echocardiography, a higher standard 
of LV mass detection.33 Several 
validation studies have calculated 
the sensitivity of echocardiography 
to be in the range of 85–100%, 
whereas the sensitivity of ECG 
reached as high as 50% in high-risk 
cardiovascular disease patient 
populations and as low as 6–17% in 
population-based studies. The costs 
and feasibility associated with the 
performance of echocardiography, 
however, make it an impractical 
option compared with the ECG, 
which is a simple, universally 
available test at the point of patient 
entry. Although echocardiography 
might have further complemented 
our findings, we believe that the 
choice to use the gender-specific 
Cornell voltage criteria and strain 
patterns was well founded, as it has 
been shown to outperform other 
ECG criteria such as Sokolow–Lyon 
voltage and Romhilt–Estes point 
score.34 
 
Additional refinement of our results 
may have been possible through 
patient attributes such as height (for 
body-surface area adjustment) and 
systolic blood pressure, which were 
not available in GUSTO IV ACS. 
 
A final limitation relates to the usual 
issue of generalizability of these 
findings to the global ACS 
population. Although patients with 
ST-depression related to pre-
existing disorders such as LVH were 
to be excluded from the GUSTO IV 
ACS trial, nearly 8% of enrolled 
patients were diagnosed with LVH 
on the admission ECG. Since the 
frequency of LVH in the overall 
general population is likely greater, 
our findings deserve exploration in 
broader patient groups. 
 
CONCLUSION 
This study highlights the important 
association of LVH and long-term 
prognosis in the ACS patient 
population. These novel findings 
should encourage careful 
assessment of LVH in ACS patients, 
particularly in females. Investigators 
should also consider this issue when 
designing future trials and 
interrogating population-based 
registries. 
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Chapter Five 
No prognostic significance of chronic 
infection with Chlamydia pneumoniae in 
acute coronary syndromes: Insights from 
the Global Utilization of Strategies to Open 
Occluded Arteries IV Acute Coronary 
Syndromes trial 
Cynthia M. Westerhout, Judy Gnarpe, Wei-Ching Chang, 
Susan FitzPatrick, Elliot S. Barnathan, Eric Boersma, 
Robert M. Califf, Lars Wallentin, Maarten L. Simoons, and 
Paul W. Armstrong, on behalf of the GUSTO IV ACS 
Investigators 
 
BACKGROUND Although relationships between chronic Chlamydia pneumoniae (Cpn) infection 
and the risk of coronary events in stable coronary artery disease patients have been reported, a 
similar link in acute coronary syndrome (ACS) patients has not been consistently observed. 
METHODS In a nested case-control substudy of the Global Utilization of Strategies to Open 
Occluded Arteries IV Acute Coronary Syndromes trial, 295 cases (30-day death/myocardial 
infarction [MI]) were matched by age, sex, baseline creatine kinase–myocardial kinase, and 
smoking status with 295 control subjects. To test the hypothesis on 1-year mortality, another 
subset (n = 276) was drawn from the 590-patient cohort; 138 patients who died at 1 year plus 
the matching controls who survived at 1 year. We measured Cpn IgG and IgA antibody titers in 
baseline serum with microimmunofluorescence. Conditional logistic regression was used to 
quantify the prognostic relevance seropositivity (IgG 1:32; IgA 1:16) and elevated titer levels. 
RESULTS The prevalence of Cpn IgG and IgA was similar between cases and controls (30-day 
death/MI: IgG, 80% vs 85%, P = 0.126; IgA, 45% vs 37%, P = 0.079), and were not statistically 
significant predictors of 30-day death/MI after baseline adjustment. Likewise, the 1-year death 
cohort had comparable proportions of Cpn IgG and IgA among cases and controls (86% vs 91% 
[ P = 0.265] and 49% vs 43% [ P = 0.334], respectively), and did not add prognostic value. 
CONCLUSIONS These findings are in concert with study results suggesting that chronic Cpn 
infection is not associated with 30-day death/MI or 1-year mortality in non-ST elevation ACS.  
Inflammation has emerged as a key 
contributor to our understanding of 
the pathophysiology of coronary 
artery disease. C-reactive protein 
(CRP), for instance, has been 
consistently associated with poor 
outcomes in patients with acute 
coronary syndromes (ACS), 
particularly during long-term follow-
up.1-3 Other indicators of 
inflammation including antibodies of 
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Chlamydia pneumoniae (Cpn) have 
received less attention than CRP, 
but have also been linked to 
increased risk of events either by 
initiating or contributing to plaque 
formation and destabilization. 
 
Infectious particles of Cpn, a 
common bacterial pathogen known 
to cause upper and lower respiratory 
tract infections, are frequently found 
in atherosclerotic plaques but not in 
healthy arterial tissues, unlike other 
organisms such as cytomegalovirus, 
which has been found in both.4,5 
Hence, Cpn could play a role in the 
induction and/or progression of 
atherosclerosis and in the 
destabilization of plaque leading to 
thrombosis. If this were the case, the 
infective status of such patients 
could prove valuable for risk 
stratification and subsequent 
medical decision-making. 
 
To investigate this issue, a nested 
case-control substudy was 
conducted in 590 of the 7800 non-
ST-elevation ACS patients enrolled 
in the Global Utilization of Strategies 
to Open Occluded Arteries IV Acute 
Coronary Syndromes trial.6 
Associations between Cpn and 
adverse outcomes at 30 days and 1 
year were examined taking into 
account CRP and other baseline 
patient characteristics. 
 
METHODS 
Study design and subjects 
Of the 7800 patients enrolled in the 
Global Utilization of Strategies to 
Open Occluded Arteries IV Acute 
Coronary Syndromes trial, 590 were 
selected for this nested case-control 
substudy (Figure 1). The details of 
this trial have been previously 
outlined, but briefly, this multicenter 
randomized clinical trial enrolled 
ACS patients presenting with either 
ST segment depression on the 
admission electrocardiogram or 
elevated levels of troponin I or T, 
and tested the efficacy of abciximab 
(bolus with 24- vs 48-hour infusion) 
compared to a placebo.6 The 
primary end point of the trial was a 
composite of death or myocardial 
infarction (MI) within 30 days of 
randomization, which was observed 
in 8.4% of 7800 patients. Death at 1 
year was a secondary end point and 
occurred in 8.3% of 7800 patients.7 
 
Selection of cases and controls 
A sample of 295 patients was 
chosen at random from the group of 
patients who had a primary event 
(i.e., died or had an acute MI within 
30 days of randomization). These 
cases were matched by 
conventional risk factors including; 
age (±5 years), sex, smoking status 
and baseline creatine kinase–
myocardial kinase (CK-MB) >2x 
upper limit of normal with patients 
who were free of these adverse 
events at 30 days (controls).8 The 
sample size was chosen to afford 
96% power to detect an odds ratio 
(OR) of 2.0 with a correlation 
between cases and controls of 0.20, 
a of 5%, and probability of exposure 
of 50%. 
A secondary analysis was 
preformed to examine the 
association between Cpn and 1-year 
mortality given the emerging 
evidence supporting the long-term 
prognostic value of inflammatory 
markers. Thus, a subset of the 
original case-control study was 
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identified (n = 276): 138 patients 
who died within 1 year and their 
previously matched partner (Figure 
1). Based on our prior assumptions, 
this substudy had 71% power to 
detect an OR of 2.0 with a 
correlation between cases and 
controls of 0.20, a of 5%, and 
probability of exposure of 50%. 
 
Blood sample collection and 
laboratory testing 
Serologic analysis of humoral IgG 
and IgA Cpn antibodies was 
performed in the Department of 
Medical Microbiology at the 
University of Alberta in Edmonton, 
Canada, according to previously 
described methods.9 Plasma 
samples were diluted 1:16 with 
phosphate-buffered saline (PBS; pH 
7.4) (Sigma, St Louis, MO), then 
serially diluted with doubling 
dilutions in PBS (pH 7.4). For IgG 
determinations, a 1:32 dilution was 
used for screening, and for IgA a 
1:16 dilution. Specimens found to be 
positive for IgG in the screening test 
were rediluted in PBS and tested up 
to a titer of 1:8192. Specimens that 
were positive for IgA in screening 
tests were rediluted to a titer of 1:16 
using Gullsorb (Gull Laboratories, 
Salt Lake City, UT) to remove 
possible interference from IgG, and 
then serially diluted to a maximum 
titer of 1:4096 with PBS. All plasma 
dilutions were incubated on the 21-
well antigen slides (Thermobio, 
Helsinki) for 16 hours at +4•C, then 
washed 3 times for 5 minutes in PBS 
to remove excess plasma before 
adding the rabbit antihuman 
fluorescein isothiocyanate 
conjugated IgG or IgA. Further 
incubation was done for 30 minutes 
at 37•C, the washing procedure was 
repeated and the slides finally 
mounted with buffered glycerol and 
read using a UV microscope at a 
Figure 1
Nested case-control study design.
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total magnification of 500X). The 
highest dilution, or titer, giving a 
homogenous positive reaction with 
the Chlamydia elementary body 
antigen was recorded. The 
investigator was unaware of 
case/control status during the 
analysis. 
 
C-reactive protein and troponin T 
were centrally analyzed by the 
Department of Clinical Chemistry at 
the University of Uppsala in 
Uppsala, Sweden as mandated by 
the trial protocol. Detailed analytical 
techniques have been previously 
published.3 
 
Statistical analysis 
Frequencies are presented as 
percentages for categorical data, 
and the median and 25th and 75th 
percentiles presented for continuous 
data. Chi-square and Wilcoxon rank 
sum tests were applied, as 
appropriate. Univariable and 
multivariable associations between 
baseline patient characteristics and 
30-day death/MI were evaluated with 
conditional logistic regression 
analysis. Baseline characteristics 
that had a moderate statistical 
association with the outcome (i.e., P 
<0.25) or were clinically plausible 
were considered in development of 
the final multivariable model. For 
example, hypertension, diabetes, 
hyperlipidemia, histories of angina, 
MI, congestive heart failure (CHF) or 
percutaneous coronary intervention 
(PCI), ST-segment depression 0.5 
mm, quartiles of troponin T, quartiles 
of CRP, and Cpn seropositivity were 
considered in the full model for 30-
day death/MI; however, after 
backward, stepwise selection, 
history of MI, history of PCI, CRP, 
and ST-segment depression 0.5 
Table I. Baseline characteristics of matched case-control population (n = 590), where a case represents a death or MI within 30 days
Control (%) Case (%) P
n 295 295
Age (y)4 71 (64-76) 71 (64-76) 1.000
Women4 34.9 34.9 1.000
Whites 97.6 96.3 .474
Body weight (kg) 75 (67-84) 75 (65-85) .943
Region of enrolment .211
Western Europe 48.5 46.8
Eastern Europe 32.2 31.5
North America 11.9 16.9
Othery 7.5 4.7
Hypertension 52.2 62.0 .020
Diabetes mellitus 25.1 29.8 .230
Hyperlipidemia requiring therapy 27.8 38.0 .011
Current smoker4 18.8 18.8 1.000
History of PCI 12.9 9.8 .299
History of CABG 8.8 9.8 .777
History of angina pectoris 53.9 57.6 .407
History of MI 38.6 47.1 .046
History of heart failure 10.8 13.9 .317
History of stroke 4.1 6.8 .203
Prior aspirin use (7 d before randomization) 77.3 75.6 .698
Aspirin use within 48 h of randomization 89.8 85.1 .106
MI diagnosis on enrollment 30.2 32.5 .594
ST segment depression z0.5 mm 76.3 85.1 .009
CK-MB N2 ULN4 31.5 31.5 1.000
Troponin T (lg/L) 0.17 (0.01-0.57) 0.21 (0.06-0.59) .045
CRP (mg/L) 3.49 (1.57-8.94) 4.34 (2.00-14.1) .042
Cpn IgG z1:32 85.4 80.3 .126
Cpn IgA z1:16 37.3 44.7 .079
Data are presented in percentages and median (25th, 75th percentile). CABG, Coronary artery bypass graft.
4Controls were matched with cases on these factors.
yOther: Australia, New Zealand, Israel, South Africa.
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mm remained in the final model. Cpn 
seropositivity was forced into the 
model to calculate adjusted 
estimates. 
 
These analyses were then repeated 
for the associations with 1-year 
death in a subset of patients. 
Diabetes mellitus, history of CHF, 
ST depression 0.5 mm, and CRP 
remained as significantly associated 
with 1-year mortality, and Cpn 
seropositivity was forced into the 
model to calculate adjusted 
estimates. 
 
RESULTS 
Baseline patient characteristics are 
presented in Table I. The median 
age of the 590 patients included in 
this nested case-control study was 
71 years (25th-75th percentile: 64-76). 
Nearly 35% of the patients in this 
study were women, and 23.4% were 
smokers at the time of enrolment. 
 
 
 
Case-control study 1: 30-day 
death or MI 
Baseline characteristic among cases 
and controls are presented in Table 
I. Cases had higher rates of 
hypertension, history of 
hyperlipidemia requiring therapy, 
prior MI and ST depression 0.5 mm 
on the baseline electrocardiogram. 
Cases also had higher median 
troponin T (P = 0.045) and CRP (P = 
0.042). IgA seropositivity (1:16) 
tended to be higher in cases than 
controls ( P = 0.079); however, IgG 
was comparable (P = .126) (Table I). 
After adjustment for previous MI, 
prior PCI and ST depression 0.5 
mm, seropositive IgG was not a 
statistically significant predictor of 
30-day death/MI (P = 0.126). 
However, there was a marginal 
association with seropositive IgA 
(adjusted OR 1.42, 95% confidence 
interval [CI] 0.97-2.07, P = 0.074) 
(Figure 2). Elevated levels of the 
antibodies were also examined; 
however, none were significantly 
associated with 30-day death/MI. 
Figure 2
Adjusted OR and 95% CI for Cpn seropositivity (IgG z1:32 or IgA
z1:16) predicting 30-day death/MI. IgG and IgA were adjusted for
history of MI, history of PCI, and ST depression z 0.5 mm.
 74 
Case-control study 2: 1-year 
death 
In a secondary case-control study, 
138 patients who died within 1 year 
(case) and their matched pair 
(control) were selected from the 
aforementioned cohort (Figure 1). 
The median age of patients was 75 
years, and 37% of the 276 patients 
were women (Table II). Cases and 
controls were reasonably matched 
on baseline characteristics; although 
patients were more likely to be 
diabetic, and had histories of angina, 
MI, and CHF, and ST depression 
0.5 mm than those who survived 
through to 1 year (Table II). Median 
CRP was higher in cases than in 
controls; there was no significant 
difference in the prevalence of 
seropositive Cpn (IgG, P = 0.205; 
IgA, P = 0.334) or elevated titer 
levels (data not shown). 
 
One-year mortality was not 
associated with Cpn seropositivity, 
even after adjustment with diabetes, 
history of CHF, ST depression 0.5 
mm, and CRP (Figure 3). However, 
patients with elevated Cpn IgG 
(1:256) titer tended to have a 
nearly 2-fold risk of 1-year death 
(adjusted OR: 1.7 (0.9-3.24), P = 
0.107). 
 
DISCUSSION 
The infectious burden of Cpn in our 
study was high in the overall patient 
group: 82.9% with IgG 1:32 and 
41.0% with IgA 1:16, which is 
comparable to healthy, elderly 
individuals.10 Cpn IgA is known to 
have a short half-life in serum in the 
absence of a continued antigenic 
stimulus, and continual, elevated 
levels are indicative of an ongoing or 
Table II. Baseline characteristics of matched case-control population (n = 276), where a case represents a patient who died within 1 year
after randomization
Control (%) Case (%) P
n 138 138
Age (y)4 75 (69-78) 75 (69-78) 1.000
Women4 37.0 37.0 1.000
Whites 97.8 95.7 .337
Body weight (kg) 74 (66-82.3) 73 (63.8-83.3) .401
Region of enrolment .388
Western Europe 44.9 47.1
Eastern Europe 34.1 36.2
North America 12.3 13.0
Othery 8.7 3.6
Hypertension 56.5 64.5 .218
Diabetes mellitus 24.6 39.9 .010
Hyperlipidemia requiring therapy 29.0 37.7 .160
Current smoker4 15.9 15.9 1.000
History of PCI 12.3 6.5 .148
History of CABG 9.4 11.6 .695
History of angina pectoris 53.6 69.6 .009
History of MI 40.6 56.5 .011
History of heart failure 11.6 23.2 .017
History of stroke 4.3 8.0 .317
Prior aspirin use (7 d before randomization) 74.6 76.8 .779
Aspirin use within 48 h of randomization 86.2 86.2 1.000
MI diagnosis on enrollment 35.5 36.2 1.000
ST-segment depression z0.5 mm 71.7 89.9 b.001
CK-MB N2 ULN4 35.5 35.5 1.000
Troponin T (lg/L) 0.20 (0.05-0.76) 0.29 (0.07-0.83) .255
CRP (mg/L) 4.01 (1.54-9.86) 6.25 (2.40-25.6) .004
Cpn IgG z1:32 90.6 85.5 .265
Cpn IgA z1:16 42.8 49.3 .334
Data are presented in percentages and median (25th, 75th percentile).
4Controls were matched with cases on these factors.
yOther: Australia, New Zealand, Israel, South Africa.
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chronic infection. Sustained high 
levels of IgG can also be a reflection 
of chronic infection, but it is not 
uncommon to find high titers of IgG 
in serum several years after a 
resolved infection. 
 
Although the pathogenic 
mechanisms responsible for 
atherosclerotic rupture are not fully 
understood, ongoing inflammation is 
thought to be 1 of the major 
contributors to these clinical events 
and the infectious agent most often 
implicated in atherosclerosis is Cpn. 
Our study, however, did not uncover 
strong links between Cpn and 
subsequent adverse events in non-
ST-elevation-ACS patients. Despite 
the signals, Cpn seropositivity did 
not have statistically significant 
prognostic value in the short term 
(i.e., 30-day death/MI) or long term 
(i.e., 1-year death). Overall, the body 
of evidence in this area is 
heterogeneous. Numerous studies in 
women and men alike have found 
little to suggest that this infectious 
agent is a contributor to adverse 
coronary outcomes,11-13 whereas 
others have found the opposite.14-18 
Based on the suggestion that 
chronic infection is a contributor to 
poor cardiac outcomes, several 
large-scale clinical trials tested 
antibiotic therapy for the secondary 
prevention of coronary heart 
disease.15,19-25 Unexpectedly, no 
clinical improvement was observed 
and as a result, 3 diverging 
conclusions may be drawn: (1) Cpn 
does not have a role in the 
progression of atherosclerotic 
disease; (2) the effects of Cpn 
infection are irreversible and have 
already occurred at an earlier stage; 
(3) Cpn in lymphocytes and 
monocytes are refractory to 
antibiotics.26 There are, however, 
some notable caveats in these trials 
that are worth mentioning. The 
selection of patient groups receiving 
Figure 3
Adjusted OR and 95% CI for Cpn seropositivity (IgG z1:32 or IgA
z1:16) predicting 1-year mortality. IgG z1:32, IgG z1:256, and
IgA z1:16 were adjusted for diabetes mellitus, history of CHF, ST
depression z0.5 mm, and CRP.
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antibiotics for putative Cpn infection 
were in most cases suboptimal and 
in some of the trials not performed at 
all, which raises some questions 
about the validity of many of these 
trials.27 Improved criteria are needed 
to identify patients who may benefit 
from antimicrobial therapy. 
 
Of note is the possible influence of 
aspirin on Cpn infection. Previous 
studies have shown aspirin to inhibit 
the growth of Cpn, which results in 
the inhibition of nuclear factor-nB 
activation and the release of the 
cytokines IL-6 and IL-8.28 In our 
study, however, Cpn seropositivity 
was similar regardless of prior 
aspirin use (1 week before 
randomization: IgA 45% [no aspirin] 
vs 38% [aspirin use], P = 0.22; IgG 
83% vs 82%, P = 1.00) or protocol-
mandated use (within 48 hours of 
randomization: IgA 41% vs 39%, P = 
0.81; IgG 77% vs 82%, P = 0.52).29 
And although there is little evidence 
that aspirin decreases CRP values 
directly, aspirin does lead to a 
decrease in the amount of 
inflammation and IL-6, which will 
inevitably lead to a decrease in CRP 
production by hepatocytes. Aspirin 
has been shown to be most effective 
in individuals who have CRP levels 
in the upper quartiles.30 
 
Limitations 
Four limitations of the current study 
should be noted. First, transient 
rises in antibody titers, which would 
verify an active infection, between 
paired specimens may have 
occurred, but could not be detected. 
However, it is very unlikely that 
many of the patients included would 
have an acute reinfection and 
transient high levels of Cpn IgA 
antibodies. 
 
Second, the timing of Cpn infection 
could have influenced our findings. A 
nested case-control study on 600 
male US military personnel 
demonstrated that the risk of AMI 
was significantly associated with 
high titers of Cpn IgA (1:64), and an 
increased risk was particularly 
evident in specimens collected 1 to 5 
years before the AMI event.16 
Unfortunately, this level of data was 
not available in the current study. 
 
The design of this study also has 
characteristic shortcomings. Case-
control studies are generally not 
considered as the best sources of 
definitive scientific evidence. 
However, case-control studies 
nested within a large, contemporary 
trial provides cost-effective 
opportunities for investigations such 
as this. At the time of study design, 
only data on 30-day events were 
available. A subset of the original 
case-control population was 
selected later on when 1-year 
mortality data were available, along 
with emerging evidence of 
inflammations association with long-
term adverse events. Hence, there 
may be concerns with the statistical 
power of the secondary case-control 
study. 
 
And finally, the associations 
between Cpn seropositivity and 
outcomes were difficult to interpret 
given the borderline P values. 
Although there was some 
suggestion that Cpn seropositivity 
(i.e., IgA 1:16 or IgG 1:256) was 
associated with poor outcomes, the 
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95% CI crossed the line of unity. We 
also considered our findings in the 
context of other studies and design 
challenges of this study, and as such 
we concluded that the evidence for 
an association between Cpn 
seropositivity and outcomes was not 
overwhelming. 
 
Future considerations 
Additional infectious parameters to 
capture the “total pathogen burden” 
should be considered in the future. 
Other infectious agents may include 
cytomegalovirus, hepatitis A virus, 
herpes simplex virus type 1, herpes 
simplex virus type 2, and 
Helicobacter pylori. In 2000, Zhu and 
colleagues31 demonstrated that the 
total pathogen burden was 
significantly associated with CRP 
levels in 890 coronary artery disease 
patients. These same investigators 
were also successful in showing that 
an increasing pathogen burden was 
significantly associated with 
increasing risk of MI or death and 
was consistent among various CRP 
levels.32 The investigators concluded 
that infection plays an important role 
in the risk of adverse coronary 
events and that the risk posed by 
infection is independently related to 
the pathogen burden. 
 
CONCLUSIONS 
Our study did not provide conclusive 
evidence for the prognostic role of 
Cpn infection in this cohort of ACS 
patients. This does not disprove the 
theory that Cpn contributes to 
cardiovascular disease, but may 
explain why antibiotic treatment of 
Cpn is not effective in advanced 
stages of the disease. 
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Chapter Six 
 
Predictors of stroke within 30 days in 
patients with non-ST-segment elevation 
acute coronary syndromes 
Cynthia M. Westerhout, Adrian V. Hernandez, Ewout W. 
Steyerberg, Hector Bueno, Harvey White, Pierre Theroux, 
David J. Moliterno, Paul W. Armstrong, Robert M. Califf, 
Lars C. Wallentin, Maarten L. Simoons, and Eric Boersma 
 
AIMS Stroke is an uncommon but serious complication after non-ST-segment elevation acute 
coronary syndrome (NSTE-ACS). We aimed to identify predictors of stroke within 30 days in 
patients who suffered NSTE-ACS. 
METHODS AND RESULTS We pooled data from six trials (n = 31 402) that randomized NSTE-
ACS patients either to platelet glycoprotein (GP) IIb/IIIa receptor blockers or to placebo/control 
therapy. Potential predictors of stroke included treatment, demographic, and clinical 
characteristics. We identified predictors using univariable and multivariable logistic models, and 
their performance was evaluated with calibration (Hosmer–Lemeshow test) and discrimination 
(c-statistic). We found 228 (0.7%) all-cause strokes: 155 (0.5%) non-haemorrhagic, 20 (0.06%) 
haemorrhagic, and 53 without computed tomography (CT) confirmation. Patients with any type 
of stroke had a 30-day mortality of 25%. Randomization to GP IIb/IIIa receptor blockers was not 
significantly associated with all-cause stroke [OR (95% CI) 1.08 (0.83–1.41)]. Older age [OR per 
10-year increase 1.5 (1.3–1.7)], prior stroke [2.1 (1.4–3.1)], and elevated heart rate [per 10-beat 
increase 1.1 (1.0–1.2)] were the strongest predictors of 30-day all-cause stroke. Similar 
predictors were found for non-haemorrhagic and haemorrhagic strokes. Smoking, previous 
myocardial infarction, diabetes, and hypertension were not independent predictors of all-cause 
stroke. The multivariable model to predict all-cause stroke was well calibrated, but its 
discrimination was only moderate [c-statistic 0.69 (0.65–0.72)]. 
CONCLUSION Stroke is a rare complication occurring early after NSTE-ACS, but is associated 
with high mortality. We found no evidence that GP IIb/IIIa receptor blockers increase stroke 
risks. A few clinical characteristics predicted higher stroke risks. Thus, incident strokes in NSTE-
ACS patients remain largely unexplained.  
Non-ST-segment elevation acute 
coronary syndrome (NSTE-ACS) is 
a heterogeneous disease. Risk 
stratification is essential for 
predicting prognosis, planning 
treatment strategy, and providing 
information to patients and relatives. 
1,2 Previous papers in patients with 
NSTE-ACS have evaluated the 
predictors associated with a range of 
clinical outcomes at 30 days or 6 
months, such as death, 
cardiovascular death, and 
cardiovascular death or myocardial 
infarction (MI).2–5 
 
Stroke is an uncommon but severe 
event in patients presenting with 
NSTE-ACS. Analyses with a few 
events in the PURSUIT trial found 
several clinical predictors of non-
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haemorrhagic stroke at 30 days.6 
These patients are also at increased 
risk for haemorrhagic strokes from 
polypharmacy anticoagulation. 
However, the confirmation of the 
importance of these predictors of 
stroke with a larger number of 
patients and events is desirable. 
 
We aimed to identify the baseline 
clinical and demographic patient 
characteristics that predict the 
development of all-cause, non-
haemorrhagic, and haemorrhagic 
strokes within 30 days. We analysed 
patients with NSTE-ACS from six 
large international trials. Moreover, 
we evaluated whether the use of GP 
IIb/IIIa receptor blockers was 
associated with an increased risk of 
stroke. 
 
METHODS 
Clinical trials 
We used individual patient data from 
six trials (PRISM, PRISM-PLUS, 
PARAGON-A, PURSUIT, 
PARAGON-B, and GUSTO IV-
ACS).7–12 These trials were reported 
since 1990 with the following 
characteristics: randomization of 
patients with NSTE-ACS, 
comparison of platelet glycoprotein 
(GP) IIb/IIIa receptor blockers with 
placebo or control therapy, no-
recommendation for early (<48 h) 
coronary revascularization during 
study-drug infusion, and enrolment 
of at least 1000 patients. Heparin 
was usually begun with 5000 IU and 
then followed with 1000 IU/h. 
Heparin was part of the study 
regimen in the PRISM, PRISM-
PLUS, and PARAGON-A trials and 
was given to all patients in the 
PURSUIT, PARAGON-B, and 
GUSTO IV-ACS trials. In addition, all 
trials excluded patients with 
thrombocytopaenia (platelets <100 
000 cells/mL). Five of the trials 
excluded patients with renal failure 
(serum creatinine >2 mg/dL or 
creatinine clearance <30 mL/min), 
except the GUSTO IV-ACS trial. All 
trials excluded patients with a prior 
stroke: PRISM, PRISM-PLUS, 
PARAGON-A, and PARAGON-B in 
the last year; PURSUIT in the last 30 
days; and GUSTO IV-ACS in the last 
2 years. Further details of the trial 
designs are available elsewhere.13 A 
total of 31 402 patients participated 
in these trials. Data on 31 387 
patients were available for this 
analysis. 
 
Potential predictors 
An electronic database consisting of 
data from individual patients in all 
eligible trials was available.13 These 
data were checked for 
completeness, internal consistency 
of patients records, and consistency 
with the published reports. For this 
analysis, we used available baseline 
demographic and clinical 
characteristics, regarded as potential 
predictors of stroke.6 Those with 
almost complete information (<1% of 
missing values) included age, 
gender, smoking, weight, and prior 
history of all the following: 
hypertension, diabetes, stroke, MI, 
heart failure, angina pectoris, 
coronary artery bypass surgery, 
percutaneous coronary intervention, 
and use of aspirin. Two variables 
had 2% of missing values: history of 
hypercholesterolaemia and ST-
depression at baseline. 
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Other variables had ~20% of 
missing data: race, heart rate, 
systolic and diastolic blood 
pressures, and baseline creatinine 
kinase MB (CK-MB). Blood pressure 
and heart rate were not recorded in 
the GUSTO IV-ACS trial (n = 7800); 
baseline CK-MB was missing in 
7469 patients across different trials. 
Variables with far more than 20% of 
missing values were excluded from 
the analysis, such as prior use of 
beta-blockers, angiotensin-
converting enzyme-inhibitors, 
nitrates, and calcium antagonists. 
Troponin levels were systematically 
collected in only two of the most 
recent trials (PARAGON-B and 
GUSTO IV-ACS), in which it was 
available in 7161 of 13 025 patients. 
Predictors with ~20% or less of 
missing values were imputed using 
the estimated mean procedure in 
SPSS (SPSS Inc., Chicago, IL, USA, 
1999).14 Atrial fibrillation (AF) and 
creatinine clearance were not 
available. The body mass index 
could not be calculated (i.e. no 
height was available) and it was not 
included in the analysis. The use of 
GP IIb/IIIa receptor blockers was 
also included as a potential predictor 
of stroke. 
 
Outcomes 
For this analysis, the primary 
outcomes defined a priori were all-
cause stroke, non-haemorrhagic 
stroke, and haemorrhagic stroke 
within 30 days of the index ACS. 
Non-haemorrhagic and 
haemorrhagic strokes needed CT 
confirmation. All-cause stroke was 
missing in 12 patients. Non-
haemorrhagic and haemorrhagic 
stroke was missing in 7434 and 
7474 patients, respectively. No 
formal attempt to impute these 
outcomes was done. 
 
Statistical analysis 
This is a prediction analysis that 
pools data from six large-scale 
randomized clinical trials, and it is 
not a formal meta-analysis. 
Univariable logistic regression 
models were used to evaluate the 
association between each potential 
predictor and the outcome. 
 
We checked the linearity assumption 
of continuous variables using 
restrictive cubic splines. The 
predictive weight of each variable 
was expressed as a chi-square 
statistic, which was calculated on the 
-2 log likelihood scale. The higher 
the number, the more important the 
predictor; a chi-square exceeding 
3.84 corresponds to P < 0.05 for a 
predictor with one degree of 
freedom. All predictors were entered 
in a multivariable logistic regression 
model without further selection to 
properly evaluate their predictive 
effects while adjusting for the effects 
of each other predictor.15 The 
performance of the multivariable 
models was studied with respect to 
discrimination and calibration. 
Discrimination refers to the ability to 
distinguish a stroke from no stroke. It 
was quantified by a measure of 
concordance, the c-statistic. For 
binary outcomes, the c-statistic is 
identical to the area under the 
receiver operating characteristic 
curve. The c-statistic lies between 
0.5 and 1 and is better if closer to 
1.16 Because the apparent c-statistic 
is optimistic with low numbers of 
events, we used a standard 
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bootstrapping procedure to correct 
the estimates.15,16 Calibration refers 
to whether the predicted risks agree 
with the observed risk frequencies. 
Calibration was measured with the 
Hosmer–Lemeshow goodness-of-fit 
test.17 Analyses were performed in 
SPSS 10.0 and S-PLUS 2000 
(Insightful Inc., Seattle, WA, USA). 
 
RESULTS 
Patient characteristics 
We found 228 (0.7%) all-cause 
strokes in the study population: 155 
(0.5%) were non-haemorrhagic, 20 
(0.06%) haemorrhagic, and 53 
(0.2%) without CT confirmation. 
Older patients with a prior stroke, 
prior MI, diabetes, hypertension, and 
patients with elevated heart rate had 
higher risks of all-cause and non-
haemorrhagic strokes (Table 1). 
Smoking was not clearly related with 
the stroke incidence. Patients with 
previous percutaneous transluminal 
coronary angioplasty were at lower 
risk to develop any stroke. Less 
clear associations were seen in 
haemorrhagic strokes, probably due 
to small numbers. The risks of 
haemorrhagic stroke due to GP 
IIb/IIIa receptor blockers were 
tirofiban 0% (0/5147), lamifiban 
0.1% (5/7507), eptifibatide 0.1% 
(7/10948), and abciximab 0.1% 
(8/7800). There was no statistical 
difference among these risks. 
 
A high proportion of patients who 
suffered a stroke died: 56 (25%) of 
those with all-cause stroke, 27 
(17%) of those with non-
haemorrhagic stroke, and 13 (65%) 
of those with haemorrhagic stroke. 
The difference in mortality between 
non-haemorrhagic and 
haemorrhagic strokes was highly 
statistically different (P < 0.001). 
Table 1 Distribution of patient baseline characteristics across stroke types (all-cause, non-haemorrhagic, and haemorrhagic)
Predictor All-cause strokes n ¼ 228 Non-haemorrhagic strokes n ¼ 155 Haemorrhagic strokes n ¼ 20
N n (%) Deaths (%)a N n (%) Deaths (%)a N n (%) Deaths (%)a
Ageb
,70 years 20 874 98 (0.5) 20 (20) 15 836 69 (0.4) 10 (15) 15 822 6 (0.03) 4 (67)
70 years 10 513 130 (1.2) 36 (28) 8 132 86 (1.1) 17 (20) 8 108 14 (0.17) 9 (64)
Prior strokeb
No 29 890 201 (0.7) 50 (25) 22 777 134 (0.6) 24 (18) 23 744 16 (0.07) 10 (63)
Yes 1 446 27 (1.9) 6 (22) 1 141 21 (1.8) 3 (14) 1 134 4 (0.35) 3 (75)
Heart rate
,75 16 807 104 (0.6) 18 (17) 12 577 70 (0.6) 11 (16) 12 564 10 (0.08) 5 (50)
75 14 580 124 (0.9) 23 (19) 11 391 85 (0.7) 10 (12) 11 364 10 (0.09) 8 (80)
Smoking
Never 11 499 68 (0.6) 15 (22) 9 516 55 (0.6) 8 (15) 9 511 7 (0.07) 4 (57)
Former 10 429 91 (0.9) 21 (23) 7 577 55 (0.7) 10 (18) 7 557 6 (0.08) 4 (67)
Current 9 307 68 (0.7) 20 (29) 6 768 44 (0.7) 9 (20) 6 753 7 (0.10) 5 (71)
Prior MI
No 20 648 125 (0.6) 31 (25) 16 345 90 (0.6) 14 (16) 16 317 14 (0.09) 9 (64)
Yes 10 646 103 (1.0) 25 (24) 7 531 65 (0.9) 13 (20) 7 519 6 (0.08) 4 (67)
Diabetes mellitus
No 24 488 159 (0.6) 43 (27) 18 612 106 (0.6) 18 (17) 18 590 16 (0.08) 11 (69)
Yes 6 860 68 (1.0) 12 (18) 5 317 49 (0.9) 9 (18) 5 299 4 (0.08) 2 (50)
Hypertension
No 14 417 81 (0.6) 21 (26) 10 908 60 (0.6) 11 (18) 10 891 7 (0.06) 5 (71)
Yes 16 935 147 (0.9) 35 (24) 13 025 95 (0.7) 16 (17) 13 002 13 (0.09) 8 (62)
GP IIb/IIIa RBc
No 13 097 91 (0.7) 21 (23) 9 928 62 (0.6) 9 (15) 9 908 6 (0.06) 2 (33)
Yes 18 290 137 (0.8) 35 (26) 14 040 93 (0.7) 18 (19) 14 020 14 (0.09) 11 (79)
N, number of patients in a defined subgroup; n, number of patients with a stroke within a subgroup, and its percentage of (n/N)  100.
aDeaths within 30 days. The percentage refers to the number of deaths in patients who suffered a stroke.
bP , 0.001 for the comparison between categories.
cPlatelet GP IIb/IIIa receptor blocker.
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Thirty-day mortality in patients 
without stroke was 3.4% (1060/31 
162), and the difference in mortality 
between patients with and without 
stroke was highly significant (chi-
square 259, P < 0.00001). No clear 
relation was observed between 
predictors and death in patients who 
suffered any type of stroke (Table 1). 
 
Predictors of stroke 
The rate of stroke was 0.8% (137/18 
291) among users of GP IIb/IIIa 
receptor blockers and 0.7% (91/13 
099) among non-users of GP IIb/IIIa 
blockers. There was no difference 
between users and non-users (chi-
square 0.3, P = 0.6). The use of GP 
IIb/IIIa receptor blockers was not 
associated with a higher incidence of 
all-cause [OR (95% CI) 1.08(0.83–
1.41)], non-haemorrhagic [1.06 
(0.77–1.47)], and haemorrhagic 
[1.70 (0.65–4.45)] strokes. A 
subgroup analysis of the 3730 
patients with positive troponin levels 
(>upper limit of normal) was 
performed. All-cause stroke was 
observed in 26 patients, and the use 
of GP IIb/IIIa antagonists was not 
associated with stroke in the 
univariate analysis (OR 0.94, 95% 
CI 0.4–2.1). 
The strongest univariable predictors 
of all-cause stroke were older age 
(chi-square = 69), prior stroke (chi-
square = 19), prior MI (chi-square = 
12), hypertension (chi-square = 10), 
elevated heart rate (chi-square = 9), 
lighter weight (chi-square = 9), 
diabetes (chi-square = 8), and 
smoking (chi-square = 6). The 
associations are shown in Table 2. 
No interactions between predictors 
were statistically significant. The 
three most important predictors were 
older age [OR (95% CI) per 10 
years: 1.5 (1.3–1.7)], prior stroke 
[2.1(1.4–3.1)], and elevated heart 
rate [per 10 beats: 1.1 (1.0–1.2)]. 
Smoking, prior MI, diabetes mellitus, 
and hypertension were not 
independent predictors of stroke. 
 
The strongest univariable predictors 
of non-haemorrhagic stroke were 
older age (chi-square = 38), prior 
stroke (chi-square = 18), elevated 
heart rate (chi-square = 9), prior MI 
(chi-square = 7), and diabetes (chi-
square = 7). Lighter weight (chi-
square = 4) and hypertension (chi-
square = 3) had minor importance. 
The three most important predictors 
of non-haemorrhagic stroke had 
comparable associations as those 
Table 2 Univariable and multivariable OR (95% CI) of predictors of stroke in NSTE-ACS patients
Predictors All-cause strokes Non-haemorrhagic strokes Haemorrhagic strokes
Univariable Multivariable Univariable Multivariable Univariable Multivariable
Independent
Age
(per 10 years)
1.68 (1.48–1.91) 1.51 (1.31–1.74) 1.59 (1.37–1.86) 1.45 (1.22–1.73) 2.26 (1.41–3.60) 2.17 (1.30–3.64)
Prior stroke 2.81 (1.87–4.21) 2.06 (1.36–3.12) 3.17 (1.99–5.04) 2.36 (1.46–3.80) 5.03 (1.68–15.06) 3.76 (1.21–11.70)
Heart rate
(per 10 beats)
1.11 (1.05–1.19) 1.11 (1.04–1.18) 1.13 (1.05–1.20) 1.13 (1.05–1.21) 1.10 (0.95–1.28) 1.15 (0.96–1.37)
Not independent
Smoking
Former 1.48 (1.08–2.03) 1.45 (1.05–2.02) 1.26 (0.86–1.83) 1.25 (0.84–1.84) 1.08 (0.36–3.21) 1.75 (0.85–5.65)
Current 1.24 (0.88–1.73) 1.37 (0.98–1.95) 1.13 (0.76–1.67) 1.50 (0.99–2.27) 1.41 (0.49–4.02) 2.48 (0.83–7.40)
Prior MI 1.60 (1.23–2.08) 1.32 (0.99–1.77) 1.57 (1.14–2.16) 1.23 (0.86–1.75) 0.93 (0.36–2.42) 0.82 (0.29–2.38)
Diabetes
mellitus
1.53 (1.15–2.04) 1.26 (0.93–1.69) 1.62 (1.16–2.28) 1.35 (0.94–1.93) 0.88 (0.29–2.62) 0.79 (0.26–2.43)
Hypertension 1.55 (1.18–2.03) 1.21 (0.91–1.61) 1.32 (0.96–1.84) 1.00 (0.70–1.40) 1.56 (0.62–3.90) 1.22 (0.46–3.22)
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described for all-cause stroke. For 
haemorrhagic strokes, the strongest 
univariable predictors were older 
age (chi-square = 12), prior stroke 
(chi-square = 8), and lighter weight 
(chi-square = 5). Similarly, the three 
most important predictors were 
those of the non-haemorrhagic 
strokes (Table 2). 
 
Performance of predictive models 
The calibration of the predictive 
model of all-cause stroke was good 
(Hosmer–Lemeshow test 10.4, P = 
0.24), but the discriminative power of 
this model was moderate [c-statistic 
(95% CI): 0.69 (0.65–0.72)]. 
Although the calibration of the 
predictive models of non-
haemorrhagic and haemorrhagic 
strokes was good, the discriminative 
power was either moderate [c-
statistic 0.67 (0.63–0.71)] or poor [c-
statistic 0.58 (0.54–0.63)], 
respectively. 
 
DISCUSSION 
Stroke occurred in 0.7% of patients 
within 30 days of presenting with 
NSTE-ACS. Two-thirds of the 
strokes were non-haemorrhagic. 
Older age, prior stroke, and elevated 
heart rate were the strongest 
predictors of all-cause, non-
haemorrhagic, and haemorrhagic 
strokes. However, the discriminative 
power of these predictors was 
moderate and especially poor for 
haemorrhagic strokes. Thus, it is 
difficult to accurately predict the 
incidence of stroke in this 
population. 
 
The incidence of 30-day all-cause 
stroke in our patients is comparable 
with that in similar populations: 0.8% 
in the GUSTO-IIb trial18 and 0.5% in 
the OPUS-TIMI 16 trial.19 However, 
in clinical practice, the incidence of 
30-day all-cause stroke may be 
larger, because the in-hospital 
incidence already reaches 0.7%.20 In 
a Spanish nationwide registry 
(DESCARTES), the incidence of 30-
day all-cause stroke was 0.9% (95% 
CI 0.4–1.3%).21 For comparison, the 
incidence of 30-day all-cause stroke 
in patients with ST-segment 
elevation-ACS (STE-ACS) treated 
with thrombolytics was 1.4% 
(between 1.2 and 1.6%) in the 
GUSTO-I trial22 and 0.8% in nine 
trials from a meta-analysis.23 The 
VALIANT registry, including both 
NSTE- and STE-ACS patients, had 
1.5% in-hospital strokes.24 The 
proportion of haemorrhagic strokes 
was ~50% of the total number of 
strokes in the GUSTO-I trial22 and 
13% in the meta-analysis.23 Strokes 
in NSTE-ACS patients were 
associated with a high mortality rate 
(25%), which is lower than that 
observed in STE-ACS patients 
(41%).22 
 
Importantly, the use of GP IIb/IIIa 
receptor blockers was not clearly 
associated with an increased 
incidence of all-cause stroke, non-
haemorrhagic stroke, or 
haemorrhagic stroke. However, it 
should be recognized that the 
conclusion regarding the effect of 
GP IIb/IIIa receptor blockers on 
haemorrhagic strokes has 
substantial uncertainty, given the low 
number of events available and, 
hence, the limited power of the 
statistical analysis. The low 
frequency of haemorrhagic stroke in 
the overall population, coupled with 
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lack of clear evidence of increased 
risk, provides reassurance that fear 
of intracranial haemorrhage should 
not be a reason to avoid these 
drugs. However, when patients 
receive these drugs on top of more 
aggressive antithrombotic therapy, 
the incidence of haemorrhagic 
strokes increases, as in patients with 
STE-ACS who received 
thrombolytics.25 In our NSTE-ACS 
patients, predictors associated with 
the incidence of haemorrhagic 
stroke were similar to those 
associated with non-haemorrhagic 
stroke. In contrast, STE-ACS 
patients who take oral 
anticoagulation before admission, 
with <70 kg, and older than 65 years 
were at increased risk of 
haemorrhagic stroke. 
 
Stroke has only been studied as an 
outcome in a secondary analysis of 
the PURSUIT trial.6 Sixty-six non-
haemorrhagic strokes in 9461 
NSTE-ACS patients were studied. 
Haemorrhagic strokes were not 
studied. The strongest predictors 
were higher heart rate, older age, 
prior anterior MI, prior stroke or 
transient ischaemic attack (TIA), and 
diabetes mellitus. Our analysis of 31 
387 patients increased the number 
of events and the power to find 
predictors of any type and all-cause 
stroke. However, the number of 
haemorrhagic strokes was still 
limited. 
 
Age was an important predictor of 
non-haemorrhagic stroke in the 
PURSUIT6 and GUSTO-I trials.26 In 
our analysis, age was the strongest 
predictor of all-cause, non-
haemorrhagic, and haemorrhagic 
strokes, and its relative importance 
was slightly higher than the results 
of the PURSUIT trial. Elderly 
patients probably have a higher risk 
of stroke because of multiple co-
morbidities associated with older 
age, such as AF, hypertension, 
physical inactivity, and 
asymptomatic carotid stenosis.27 
 
Prior stroke has been described as a 
predictor of stroke in the OPUS-TIMI 
16 trial.28 In this trial, the proportion 
of 10-month all-cause stroke was 
2.9% in 1173 patients with prior 
extra-cardiac vascular disease 
(peripheral + stroke + TIA) in 
comparison with 1.1% in 9108 
patients without prior extra-cardiac 
vascular disease. In the PURSUIT 
and GUSTO-I trials, 26 prior stroke 
was analysed in conjunction with 
prior TIA, and this combined 
predictor was important. Prior stroke 
may be a marker of underlying 
cardiac, carotid, or cerebral vascular 
disease in ACS patients. 
 
Elevated heart rate was very 
important in the PURSUIT6 and 
GUSTO-I trials.26 An explanation for 
the association between elevated 
heart rate and stroke is not clear.6 
The heart rate may correlate with 
larger infarctions that predispose 
patients to a higher likelihood of 
atrial arrhythmia and left ventricular 
thrombi. Heart rate is strongly 
associated with the presentation of 
AF in patients with NSTE-ACS.29 AF 
is a common complication in these 
patients, occurring in 6.4% of 
patients enrolled.30 Moreover, an 
elevated baseline heart rate may 
simply be an expression of a prior 
AF. Unfortunately, our data set did 
 88 
not provide information over prior or 
incident AF. Finally, a high heart rate 
may be an expression of a 
decompensated heart failure, related 
to the extent of the MI. Heart failure 
on admission has been described as 
an independent predictor of in-
hospital all-cause stroke in the 
VALIANT registry.24 
 
Diabetes and prior MI were 
independent predictors of stroke in 
the PURSUIT trial,6 but not in our 
analysis. Diabetes has a known 
association with a widespread 
atherosclerosis, and prior MI is 
associated with the formation of 
mural thrombus and emboli. Finally, 
lighter weight was weakly associated 
with haemorrhagic stroke. This was 
probably related to doses of GP 
IIb/IIIa receptor blockers and 
anticoagulants that were not 
reduced in lighter patients, and 
especially for the elderly. 
 
Our study has some limitations. We 
had about 7500 patients with 
missing values for the non-
haemorrhagic and haemorrhagic 
stroke outcomes. The number of 
non-haemorrhagic strokes was still 
larger (n = 155) than the largest 
previously published (n = 66).6 
Although we had a few 
haemorrhagic strokes (n 1 = 20), 
regression coefficients of the 
multiple regression model for 
haemorrhagic stroke are not biased. 
Although the performance of the 
prognostic model may be optimistic, 
it was internally validated using the 
bootstrap procedure. We imputed 
several patient characteristics. Of 
them, only heart rate remained as a 
strong predictor, as demonstrated 
previously.6 
 
In conclusion, stroke is an infrequent 
but serious early complication of 
patients with NSTE-ACS. Mortality is 
high, especially for haemorrhagic 
strokes. Platelet GP IIb/IIIa receptor 
blockers were not significantly 
associated with any type of stroke. 
Three main predictors of stroke were 
older age, prior stroke, and elevated 
heart rate. Because the 
discriminative ability of these patient 
characteristics was at best 
moderate, it is difficult to predict 
which ACS patients will suffer a 
stroke. 
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Chapter Seven 
 
Risk-benefit analysis of platelet 
glycoprotein IIb/IIIa inhibitors in 
acute coronary syndromes 
Cynthia M Westerhout and Eric Boersma 
 
Four intravenous glycoprotein IIb/IIIa receptor inhibitors (GPIs) (abciximab, eptifibatide, tirofiban 
and lamifiban) have been tested extensively over the last decade for their efficacy and safety in 
patients with acute coronary syndromes (ACS). GPIs are well-established adjunct agents for 
patients undergoing percutaneous coronary intervention, and considerable effort has gone into 
evaluating these agents in patients who are not scheduled to undergo coronary 
revascularisation. In the current article, six major randomized clinical trials conducted in the latter 
patient population are reviewed. Based on a recent meta-analysis of these trials, GPIs reduced 
the incidence of death or myocardial infarction in patients not scheduled for early 
revascularisation, with the greatest reduction observed in patients at high risk of thrombotic 
complications. Major bleeding complications were more frequent in those receiving GPIs, 
however, the incidences of intracranial haemorrhage and stroke were similar in both treatment 
groups. Despite these risks, the benefits of GPI therapy in addition to conventional treatment, 
such as aspirin and heparin, should be considered for these high-risk patients.  
Antiplatelet therapy has long been a 
cornerstone of the treatment 
strategies available to patients with 
acute coronary syndromes (ACS). In 
recent decades, progress in the 
understanding of the 
pathophysiology of ACS has brought 
about innovations in anti-platelet 
therapy. In particular, an 
appreciation for the role of platelet 
aggregation, through the 
identification of the platelet 
glycoprotein IIb/IIIa (gp IIb/IIIa) 
receptor (IIb3 integrin), has initiated 
the creation of a new class of 
pharmaceutical agents, gp IIb/IIIa 
receptor inhibitors (GPIs) [1]. 
 
The blockade of this receptor has 
proven to be remarkably effective in 
patients undergoing percutaneous 
coronary intervention (PCI) by 
means of a 38% reduction in the 
incidence of peri-procedural death or 
myocardial infarction (MI) [2]. 
However, the efficacy of these 
agents in patients who are not 
scheduled for early revascularisation 
is less certain. In this review, the 
benefits and risks of GPI therapy in 
patients suffering from ACS without 
ST-segment elevation will be 
evaluated. Specifically, this expert 
appraisal is based on six large-
scale, Phase III, randomised clinical 
trials, and meta-analyses of these 
trials, which evaluated intravenous 
GPIs (abciximab, eptifibatide, 
tirofiban or lamifiban) against 
placebo (or standard care) (Table 1).  
 
Pathophysiology of acute 
coronary syndromes 
The acute phase of coronary artery 
disease represents a spectrum of 
 diagnoses ranging from unstable 
angina (UA) to acute MI (Figure 1). 
Although further distinctions can be 
made through the evaluation of the 
electrocardiogram (ECG) taken at 
admission and the measurement of 
serum biomarkers such as creatine 
kinase-MB isoenzyme (CK-MB) 
and/or cardiac-specific troponins, a 
common pathophysiological 
mechanism unites these acute 
coronary events [3]. Arterial plaques, 
characterized by a large lipid core 
and a thin fibrous capsule, are 
susceptible to rupture as a result of 
increased inflammatory activity 
within the intima. The rupture of the 
plaque can precipitate thrombus 
formation, in which case a 
permanent occlusion may trigger a 
MI, or a transient occlusion may lead 
to UA. 
 
Fundamental to the understanding of 
thrombus formation is an 
appreciation for the role of the 
platelet. During haemostasis, 
platelets are in an antithrombogenic 
condition and circulate smoothly 
throughout the vasculature. 
However, under the conditions of 
plaque rupture, adhesion molecules 
on the platelet bind to the highly 
thrombogenic subendothelial matrix. 
Subsequently, the platelets enter 
into an activated state, which is 
indicated by the activation and 
expression of approximately 80,000 
– 100,000 gp IIb/IIIa receptors on 
the exterior of the platelet (and even 
more when accounting for the 
internal source of these receptors) 
[4]. These receptors bind fibrinogen, 
von Willebrand factor and soluble 
ligands (such as thrombin, ADP or 
adrenaline); in turn, a dense network 
of platelets and connecting fibres 
creates a thrombus [1]. Thus, the 
blockade of gp IIb/IIIa receptors is 
central to the inhibition of thrombosis 
and offers novel opportunities in 
anti-platelet therapy [5]. 
 
Intravenous glycoprotein IIb/IIIa 
receptor inhibitors 
Four intravenous agents have been 
investigated for their efficacy and 
safety in ACS patients without ST-
segment elevation and who are not 
scheduled for coronary 
revascularisation (Table 2). 
Abciximab is a humanised 
monoclonal antibody fragment that 
has a strong affinity for gp IIb/IIIa 
receptors, vitronectin receptors (on 
endothelial cells) and MAC-1 (a 
component of integrins and a 
member of the leukocyte–integrin 
adhesion molecule family; otherwise 
known as CD11b) receptors (on 
leukocytes). Eptifibatide, tirofiban 
and lamifiban are smaller in 
molecular weight than abciximab 
and inhibit the gp IIb/IIIa receptor via 
their unique amino acid-binding 
sequences, which correspond to 
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 those found in fibrinogen, von 
Willebrand factor and other ligands 
of the gp IIb/IIIa receptor [6,7]. 
Unlike abciximab, the small-
molecule GPIs have plasma half-
lifes of approximately 2 h and lower 
binding affinity relative to abciximab. 
All of these agents, except for 
lamifiban, have received approval 
from North American and European 
regulatory bodies for commercial 
use. 
 
Efficacy of intravenous 
glycoprotein IIb/IIIa receptor 
inhibitors 
For patients with high-risk clinical 
features for whom PCI is not 
appropriate or available in the early 
phase of treatment, standard care 
has included anti-platelet therapy 
such as aspirin. Although aspirin is a 
well-established anti-platelet agent, 
platelet aggregation is not 
completely inhibited. By preventing 
the formation of thromboxane A2, 
aspirin blocks only one of the 
pathways leading to platelet 
aggregation. In contrast, GPIs 
provide more complete inhibition of 
platelet aggregation through the 
blockade of fibrinogen-binding 
receptors (gp IIb/IIIa), otherwise 
known as the final common 
pathway. Hence, GPIs were 
evaluated by six large-scale, 
randomised clinical trials with the 
anticipation that GPIs would provide 
additional benefits over traditional 
therapy (Tables 1 and 3). 
 
Abciximab 
Abciximab was the first GPI agent 
tested in patients undergoing PCI, 
and yet is one of the most recently 
tested agents evaluated in the early 
medical treatment of ACS. The 
investigators of the GUSTO-IV-ACS 
trial compared the effect of two 
different durations of abciximab 
infusion (i.e., 24- and 48-h) against a 
placebo bolus and infusion in ACS 
patients who were not scheduled to 
undergo early PCI [8] (Table 3). 
Enrolled patients also presented with 
either a positive troponin T or I test 
according to local laboratory 
measurements, or transient or 
persistent ST-segment depression 
( 0.5 mm). Unlike the investigations 
of abciximab in patients with 
unstable refractory angina 
undergoing PCI [9], no additional 
benefit from the use of abciximab 
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 was observed at 30 days (death or 
MI at 30 days; 8.0% placebo versus 
8.2% 24-h abciximab, p = non-
significant; 8.0% placebo versus 
9.1% 48-h abciximab, p = non-
significant) (Figure 2). A lack of 
effect was also observed in most 
subgroups, except for gender. 
Unexpectedly, women who received 
the 48-h infusion of abciximab 
experienced significantly more 
events at 30 days than those who 
received placebo. 
 
The reasons for the failure to 
observe an apparent benefit are 
unclear, but there are suggestions 
that the unique patient population, 
study design, dose regimen of 
abciximab, or the sample size may 
have contributed to these 
unexpected results [8]. Lower rates 
of revascularisation compared to 
other GPI trials (PURSUIT) may also 
explain these data. It is clear, 
however, that additional 
investigations are needed to 
determine the appropriateness of 
abciximab in the medical 
management of ACS. 
 
Eptifibatide 
In contrast to abciximab, eptifibatide 
has been successful in reducing 
ischaemia and adverse clinical 
outcomes. In the follow-up to the 
promising results of Schulmans 
dose-finding trial, the PURSUIT trial 
investigators tested the hypothesis 
that eptifibatide could significantly 
reduce death and MI beyond 
standard therapy with aspirin and 
heparin [10,11] (Figure 2; Table 3). 
A distinguishing feature of this trial is 
its real-world-based protocol; that 
is, allowing the physician to make 
decisions on treatment strategies, 
including cardiac catheterisation and 
revascularisation, at their own 
discretion, thereby providing insight 
into the use of eptifibatide in actual 
clinical practice. 
 
The use of eptifibatide in these 
patients led to a significant reduction 
in death or non-fatal MI at each time 
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point. A 1.5% absolute reduction 
was achieved early after the 
initiation of treatment and was 
consistently maintained for 30 days 
(9.6% relative reduction at 30 days 
compared to those who received the 
placebo [15.7% placebo versus 
14.2% eptifibatide, p = 0.03]) (Figure 
2). A favourable treatment effect was 
noted in all subgroups, with the 
exception of women (odds ratio [OR] 
1.10; 95% confidence interval [CI] 
0.91 – 1.34). There appears to be no 
plausible biological reasoning behind 
this association and caution should 
be exercised when interpreting this 
result, especially in subgroup 
analyses. 
 
The most dramatic results were 
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realised in those who received 
eptifibatide and underwent PCI 
within 72 h after randomisation (31% 
relative risk reduction in death and 
non-fatal MI at 30 days [11.6% 
eptifibatide versus 16.7% placebo, 
p = 0.01]); whereas, the relative 
reduction in adverse events 
experienced by patients not 
undergoing a procedure was 
substantially attenuated (7% relative 
risk reduction; 14.5% eptifibatide 
versus 15.6% placebo, p = 0.23). 
 
Tirofiban 
The use of tirofiban in combination 
with or in comparison to standard 
therapies has been evaluated in two 
major trials, PRISM and PRISM-
PLUS [12,13] (Table 3). While a 
strong body of evidence indicates 
that aspirin and heparin reduce the 
incidence of adverse cardiac events, 
the inconsistent pharmacodynamic 
response to heparin is cause for 
some concern. Thus, the intention of 
the PRISM trial was to evaluate the 
efficacy and safety of tirofiban 
against heparin in the medical 
management of UA patients 
receiving aspirin [12]. Patients 
receiving tirofiban benefited from a 
32% relative reduction in the 
composite end point of death, 
refractory ischaemia or MI at 48 h 
when treated with tirofiban and 
aspirin compared to heparin and 
aspirin (3.8% tirofiban versus 5.6% 
heparin, relative risk ratio 0.67; 95% 
CI 0.48 – 0.92, p = 0.01). Although 
similar reductions in the composite 
end point were not consistently 
sustained through follow-up at 7 and 
30 days (Figure 2), mortality at 30 
days was significantly lower in those 
receiving tirofiban and aspirin (3.6% 
tirofiban versus 2.3% placebo; OR 
0.62; 95% CI 0.41 – 0.93, p = 0.02). 
 
The PRISM-PLUS investigators 
compared the efficacy and safety of 
three treatment arms in patients who 
were diagnosed with UA or non-Q 
wave MI and who were also 
receiving aspirin, tirofiban alone, 
tirofiban and heparin or heparin 
alone [13]. At the end of the first 
interim analysis, the tirofiban-alone 
treatment arm was terminated due to 
excess mortality at 7 days. In the 
remaining patients, tirofiban 
administered in combination with 
aspirin and heparin reduced the 
composite end point of death, MI or 
refractory ischaemia at 7 days, 
compared to those who had only 
received aspirin and heparin (12.9% 
tirofiban and heparin versus 17.9% 
heparin, relative risk ratio 0.68; 95% 
CI 0.53 – 0.88, p = 0.004). The 
benefits of tirofiban therapy were 
observed in various subgroups of 
patients and during long-term (i.e., 
30 days and 6 months) follow-up 
(Figure 2). 
 
Lamifiban 
Unlike the previously described 
agents, lamifiban is not approved for 
commercial use. The inconclusive 
results of the two clinical trials, 
PARAGON-A and -B, may account 
for the delay in its approval [14,15] 
(Table 3). Based on promising 
results from the Canadian Lamifiban 
Study [16], the PARAGON-A trial 
was aimed at testing the effects and 
safety of two doses of lamifiban, with 
and without heparin, in patients with 
UA and non-Q wave MI. 
Unexpectedly, the use of lamifiban 
did not significantly reduce the 
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primary composite end point of 
death or non-fatal MI at 30 days 
(Figure 2); however, the low-dose 
lamifiban performed better than 
aspirin and heparin at 6 months 
(17.9% control, 13.7% low-dose 
[versus control p = 0.027], 23.5% 
relative risk reduction, 16.4% high-
dose [versus control p = 0.450], 8% 
relative risk reduction). Overall, it 
appeared that low-dose lamifiban 
might have additional value over 
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 lamifiban at higher doses. 
Compared to standard therapy, 
patients receiving low-dose lamifiban 
used in combination with heparin 
experienced the largest reduction in 
the composite end point at 30 days 
(12%, non-significant) and at 6 
months (30%, p = 0.025). 
 
Several explanations for these 
unexpected results have been 
suggested. First, the authors 
indicated that the statistical power of 
the PARAGON-A trial might have 
been inadequate to produce reliable 
results. Second, a retrospective 
pharmacokinetic analysis revealed 
that the study dose regimen was 
possibly suboptimal. Consequently, 
PARAGON-B was designed to 
evaluate the effects of titrated 
dosing, which were intended to 
achieve and maintain acceptable 
plasma levels of lamifiban [15]. 
Despite these modifications to the 
dosing regimen, no significant 
difference in the 30-day or 6-month 
composite end point of death, MI, or 
severe recurrent ischaemia was 
observed (30-day: 12.8% placebo 
versus 11.8% lamifiban, p = 0.329; 
6-month: 15% placebo versus 14% 
lamifiban, p = 0.284) (Figure 2). 
Similar to PARAGON-A, the lack of 
statistical power in this trial should 
be taken into account when 
interpreting these results.  
 
Overview of intravenous 
glycoprotein IIb/IIIa receptor 
inhibitors 
Although there have been no direct 
comparisons of GPI therapy in this 
patient population, two 
comprehensive meta-analyses 
provide insight into the class effect 
of these agents [2,17]. Kong et al. 
observed that mortality, at any time 
point, was not significantly reduced 
with the use of GPI agents. 
However, the combined end point of 
death or nonfatal MI was reduced in 
those patients receiving GPI therapy 
at 48 – 96 h (OR 0.77; 95% CI 0.71 
– 0.92), 30 days (OR 0.88; 95% CI 
0.81 – 0.97) and 6 months (OR 0.88; 
95% CI 0.79 – 0.97). With the 
addition of revascularisation into the 
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composite end point, similar benefits 
of GPI therapy were observed [2]. 
 
The meta-analysis conducted by 
Boersma et al. [17] provides a 
contemporary perspective of this 
class of agents with the inclusion of 
the PARAGON-B and GUSTO-IV-
ACS trials and the exclusion of trials 
enrolling fewer than 1000 patients 
[11,16]. Overall, there was a 9% 
relative reduction in the odds of 
death or MI at 30 days with the use 
of GPI agents (p = 0.015) (Figure 2). 
When the effects of GPI therapy 
were examined according to 
prognostically important subgroups, 
such as age, diabetes mellitus, 
cardiovascular disease history and 
condition on admission, improved 
outcomes with GPI therapy were 
consistently noted. Significant 
interactions between allocated study 
treatment and cardiac troponin 
levels and gender were observed. In 
35% of the 31,402 patients with data 
on cardiac troponins, patients with 
positive troponin levels (troponin T 
or I  0.1 g/l) experienced a 15% 
relative risk reduction of death or MI 
at 30 days when GPI agents were 
administered compared to placebo 
or control (10.3% versus 12.0; OR 
0.85; 95% CI 0.71 – 1.03). 
Conversely, there appeared to be no 
treatment effect in those patients 
with negative troponin 
concentrations (7.0% GPI versus 
6.2% placebo/control; OR 1.17; 95% 
CI 0.94 – 1.44). 
 
With respect to gender, men who 
received GPI therapy experienced a 
19% relative reduction in the risk of 
death or MI at 30 days compared to 
placebo or control (10.4% versus 
12.6%; OR 0.81; 95% CI 0.75 – 
0.89), whereas the use of GPIs in 
women was associated with a 15% 
relative risk increase in death or MI 
at 30 days (11.5% versus 10.4%; 
OR 1.15; 95% CI 1.01 – 1.30). 
However, once patients were 
stratified according to cardiac 
troponin status, the benefits of GPI 
therapy were observed in both men 
and women with elevated troponin 
levels. Reductions in the risk of 
death or MI were not observed in 
men or women with negative 
troponin levels. 
 
Adverse effects 
The pharmacological mechanism 
behind GPIs acts to influence the 
restoration of haemostasis and, as 
such, patients with active bleeding or 
a history of bleeding disorders 
including diathesis, gastrointestinal 
or genitourinary bleeding (within the 
last 6 months) may be at an 
increased risk of excessive bleeding 
complications. Other 
contraindications include 
uncontrolled hypertension ( 180 
mmHg systole and/or  110 mmHg 
diastole), severe anaemia and 
thrombocytopenia [18]. Likewise, 
patients who have undergone major 
surgery within the past 3 months, or 
have a history of stroke or recent 
trauma, are not recommended for 
GPI therapy [18]. 
 
Even in patients in whom GPI is 
indicated, bleeding complications 
may occur and are important safety 
concerns. Based on the meta-
analysis of Boersma et al., the use 
of intravenous GPIs was associated 
with a 62% relative increase in the 
incidence of major bleeding 
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complications, regardless of the use 
of heparin (OR 1.62; 95% CI 1.36 – 
1.94) (Table 4) [17]. As noted by 
GUSTO-IV-ACS investigators, 
factors associated with bleeding 
events include the use of low 
molecular weight heparin, duration 
of abciximab infusion, region of 
enrolment, performance of coronary 
bypass or PCI, advanced age and 
female gender [19]. When the 
incidence of major bleeding 
complications were compared in 
men and women in all six trials, 
women were at slightly higher risk 
compared to men (women: 3.0% 
GPI versus 1.4% placebo/control; 
OR 2.2; 95% CI 1.6 – 2.9; men: 
2.1% GPI versus 1.4% 
placebo/control; OR 1.6; 95% CI 1.3 
– 2.0) [18]. However, there was no 
evidence of heterogeneity (p = 0.10). 
 
Other putative safety concerns of 
GPI therapy include intracranial 
haemorrhage (ICH), stroke and 
thrombocytopenia. The incidence of 
ICH was low (i.e., < 0.1%) in these 
trials, and its use with or without 
heparin was not associated with an 
increased incidence of ICH (Table 4) 
[17]. Similarly, the incidence of 
stroke was also not associated with 
the use of these agents [17].  
 
Thrombocytopenia is a potential but 
uncommon adverse effect of GPI 
therapy. Severe thrombocytopenia 
(< 50,000 platelets/mm3) occurs in < 
2.0% of patients who receive 
abciximab and in < 1.0% of patients 
who receive tirofiban (Table 4). The 
incidence of profound 
thrombocytopenia (< 20,000 
platelets/mm3) is estimated to be 
between 0.3 and 1.0% in patients 
who receive abciximab and < 0.2% 
in those who receive eptifibatide 
[20]. Platelet function should be 
continually monitored during 
administration of the GPI agent, and 
if thrombocyptopenia develops, the 
cessation of the GPI agent and 
platelet transfusions (if necessary) 
should improve platelet function. 
 
Treatment guidelines 
Antiplatelet and anticoagulation 
therapies modulate the progression 
of coronary artery disease and, as 
such, they are integral components 
in the treatment of ACS. Assessing 
the individual risk of patients 
provides an opportunity for tailoring 
these treatment strategies. For 
patients who have been diagnosed 
with definite ACS and are 
experiencing ongoing ischaemia, 
have high-risk characteristics or will 
undergo a planned intervention, a 
combination of aspirin, 
(unfractionated) heparin and GPIs is 
recommended by both American 
and European professional societies 
[21,101]. Such high-risk features 
include elevated troponin levels, ST-
segment changes, diabetes mellitus, 
advanced age or recurrent 
ischaemia. In patients with 
persistent ischaemia and in whom 
PCI is not planned, eptifibatide or 
tirofiban should be administered in 
combination with aspirin and heparin 
[101]. 
 
These risk criteria are based on the 
development of comprehensive, yet 
clinically applicable, risk stratification 
models [22,23]. Key predictors of 
death or the composite of death and 
(re)MI at 30 days in the PURSUIT 
trial included advanced age, heart 
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rate, systolic blood pressure, ST-
segment depression, signs of heart 
failure and elevated cardiac 
biomarkers [22]. The TIMI 
(Thrombolysis In MI) risk score, 
which was developed in the unstable 
angina/non-ST elevation MI patient 
populations of the TIMI-11B and 
ESSENCE (Efficacy and Safety of 
Subcutaneous Enoxaparin in Non-Q 
wave Coronary Events) trials, found 
a similar array of predictors of death, 
(re)MI or urgent revascularisation at 
14 days [23]. The application of 
these types of models is valuable in 
the pursuit of timely and optimal 
triage of patients. 
 
Conclusion and expert opinion 
The use of GPI therapy seems to 
reduce the incidence of death or MI 
in patients with ACS who are not 
scheduled for early 
revascularisation. These benefits 
were most evident in patients who 
were considered to be at high risk 
for thrombotic complications, e.g., 
patients with elevated cardiac 
troponins levels or ST-segment 
deviations, among others. The risk 
of major bleeding complications is 
higher with the use of GPI therapy; 
however, these risks should not 
suppress the benefits of this 
therapy. Therefore, GPI agents 
should be considered as part of the 
early medical management of high-
risk patients. 
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Chapter Eight 
 
Platelet Glycoprotein IIb/IIIa Inhibitors in 
the Treatment of Non-ST-segment 
Elevation Acute Coronary Syndromes in 
the Elderly 
Cynthia M. Westerhout and Eric Boersma 
 
The chain of events leading to 
acute coronary syndromes (ACS), 
including unstable angina (UA) and 
non-ST-segment elevation (NSTE) 
or ST-segment elevation myocardial 
infarction (STEMI), is triggered by 
the disruption of an atherosclerotic 
plaque, which leads to the formation 
of a platelet-rich thrombus within a 
coronary artery.1,2 The inhibition of 
platelet aggregation is fundamental 
to the treatment of these patients; 
however,  standard anti-platelet 
agents such as aspirin do not 
completely obstruct this activity. 
Advances in understanding the 
pathophysiology of ACS have to the 
recognition of the activation of the 
glycoprotein IIb/IIIa (Gp IIb/IIIa) 
receptors on platelets as the final 
common pathway leading to platelet 
aggregation. With this target in mind, 
pharmacological treatment of ACS 
has been propelled into a new era 
with agents that completely inhibit 
platelet aggregation.3 
 
In this second of two reviews 
examining the impact of platelet 
glycoprotein IIb/IIIa receptor inhibitor 
(GPI) therapy on patients suffering 
from ischemic heart disease, the 
efficacy and safety issues 
associated with these agents in the 
medical management of non-ST-
segment elevation ACS (NSTE-
ACS) will be discussed. Specifically, 
this appraisal is based on large-
scale, phase III, randomized clinical 
trials and meta-analyses evaluating 
intravenous (abciximab, eptifibatide, 
tirofiban and lamifiban) and oral 
agents (sibrafiban and orbofiban), 
with particular emphasis on the 
elderly (as defined in the trials) 
(Table 1). 
 
Intravenous GPIs 
Abciximab 
Although it was the first GPI to be 
tested in patients undergoing 
percutaneous coronary intervention 
(PCI), abciximab is one of the most 
recent to be tested in the front-line 
medical treatment of NSTEACS. The 
investigators of the GUSTO-IV ACS 
(see Table 1 for full trial names) trial 
compared the effect of two different 
lengths of abciximab infusion (24-
hour and 48-hour) against a placebo 
bolus and infusion in NSTE-ACS 
patients who were not undergoing 
early PCI (Table 2, page 27).4 In 
patients with either a positive 
troponin T or I test, or transient or 
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persistent ST-segment depression 
( 0.5mm), there was no benefit 
from the administration of abciximab, 
regardless of the length of infusion, 
at 30 days ((death or MI at 30 days) 
8.0% placebo versus 8.2% 24-hour 
abciximab, odds ratio (OR) 1.0, 95% 
confidence interval (CI) (0.83-1.24); 
and 9.1% 48-hour abciximab, OR 
1.1, 95% CI(0.94, 1.39)). This lack of 
effect was also evident in both 
younger (<65 years) and older (( 65 
years) patients (Figure 1). Unlike the 
investigations of abciximab in 
patients with refractory angina and in 
those undergoing PCI, it seems that 
no additional benefit was derived 
from the use of abciximab in the 
medical management of NSTE-ACS. 
 
Eptifibatide 
On the heels of the success of Gp 
IIb/IIIa receptor inhibition in patients 
undergoing PCI, it was suspected 
that eptifibatide, a small-molecule 
GPI, could reduce ischemia in UA 
patients. To follow-up on the 
promising results of Schulmans 
dose-finding trial, the PURSUIT trial 
investigators tested the hypothesis 
that eptifibatide could significantly 
reduce death and MI beyond 
standard therapy, such as aspirin 
and heparin, in ACS patients without 
persistent ST-segment elevation 
(Table 2).5,6 A unique feature of this 
trial was its practice-based protocol, 
which mandated that decisions on 
treatment strategies, including 
cardiac catheterization and 
revascularization, were made at the 
discretion of the treating physicians. 
 
Overall, the use of eptifibatide in 
these patients led to a significant 
reduction in death or non-fatal MI at 
each time point. On the fourth day 
after randomization, a 1.5% absolute 
reduction was achieved and was 
consistently maintained for 30 days 
(9.6% relative reduction at 30 days 
compared to those who received the 
placebo (15.7% placebo versus 
14.2% eptifibatide, p=0.03)). The 
benefits of eptifibatide therapy were 
consistent across all age groups 
(Figure 1). 
 
Glossary of Intravenous and Oral GPI Trials for the Medical
Management of NSTE-ACS Patients
GUSTO-IV-ACS Global Utilization of Strategies to Open Occluded 
Coronary Arteries Trial IV in Acute Coronary Syndromes
PURSUIT Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor 
Suppression using Integrilin Therapy
PRISM Platelet Receptor Inhibition for Ischemic Syndrome 
Management
PRISM-PLUS PRISM-in Patients Limited to very Unstable Signs and symptoms
PARAGON -A Platelet GP IIb/IIIa Antagonist for the Reduction of 
and -B Acute Coronary Syndrome Events in a Global 
Organisation Network-A and -B
OPUS TIMI-16 Orbofiban in Patients with Unstable Coronary Syndromes
1st & 2nd Sibrafiban versus aspirin to Yield Maximum Protection from
SYMPHONY Ischemic Heart events post acute coronary syndromes
Table 1
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Interestingly, the incidence of death 
or nonfatal MI was reduced by 31% 
(relative) at 30 days in those who 
received eptifibatide and underwent 
PCI within 72 hours after 
randomization (11.6% eptifibatide 
versus 16.7% placebo, p=0.01), 
whereas, the relative reduction in 
patients not undergoing a procedure 
was substantially attenuated (7% 
relative risk reduction, 14.5% 
eptifibatide versus 15.6% placebo, 
p=0.23). 
 
Tirofiban 
In the late 1990s, another small-
0 0.5 1 1.5 2
GUSTO-IV ACS
<65
≥65
<65
65-74
PRISM
PURSUIT
>75
>65
PRISM-PLUS <65
≥65
<65
≥65
PARAGON-B <65
≥65
<60
60-69
Boersma et al.
≥70
Figure 1.  Age subgroup analysis of primary composite endpoints of trials evaluating 
intravenous GPIs in NSTE-ACS patients.
(No age subgroup analysis reported for PARAGON-A.)
GUSTO-IV ACS 24-hour abciximab infusion versus placebo;
  48-hour abciximab infusion versus placebo;
PURSUIT        eptifibatide versus placebo; 
PRISM          tirofiban versus placebo; 
PRISM-PLUS       tirofiban versus placebo; 
PARAGON B     lamifiban versus placebo; 
Boersma et al      GPIs  versus placebo/control.
Gp IIb/IIIa inhibitors better Placebo/ control better
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molecule GPI, tirofiban, was tested 
for its efficacy in the medical 
management of NSTE-ACS (Table 
2). In the PRISM trial, UA patients 
benefited from a 32% relative 
reduction in the composite endpoint 
of death, refractory ischemia or MI at 
48 hours when treated with tirofiban 
and aspirin compared to heparin and 
aspirin (5.6% placebo versus 3.8% 
tirofiban, p=0.01).7 This relative 
benefit was homogenous across all 
age groups (Figure 1). However, 
these results were not sustained 
Summary of Trials of Intravenous GPIs in the Medical Management of NSTE-ACS
Study No. of Entry Criteria Study Medication Primary Efficacy
(Enrolment period) Patients Endpoints
ABCIXIMAB
GUSTO-IV ACS 7800 Patients ≥21 Randomly assigned to: Death or MI at 
(1998–2000) years old with a) abciximab bolus + 24 h infusion (2590) 30 days.
NSTE-ACS. b) abciximab bolus + 48 h infusion (2612)
c) Placebo (2598)
Abciximab dose: 0.25 mg/kg bolus + 0.125 µg/kg infusion
All patients received aspirin, and heparin for 
non-LMWH-sub-study participants.
EPTIFIBATIDE
PURSUIT 10948 Patients with Randomly assigned to: Death or non-
(1995–1997) NSTE-ACS. a) eptifibatide 180 µg/kg + eptifibatide 1.3 µg/kg/min fatal MI at
infusion (1487) (terminated at the interim analysis as 30 days.
high-dose eptifibatide proved safe)
b) eptifibatide 180 µg/kg + eptifibatide 2.0 µg/kg/min
infusion (4722)
c) placebo bolus + infusion (4739) 
Infusion of 72 h or until discharge.
All patients received aspirin and were allowed 
to receive heparin.
TIROFIBAN
PRISM 3232 Patients with Randomly assigned to: Death, MI, or
(1994–1996) UA. a) tirofiban 0.6 µg/kg/min for 30 mins + 0.15 µg/kg for refractory 
47.5 h infusion + placebo heparin (1616) ischemia at
b) placebo tirofiban + heparin (1616) end of 48 h
All received aspirin. infusion.
PRISM-PLUS 1915 Patients with Randomly assigned to: Death, new MI,
(1994–1996) NSTE-ACS. a) tirofiban 0.6 µg/kg/min for 30 mins + 0.15 µg/kg or refractory
for 48 h infusion + placebo heparin (345) ischemia, or
b) tirofiban 0.4 µg/kg/min for 30 mins + 0.10 µg/kg re-hospitalization
for 48 h infusion + dose-adjusted heparin (773) for unstable
c) dose-adjusted heparin + placebo tirofiban (797) angina within
All received aspirin. 7 days. 
LAMIFIBAN
PARAGON A 2282 Patients with Randomly assigned to: Death or 
(1995–1996) NSTE-ACS. a) lamifiban 750 µg bolus + 5.0 µg/min infusion for non-fatal (re)MI
3–5 days + heparin (373) at 30 days.
b) lamifiban 750 µg bolus + 5.0 µg/min infusion for
3–5 days + heparin placebo (396)
c) lamifiban 300 µg bolus + 1.0 µg/min infusion for
3–5 days + heparin (377)
d) lamifiban 300 µg bolus + 1.0 µg/min infusion for
3–5 days + heparin placebo (378)
e) lamifiban placebo + heparin (758)
All patients received heparin.
PARAGON B 5167 Patients ≥21 Randomly assigned to:
(1998–1999) years old with a) 500 µg bolus lamifiban + dose-adjusted lamifiban infusion Death, MI or
NSTE-ACS. ≤ 72 h or until discharge (2597) severe, recurrent
b) placebo (2570) ischemia at
All patients received aspirin and heparin. 30 days.
MI, myocardial infarction; NSTE-ACS, non ST-segment elevation acute coronary syndromes; UA, unstable angina.
Table 2
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when evaluated at seven and 30 
days. 
 
In the second trial, the PRISM-PLUS 
investigators compared the efficacy 
of tirofiban alone, tirofiban and 
heparin in combination, or heparin 
alone in patients diagnosed with UA 
or non-Q-wave MI.8 After the first 
interim safety analysis, the tirofiban 
arm was terminated for safety 
reasons, as excess mortality at 
seven days was evident in this 
group. In the remaining patients, 
tirofiban administered in combination 
with aspirin and heparin appeared to 
reduce the incidence of death, MI, or 
refractory ischemia at seven days 
compared to those who had only 
received aspirin and heparin (17.9% 
heparin alone versus 12.9% 
tirofiban, p=0.004, 28% relative risk 
reduction). Longer-term (i.e., 30 
days and six months) benefits were 
also realized. When the composite 
was analyzed according to 
subgroups of age, the investigators 
found that patients who were 65 
years or older and were treated with 
tirofiban and heparin experienced 
fewer events (death, MI, refractory 
ischemia or re-hospitalization for 
unstable angina) at seven days than 
did those who were treated with 
aspirin and heparin (17.8% versus 
23.5%, 24% relative risk reduction) 
(Figure 1). Similar benefits were also 
realized in those less than 65 years 
of age (8.5% versus 12.4%, 31% 
relative risk reduction). 
 
Lamifiban 
Of the four intravenously 
administered GPIs, only Lamifiban is 
commercially unavailable. 
Inconclusive results of the two large-
scale efficacy trials, PARAGON-A 
and -B, may account for the delay in 
its approval (Table 2).9,10 
PARAGON-A tested the effects of 
two doses of lamifiban, with or 
without heparin and aspirin in UA 
0 0.5 1 1.5 2
<75
≥75
SYMPHONY
≤65
>65
OPUS-TIMI-16
Figure 2.  Age subgroup analysis of primary composite endpoints of trials evaluating 
oral GPIs in NSTE-ACS patients. (No age subgroup analysis reported for the Second 
SYMPHONY trial.)
SYMPHONY (90-day composite endpoint)      
 low-dose sibrafiban versus placebo;      
 high-dose sibrafiban versus placebo; 
OPUS-TIMI-16 (10-month composite endpoint)      
 orbofiban versus placebo.
Gp IIb/IIIa inhibitors better Placebo/ control better
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and non-Q wave MI patients. The 
use of lamifiban did not significantly 
reduce ischemic events at 30 days; 
however, at six months, the low-
dose lamifiban performed better than 
did aspirin and heparin (17.9% 
control, 13.7% low-dose (versus 
control p=0.027), 23.5% relative risk 
reduction, 16.4% high-dose (versus 
control p=0.450), 8% relative risk 
reduction). Compared to standard 
therapy, patients receiving low-dose 
lamifiban used in combination with 
heparin experienced the largest 
reductions in the composite endpoint 
at 30 days (12%, non-significant) 
and at 6 months (30%, p=0.025). 
However, this study was not 
adequately powered to draw clear 
conclusions from this data. 
 
Based on retrospective 
pharmacokinetic analyses of 
PARAGON-A, it was revealed that a 
steady-state concentration of 18 to 
24 ng/mL lamifiban lead to a 
significant reduction (40%) in 
adverse outcomes. A new trial, 
PARAGON-B, was designed to 
evaluate the effects of titrated dosing 
in order to achieve and maintain 
acceptable plasma levels of 
lamifiban. Despite these 
modifications to the dose regime, no 
significant effect on the 30-day or 
six-month composite endpoint of 
death, MI, or severe recurrent 
ischemia was observed (30-day: 
12.8% placebo versus 11.8% 
lamifiban, p=0.329; six-month: 15% 
placebo versus 14% lamifiban, 
p=0.284). A lack of effect was 
evident in both younger ( 65 years) 
and older (>65 years) patients when 
Summary of Oral GPIs for the Secondary Prevention in Acute Coronary Syndrome Patients
Study No. of Indication Study Treatment Arms Primary Efficacy 
(Enrolment period) Patients Endpoint
ORBOFIBAN
OPUS-TIMI 16 10288 Patients ≥18 Randomly assigned to:
(1997–1998) years old a) 50 mg orbofiban twice daily (3537) Death, MI, recurrent
with ACS. b) 50 mg orbofiban twice daily for 30 days ischemia at rest leading
+30 mg orbofiban twice daily (3330) to rehospitalization or
c) placebo (3421) urgent revascularization
All patients received aspirin. or stroke at 14 and
30 days, and every
3 months afterwards
up until 1 year 
(6 month minimum).
SIBRAFIBAN
SYMPHONY 
(1997–1998) 9233 Patients with Randomly assigned to: Death, non-fatal (re)MI,
ACS. a) low-dose (weight-adjusted) sibrafiban (3105) or severe recurrent
b) high-dose (weight-adjusted) sibrafiban (3039) ischemia at 90 days.
c) aspirin (80 mg twice daily) control (3089)
Second SYMPHONY 
(1999)
6671 Patients with Randomly assigned to: Time to death, MI or
ACS. a) low-dose (weight-adjusted) sibrafiban + recurrent ischemia.
aspirin (80 mg twice daily) (2232)
b) high-dose (weight-adjusted) sibrafiban (2174)
c) aspirin (80 mg twice daily) control (2231)
ACS, acute coronary syndromes; MI, myocardial infarction.
Table 3
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the primary composite endpoint was 
evaluated at six months (Figure 2). 
Similarly to PARAGON-A, the lack of 
power in this trial should be taken 
into account when evaluating these 
results. 
 
Overview of Intravenous GPIs 
in Elderly Patients 
In general, the trials of intravenous 
GPIs in NSTE-ACS patients 
revealed significant reductions in 
adverse cardiac events; however, a 
problem among some of the trials 
was inadequate power for the 
detection of a large treatment effect. 
To provide a global picture of these 
agents, a meta-analysis of combined 
trial data was performed.11 Overall, 
GPIs significantly reduced (8% 
relative) the composite endpoint of 
death or non-fatal MI at 30 days 
(11.8% control/placebo versus 
10.8% GPIs, OR 0.91, 95% CI 
(0.85,0.98), p=0.015). Similarly, 
these benefits were observed in the 
reduction of the composite endpoint 
of death or MI in patients of all ages 
(p (for interaction) = 0.10) (Figure 1). 
However, reductions in death (3.7% 
control versus 3.4% GPIs, OR 0.91, 
95%CI (0.81, 1.03), p=0.14) and in 
the composite of death, MI or 
revascularization (44.3% control 
versus 42.7% GPIs, OR 0.98 (0.93, 
1.02), p=0.33) were not statistically 
Bleeding Complications, Intracranial Hemorrhage and Stroke at 30 days in Patients
Enrolled in Trials of Intravenous GPIs in NSTE-ACS Patients
Trial Study Drug Major Minor Intracranial Stroke (%)
(no. of patients) bleeding (%) bleeding (%) hemorrhage (%)
GUSTO-IV ACS Placebo (2598) 0.3 2.0 -- --
Abciximab 24-h infusion (2590) 0.6 3.0* -- --
Abciximab 48-h infusion (2612) 1.0* 4.0* -- --
PURSUIT Placebo (4696) 9.1 7.4 0.1 0.8
Eptifibatide (4679) 10.6* 12.9 0.1 0.7
PRISM Heparin (1616) 0.4 1.9 0.1 --
Tirofiban (1616) 0.4 2.0 0.1 --
PRISM-PLUS Heparin (797) 0.8 -- 0 --
Tirofiban + heparin (773) 1.4 -- 0 --
PARAGON-A Placebo + heparin (758) 0.8 -- -- 0.4
Low-dose lamifiban + heparin (377) 0.5 -- -- 1.1
Low-dose lamifiban + no heparin (378) 0.8 -- -- 1.1
High-dose lamifiban +heparin (373) 2.4 -- -- 0.5
High-dose lamifiban + no heparin (396) 1.3 -- -- 0.8
PARAGON-B Placebo (2564) 0.9 11.5 0.1 0.6
Lamifiban (2594) 1.3 14.0** 0.1 1.1t
Boersma et al.11 Placebo (13 105) 1.4 -- 0.06 0.69
Any GPI (incl. & excl. heparin) (18 297) 2.4 -- 0.09 0.75
Placebo (incl. heparin) (11 489) 1.4 -- 0.05 0.67
Any GPI (incl. heparin) (15 562) 2.5 -- 0.08 0.73
Placebo (incl. heparin) (2735) 1.8 -- 0.06 0.69
Any GPI (excl. heparin) (3171) 1.3 -- 0.11 0.88
Placebo (incl. heparin) (10 507) 1.0 -- 0.07 0.71
Eptifibatide or Tirofiban 1.6 -- 0.07 0.80
(incl. and excl. heparin) (13 095)
Bleeding complications defined by Thrombolysis In Myocardial Infarction (TIMI) study group. (21) *p<0.05 for comparison with placebo;
**p=0.002 for comparison with placebo (intermediate bleeding (non-TIMI bleeding classification)). (incl., including; excl., excluding)
tp<0.0006 for comparison to placebo.
Table 4
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significant with GPI therapy. 
 
Oral GPIs in Elderly Patients 
Orbofiban & Sibrafiban 
The prolonged use of oral GPIs may 
extend the benefits of intravenous 
agents and play a role in secondary 
prevention. However, the results of 
the trials on the first generation of 
oral GPIs, OPUSTIMI- 
16 (orbofiban) and the first and 
Second SYMPHONY (sibrafiban) 
trials did not show significant 
reductions in clinical events (Figure 
2).12-14 In the older population, those 
patients receiving the placebo or 
control experienced fewer events 
than did those who received the oral 
GPI. For instance, the administration 
of orbofiban resulted in an increase 
in the incidence of the composite 
endpoint at 10 months in patients 
over 65 years when compared to 
those treated with placebo (Figure 
2).12 In addition, in patients over the 
age of 75 years who were enrolled in 
the first SYMPHONY trial, those who 
received high-dose sibrafiban 
experienced more death, non-fatal 
(re)-MI or recurrent ischemia at 90 
days than did those receiving aspirin 
(Figure 2).13 
 
The next generation of oral agents 
may find success if the challenges of 
inter-patient variation in inhibition 
levels (due to differences in 
bioavailability or genetics), 
establishment of titrated doses and 
development of longer half-lives with 
higher binding affinities to increase 
the level of stable inhibition are 
resolved.15,16 
 
Contraindications and Adverse 
Effects 
Patients with active bleeding or a 
history of bleeding diathesis, 
gastrointestinal or genitourinary 
bleeding (within last six months), 
major surgery within the past three 
months, a history of stroke and a 
history of recent trauma are not 
recommended recipients of this 
therapy.17 Other contraindications 
include uncontrolled hypertension ( 
180 mmHg systole and/or  
110mmHg diastole), severe anemia 
and thrombocytopenia.17 
 
Bleeding Complications, Intracranial Hemorrhage and Stroke at 30 days in Patients
Enrolled in Trials of Oral GPIs
Trial Study Drug Major Minor Intracranial Stroke (%)
(no. of patients) bleeding (%) bleeding (%) haemorrhage (%)
OPUS-TIMI 16 Placebo (3421) 1.20 5.8 0.1 0.4
Low-dose orbofiban (3537) 2.0** 11.0‡ 0.1 0.5
High-dose orbofiban (3330) 2.3t 11.9‡ 0.1 0.7
SYMPHONY Aspirin (3075) 3.9 12.6 -- 0.81
Low-dose sibrafiban (3083) 5.2§ 17.7§ -- 0.84
High-dose sibrafiban (3014) 5.7§ 24.6§ -- 0.56
Second SYMPHONY Aspirin (2229) 4.0 10.5 -- 0.6
Low-dose sibrafiban + aspirin (2235) 5.7§ 19.9§ -- 0.7
High-dose sibrafiban (2173) 4.6 21.0§ -- 0.7
Bleeding complications defined in OPUS-TIMI-16 and the first and Second SYMPHONY trials by Thrombolysis In Myocardial Infarction (TIMI) study
group. (21) **p=0.007 for comparison to placebo; tp=0.0006 for comparison to placebo; ‡p<0.0001 for comparison to placebo. 90-day and 7-
day safety endpoints evaluated in the first SYMPHONY and Second SYMPHONY trials, respectively. §p<0.05 for comparison to aspirin.
Table 5
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In general, the use of intravenous 
GPIs in NSTE-ACS patients was 
related to an increase in the 
incidence of major bleeding 
complications (Table 4).11 GPI 
therapy was also a suspected 
contributor to excess intracranial 
hemorrhage and stroke; however, 
the incidence of intracranial 
hemorrhage (ICH) was rare in the 
trials of intravenous GPIs in the 
medical management of NSTE-ACS 
patients, and its use with or without 
heparin was not associated with an 
excess incidence of ICH (Table 4).11 
Similarly, the incidence of stroke 
was also not associated with this 
therapy.11 
 
Thrombocytopenia is another 
possible, but infrequent, side effect 
of this therapy. The incidence of mild 
thrombocytopenia (< 100 000 
platelets/mm3) was 5% in those 
receiving 24-hour infusion of 
abciximab (p<0.05 versus placebo) 
and 7% (48-hour infusion; p<0.05 
versus placebo) compared to 1% 
(placebo) in the GUSTO-IVACS 
trial.4 When this safety endpoint was 
evaluated in the PURSUIT trial, 
eptifibatide was not associated with 
excess mild thrombocytopenia (6.8% 
eptifibatide versus 6.7% placebo). 
However, those receiving eptifibatide 
were more likely to suffer from 
severe thrombocytopenia (< 20 000 
platelets/mm3) than were those 
receiving placebo (0.2% versus 
<0.1%; relative risk 5.0, 95% CI(1.3, 
32.4)).6 The PRISM and PRISM-
PLUS trials also noted that tirofiban 
was significantly associated with 
thrombocytopenia (defined as fewer 
than 90 000 platelets/mm3), but the 
number of actual patients affected is 
quite low.7,8 When compared to the 
placebo, the use of lamifiban was 
not associated with the incidence of 
thrombocytopenia.10 
 
Safety concerns with the use of oral 
GPIs are minor and are mainly due 
to gastric bleeding (Table 5). 
Typically, bleeding was not severe 
and posed more of an annoyance to 
patients through bruising and 
bleeding of the gums, nose, 
hemorrhoids and menses. 
 
CONCLUSION 
Although the age- and sex-
standardized mortality due to 
ischemic heart disease has declined 
over the past two decades, the 
incidence of acute coronary 
syndromes is expected to increase 
as the proportion of the Canadian 
population above age 65 increases 
from 13 to 21% over the next twenty 
years.18,19 In addition to advanced 
age, the clinical profile of these 
patients often includes comorbidities 
such as diabetes mellitus and 
hypertension, which add to the 
overall complexity of medical 
decision-making. Despite this, older 
patients do derive similar relative, 
and hence, greater absolute benefit 
from GPI therapy in the medical 
management of NSTE-ACS 
compared to their younger 
counterparts.20 
 
The majority of the trials only 
compare the primary composite 
clinical endpoint in patients younger 
than 65 years to those over the age 
of 65 years. Efforts should be made 
to report more in-depth, age-specific 
analyses, particularly on safety 
endpoints. Future investigations 
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should specifically address optimal 
strategies for this rapidly expanding 
proportion of the population.  
 
REFERENCES 
1. Ambrose JA. Plaque disruption 
and the acute coronary syndromes 
of unstable angina and myocardial 
infarction: if the substrate is similar, 
why is the clinical presentation 
different? J Am Coll Cardiol 1992; 
19:1653-8. 
2. Libby P. Coronary artery injury 
and the biology of atherosclerosis: 
inflammation, thrombosis, and 
stabilization. Am J Cardiol 2000; 
86:3J-8J. 
3. Coller BS. The role of platelets in 
arterial thrombosis and the rationale 
for blockade of platelet GPIIb/IIIa 
receptors as antithrombotic therapy. 
Eur Heart J 1995; 16 Suppl L:11-5. 
4. Simoons ML. Effect of 
glycoprotein IIb/IIIa receptor blocker 
abciximab on outcome in patients 
with acute coronary syndromes 
without early coronary 
revascularisation: the GUSTO IV-
ACS randomised trial. Lancet 
2001; 357:1915-24. 
5. Schulman SP, Goldschmidt-
Clermont PJ, Topol EJ et al. Effects 
of Integrilin, a platelet glycoprotein 
IIb/IIIa receptor antagonist, in 
unstable angina. A randomized 
multicenter trial. Circulation 1996; 
94:2083-9. 
6. The PURSUIT Trial Investigators. 
Inhibition of platelet glycoprotein 
IIb/IIIa with eptifibatide in patients 
with acute coronary syndromes. 
Platelet Glycoprotein IIb/IIIa in 
Unstable Angina: Receptor 
Suppression Using Integrilin 
Therapy. N Engl J Med 1998; 
339:436-43. 
7. Platelet Receptor Inhibition in 
Ischemic Syndrome Management 
(PRISM) Study Investigators. 
Acomparison of aspirin plus tirofiban 
with aspirin plus heparin for unstable 
angina. N Engl J Med 1998; 
338:1498-1505. 
8. Platelet Receptor Inhibition in 
Ischemic Syndrome Management in 
Patients Limited by Unstable Signs 
and Symptoms (PRISMPLUS) 
Study Investigators. Inhibition of the 
platelet glycoprotein IIb/IIIa receptor 
with tirofiban in unstable angina and 
non-Q-wave myocardial infarction. N 
Engl J Med 1998; 338:1488-97. 
9. Platelet IIb/IIIa Antagonism for the 
Reduction of Acute coronary 
syndrome events in a Global 
Organization Network. International, 
randomized, controlled trial of 
lamifiban (a platelet glycoprotein 
IIb/IIIa inhibitor), heparin, or both in 
unstable angina. Circulation 1998; 
97:2386-95. 
10. The PARAGON-B Investigators. 
Randomized, placebo-controlled trial 
of titrated intravenous lamifiban for 
acute coronary syndromes. 
Circulation 2002; 105:316-21. 
11. Boersma E, Harrington RA, 
Moliterno DJ et al. Platelet 
glycoprotein IIb/IIIa inhibitors in 
acute coronary syndromes: a meta-
analysis of all major randomised 
clinical trials. Lancet 2002; 359:189-
98. 
12. Cannon CP, McCabe CH, Wilcox 
RG et al. Oral glycoprotein IIb/IIIa 
inhibition with orbofiban in patients 
with unstable coronary syndromes 
(OPUS-TIMI 16) trial. Circulation 
2000; 102:149-56. 
13. Sibrafiban versus Aspirin to Yield 
Maximum Protection from Ischemic 
Heart Events Postacute Coronary 
 117 
Syndromes Investigators. 
Comparison of sibrafiban with 
aspirin for prevention of 
cardiovascular events after acute 
coronary syndromes: a randomised 
trial. Lancet 2000; 355:337-45. 
14. The Second SYMPHONY 
Investigators. Randomized trial of 
aspirin, sibrafiban, or both for 
secondary prevention after acute 
coronary syndromes. Circulation 
2001; 103:1727-33. 
15. OConnor FF, Shields DC, 
Fitzgerald Aet al. Genetic variation in 
glycoprotein IIb/IIIa (GPIIb/IIIa) as a 
determinant of the responses to an 
oral GPIIb/IIIa antagonist in patients 
with unstable coronary syndromes. 
Blood 2001; 98:3256-60. 
16. Theroux P. Oral inhibitors of 
platelet membrane receptor 
glycoprotein IIb/IIIa in clinical 
cardiology: issues and opportunities. 
Am Heart J 1998; 135(5 Pt 2 
Su):S107-12. 
17. Bhatt DL, Topol EJ. Current role 
of platelet glycoprotein IIb/IIIa 
inhibitors in acute coronary 
syndromes. JAMA 2000; 284:1549-
58. 
18. Heart and Stroke Foundation of 
Canada. Heart and Stroke 
Foundation of Canada: The 
changing face of heart disease in 
Canada. 1-107. 1999. Ottawa, 
Canada, Heart and Stroke 
Foundation of Canada. 
19. Statistics Canada. Population 
projections for 2001, 2006, 2011, 
2016, 2021 and 2026. 
http://www.statcan.ca/english/Pgdb/
People/Population/demo23a. 
htm . Accessed 28-2-2002. 
20. Cannon CP. Elderly patients with 
acute coronary syndromes: Higher 
risk and greater benefit from 
antithrombotic and interventional 
therapies. Am J Geriatric Cardiol 
2000; 9:265-70. 
21. Rao AK, Pratt C, Berke Aet al. 
Thrombolysis in Myocardial 
Infarction (TIMI) Trial--phase I: 
hemorrhagic manifestations and 
changes in plasma fibrinogen and 
the fibrinolytic system in patients 
treated with recombinant tissue 
plasminogen activator and 
streptokinase. J Am Coll Cardiol 
1988; 11:1-11. 
 118 
 119 
Chapter Nine 
 
Effects of platelet glycoprotein IIb/IIIa 
receptor blockers in non-STsegment 
elevation acute coronary syndromes: 
Benefit and harm in different age 
subgroups 
Adrián V. Hernández, Cynthia M. Westerhout, Ewout W. 
Steyerberg, John P.A. Ioannidis, Héctor Bueno, Harvey 
White, Pierre Theroux, David J. Moliterno, Paul W. 
Armstrong, Robert M. Califf, Lars C. Wallentin, Maarten L. 
Simoons, Eric Boersma 
 
OBJECTIVE To investigate whether beneficial and harmful effects of platelet glycoprotein (GP) 
IIb/IIIa receptor blockers in non-ST-elevation acute coronary syndromes (NSTE-ACS) depend on 
age. 
METHODS A meta-analysis of 6 trials of GP IIb/IIIa receptor blockers in NSTE-ACS patients 
(PRISM, PRISM-PLUS, PARAGON-A, PURSUIT, PARAGON-B, GUSTO IV-ACS; n=31,402) 
was performed. We applied multivariable logistic regression analyses to evaluate the drug 
effects on death or non-fatal MI at 30 days, and on major bleeding, by age subgroups (<60, 60-
69, 70-79, 80 years). We quantified the reduction of death or MI as number needed to treat 
(NNT), and the increase of major bleeding as number needed to harm (NNH). 
RESULTS Subgroups had 11,155 (35%), 9,727 (31%), 8,468 (27%), and 2,049 (7%) patients, 
respectively. The relative benefit of GP IIb/IIIa receptor blockers did not differ significantly 
(p=0.5) across age subgroups (odds ratio [95% CI] for death or MI: 0.86 [0.74-0.99], 0.90 [0.80-
1.02], 0.97 [0.86-1.10], 0.90 [0.73-1.16]; overall 0.91 [0.86-0.99]). Odds ratios for major bleeding 
were 1.9 (1.3- 2.8), 1.9 (1.4-2.7), 1.6 (1.2-2.1), and 2.5 (1.5-4.1). Overall NNT was 105, and 
overall NNH was 90. The oldest had larger absolute increases in major bleeding, but also had 
the largest absolute reductions of death or MI. Patients 80 years had half of the NNT and a 
third of the NNH in comparison with patients <60 years. 
CONCLUSIONS In patients with NSTE-ACS, the relative reduction of death or non-fatal MI with 
GP IIb/IIIa receptor blockers was independent of patient age. Larger absolute outcome 
reductions were seen in the elderly, but with a higher risk of major bleeding. A close monitoring 
of these patients is warranted. 
 
Platelet glycoprotein (GP) IIb/IIIa 
receptor blockers decrease the risk 
of death or non-fatal myocardial 
infarction (MI) at 30 days in patients 
with non-ST elevation acute 
coronary syndromes (NSTE-ACS) 
who are not routinely scheduled for 
early revascularization [1-4]. Age is 
an important risk factor for these 
patients, and if the relative benefits 
of effective interventions are the 
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same across age groups, physicians 
should treat the elderly even more 
aggressively than the younger, since 
the absolute benefit may be larger 
[5]. However, in clinical practice, the 
utilization of GP IIb/IIIa receptor 
blockers is lower among elderly 
patients [6]. 
 
Elderly patients may be under-
treated because of several reasons: 
they were underrepresented or 
excluded from randomized clinical 
trials (RCTs), clinicians may believe 
that benefits in younger may not 
generalize to the elderly, or they 
may be worried about harmful 
effects in elderly patients [5]. 
Researchers have argued that the 
benefit of GP IIb/IIIa receptor 
blockers is greater in younger 
patients [7], similar in old and 
younger patients [8], or greater in 
older patients given their higher 
baseline risk [5, 9]. 
 
Yet, it is difficult to determine how 
the efficacy of GP IIb/IIIa receptor 
blockers varies among 
age subgroups because most trials 
are not large enough to provide a 
reliable answer. Individual ACS 
trials have been inconclusive or 
even conflicting regarding the 
presence or absence of relative 
differences in drug effects across 
ages [10-15]. Usually, the patient 
population was only split in two age 
groups (e.g. <65 years, 65 years) 
[11, 13-15], and different primary 
endpoints were considered. An 
evaluation of the drug effects across 
age groups in a meta-analysis using 
individual data can better define its 
relative and absolute efficacies in 
older vs. younger patients. 
One more issue is relevant in the 
interpretation of the effects of GP 
IIb/IIIa receptor blockers by age 
groups. The incorporation of harmful 
major bleeding rates in the 
evaluation of effects should be 
considered to further understand the 
net drug effectiveness across age 
strata [5, 9, 16]. 
 
We investigated whether the relative 
effects of GP IIb/IIIa receptor 
blockers were consistent across age 
subgroups in non-ST-segment 
elevation ACS patients. Further, we 
evaluated whether the absolute 
benefits and harms differed across 
age subgroups.  
 
METHODS 
Trial selection 
A meta-analysis of individual patient 
data was performed, including trials 
reported since 1990 with the 
following characteristics: 
randomization of patients with 
NSTE-ACS, comparison of a GP 
IIb/IIIa receptor blocker with placebo 
or control therapy, no-
recommendation for early (<48h) 
coronary revascularization during 
study-drug infusion, and enrolment 
of at least 1000 patients. Six trials 
met the inclusion criteria -PRISM, 
PRISM-PLUS, PARAGON-A, 
PURSUIT, PARAGON-B, and 
GUSTO IVACS- [10-15] with a total 
of 31,402 patients. Details of the trial 
designs are available elsewhere [3]. 
 
Patient baseline characteristics 
An electronic database consisting of 
data from individual patients in all 
eligible trials was available [3]. 
These data were checked for 
completeness, for internal 
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consistency of patients records, and 
for consistency with the published 
reports. For this analysis, baseline 
characteristics regarded as 
important predictors of the outcome 
for which information was almost 
complete (i.e. less than 1% missing) 
were age, gender, diabetes, 
smoking, previous myocardial 
infarction [MI], previous heart failure 
[HF], previous coronary artery 
bypass surgery (CABG), previous 
percutaneous coronary intervention 
(PCI), and ST-segment depression. 
Other important predictors had more 
than 20% of missing data: blood 
pressure and heart rate were not 
recorded in the GUSTO IV-ACS trial 
(n=7800, 25%); and baseline 
creatine kinase MB (CK-MB) was 
missing in 7469 patients (24%) 
across different trials. Blood 
pressure, heart rate and CK-MB 
were used in addition to the other 
predictors in secondary analyses 
that yielded largely similar results. 
 
Endpoints 
For this analysis, the primary 
efficacy endpoint was defined a 
priori as the composite of death of 
any cause or non-fatal MI at 30 
days. MI was part of the composite 
outcome of all trials. The MI 
definitions had subtle differences 
across trials regarding the CK-MB 
threshold [3] (Table 1). However, all 
trials had pre-specified definitions of 
Table 1: Definitions of primary efficacy and harm endpoints across trials 
 PRISM PRISM-
PLUS 
PARAGON-A       PURSUIT PARAGON-
B 
GUSTO 
ACS-IV 
Primary 
efficacy end 
point 
Death, MI 
or refractory 
ischemia at 
48 hours 
Death, MI 
or refractory 
ischemia at 
7 days 
Death of MI 
at 30 days 
Death or MI 
at 30 days 
Death, MI or 
severe, 
recurrent 
ischemia at 30 
days  
 
Death or MI 
at 30 days 
Required 
level of CK 
or CK-MB 
elevation in 
MI 
definition 
2xULN 2xULN; in 
relation to 
PCI: 
3xULN 
2xULN 1xULN; in 
relation to 
PCI: 3xULN; 
in relation to 
CABG: 
5xULN 
2xULN; in 
relation to 
PCI: 3xULN; 
in relation to 
CABG: 
5xULN 
 
3xULN 
Primary 
harm end 
point: 
major 
bleeding 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
decrease in 
hemoglobin 
concentration 
≥50 g/L; or 
cardiac 
tamponade 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
decrease in 
hemoglobin 
concentration 
≥40 g/L; 
bleeding 
requiring 
transfusion 
≥2 units 
blood; or 
bleeding 
requiring 
surgery  
Intracraneal 
hemorrhage; 
bleeding 
leading to 
hemodynamic 
compromise 
requiring 
intervention 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
hemodynamic 
compromise 
requiring 
intervention 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
hemodynamic 
compromise 
requiring 
intervention 
Intracraneal 
hemorrhage; 
bleeding 
leading to 
decrease in 
hemoglobin 
concentration 
≥ 50 g/L 
MI: myocardial infarction; CK: creatine kinase; CK-MB: creatine kinase fraction MB; ULN: Upper limit of normal;  
PCI: Percutaneous coronary intervention; CABG: Coronary-artery bypass graft 
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MI [17, 18]. Secondary endpoints 
were: death; non-fatal MI; coronary 
artery bypass graft (CABG); 
percutaneous coronary intervention 
(PCI); and CABG or PCI. The 
primary harm endpoint was major 
bleeding within 30 days. Individual 
trial definitions of major bleeding had 
also at most subtle differences, and 
trial-specific definitions were 
retained [3]. We should 
acknowledge that death or non-fatal 
MI and major bleeding do not have 
the same utility, and therefore are 
not comparable events. A few 
patients with major bleeding die or 
have an MI within 30 days, and not 
all of the remaining patients have 
long-term negative outcomes. 
Determining the relative weights of 
these events is largely subjective. A 
recent review identified that the 
weight of a major bleeding related to 
a drug in the context of an acute 
coronary syndrome was 0.87, in 
comparison with the weight of death, 
which was equal to zero [19]. 
 
Efficacy analysis by age 
We divided the patient data into four 
subgroups according to age: <60, 
60-69, 70-79, and 80 years old. 
The decision to group patients in 
these intervals was made a priori, 
and was based on decade intervals 
of common clinical use. The choice 
 
Table 2. Patient characteristics by age subgroups. 
 
<60 years  
(n=11,155) 
   60-69 years 
(n=9,727) 
 70-79 years 
(n=8,468) 
≥80 years  
(n=2,049) 
 
N %  N %  N % 
 
N % 
Gender   
   Male 
 
  8275 
 
 74 
 
 
 
   6274 
 
65 
 
 
 
  4841   
  
57 
  
    997 
   
49 
Diabetes  
   Yes 
 
  1771 
 
 16 
  
   2360 
 
24 
 
  
 
  2269 
  
27 
  
    461 
   
  23 
Smoking  
   Never 
   Former 
   Current 
 
  3931 
  3144 
  4036 
 
 35 
 28 
 36 
  
   3439 
   3537 
   2709 
 
36 
37 
28 
  
  3269 
  3133 
  2015 
  
39 
37 
24 
  
    861 
    621 
    552 
   
  42 
  31 
  27 
Previous MI  
   Yes 
 
  3164 
 
 28 
  
   3445 
 
36 
  
  3162 
   
37 
  
    877 
   
  43 
Previous HF  
   Yes 
 
    578 
 
   5 
  
     962 
 
10 
  
  1191 
  
14 
  
    437 
   
  21 
Previous CABG  
   Yes 
 
  1088 
 
 10 
  
   1305 
 
13 
  
  1194 
  
14 
  
    185 
   
    9 
Previous PCI 
   Yes 
 
  1454 
 
 13 
  
   1251 
 
13 
  
    956 
   
11 
  
    162 
   
    8 
ST depression 
   Yes 
 
  5096 
 
 46 
  
   5475 
 
57 
  
  5441 
  
65 
  
  1403 
   
  69 
Trial 
   PRISM 
   PRISMPLUS 
   PARAGON-A 
   PURSUIT 
   PARAGON-B 
   GUSTO IV 
 
  1274  
    693 
    737 
  4082 
  1976 
  2393 
 
 11 
   6 
   7 
 37 
 18 
 21 
  
   1005 
     603 
     728 
   3553 
   1513 
   2325 
 
10 
  6 
  8 
37 
16 
24 
  
    781 
    495 
    631 
  2763 
  1374 
  2424 
 
  9 
  6 
  8 
33 
16 
29 
  
    172 
    124 
    183 
    550 
    362 
    658 
 
    8 
    6 
    9 
  27 
  18 
  32 
MI denotes myocardial infarction, HF: heart failure, CABG: coronary artery bypass graft, PCI: percutaneous 
coronary intervention, y: years. Differences among age subgroups were highly significant (p<0.001). 
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of other cut-off points (e.g. quartiles) 
yielded similar results (not shown). 
Relative differences between GP 
IIb/IIIa receptor blockers and 
placebo/control on the primary 
endpoint by age subgroups were 
assessed, within each trial and 
across all trials. Logistic regression 
models were used, and odds ratios 
(OR) and corresponding 95% 
confidence intervals (95% CI) were 
calculated. To evaluate GP IIb/IIIa 
receptor blocker effect modification 
by age in each individual trial and in 
all trials, interaction tests were used 
[20]. These tests also evaluated 
heterogeneity of effects across trials. 
The effects of GP IIb/IIIa receptor 
blockers and the interactions were 
adjusted for the previously described 
predictors, for trial, and for potential 
differences in age-related trends 
between trials. These effects were 
combined using random effects 
calculations [21]. Heterogeneity of 
interactions across trials was 
evaluated with the random effects 
inverse variance model (with trial 
being the random effect) [22]. 
 
Benefit and harm of GP IIb/IIIa 
receptor blockers by age 
subgroups 
We performed analyses that 
incorporated the relation among the 
baseline risk (eBR, proportion of 
patients in the placebo/control group 
with the primary efficacy endpoint), 
the efficacy Odds Ratio (eOR), and 
the respective number needed to 
treat [NNT]. The calculation of NNT 
was done using eBR and eOR, with 
the formula: [1-eBR(1-eOR)]/ 
[eBR(1-eBR)(1-eOR)] [22]. The NNT 
is the number of patients who need 
to be treated in order to prevent one 
additional death or non-fatal MI. It is 
the inverse of the absolute risk 
reduction (ARR). Further, we looked 
at the relation among the baseline 
proportion of the primary harm 
endpoint in the placebo/control 
group (hBR), the harm Odds Ratio 
(hOR), and the respective number 
needed to harm [NNH]. The NNH 
was calculated using hBR and hOR, 
Table 3. Treatment effect on various endpoints at 30 days according to age subgroups. 
 
 <60y (n=11,155)    60-69y (n=9,727)  70-79y (n=8,468)  ≥80y (n=2,049) 
 Events % OR*  
(95% CI) 
 Events %     OR 
    (95% CI) 
   Events  % OR 
(95% CI) 
 Events % OR 
(95% CI) 
Death† 
   GP IIb/IIIa 
   Placebo/Control 
 
  70 
  58 
  
1.1 
1.2  
 
0.86 
(0.61-1.23) 
  
  165   
  124   
 
2.9 
3.0 
 
0.98 
(0.77-1.24) 
  
  281 
  215 
 
5.6 
6.2 
 
0.91 
(0.75-1.09) 
  
  115 
    88 
 
9.5 
10.5 
 
0.90 
(0.67-1.21) 
Nonfatal MI‡ 
   GP IIb/IIIa 
   Placebo/Control 
 
 372 
 316 
 
5.7 
6.8 
 
0.83 
(0.72-0.97) 
  
  428 
  365   
 
7.6 
  8.8 
 
0.85 
(0.74-0.99) 
  
  437 
  299 
 
  8.8 
  8.6 
 
1.02 
(0.87-1.19) 
  
  112 
    85 
 
  9.3 
10.1 
 
0.91 
(0.68-1.23) 
Death or MI 
   GP IIb/IIIa 
   Placebo/Control 
 
 442 
 374 
 
6.8 
8.0 
 
0.86 
(0.74-0.99) 
  
  593 
  489 
 
10.6 
11.9 
 
0.90 
(0.80-1.02) 
  
  718 
  514 
 
14.4 
14.8 
 
0.97 
(0.86-1.10) 
  
  227 
  173 
 
18.8 
20.5 
 
0.90 
(0.73-1.16) 
CABG 
   GP IIb/IIIa 
   Placebo/Control 
 
 828 
 590 
 
12.7 
12.7 
 
1.00 
(0.90-1.13) 
  
  931 
  732 
 
16.6 
17.7 
 
0.92 
(0.83-1.03) 
  
  860 
  603 
 
17.2 
17.3 
 
0.99 
(0.88-1.11) 
  
  102 
    67 
 
8.5 
8.0 
 
1.07 
(0.77-1.47) 
PCI 
   GP IIb/IIIa 
   Placebo/Control 
 
 1839 
 1404 
 
28.3 
30.1 
 
0.92 
(0.84-0.99) 
  
1369 
  991 
 
24.4 
24.0 
 
1.02 
(0.93-1.12) 
  
  894 
  684 
 
17.9 
19.7 
 
0.89 
(0.80-1.00) 
  
  171 
  131 
 
14.2 
15.6 
 
0.90 
(0.70-1.15) 
CABG or PCI 
   GP IIb/IIIa 
   Placebo/Control 
 
 2618 
 1960 
 
40.3 
42.1 
 
0.93 
(0.86-1.00) 
  
2264 
1699 
 
40.4 
40.8 
 
0.97 
(0.89-1.05) 
  
1721 
1258 
 
34.5 
36.2 
 
0.93 
(0.85-1.02) 
  
  268 
  197 
 
22.2 
23.4 
 
0.93 
(0.76-1.15) 
Major bleeding 
   GP IIb/IIIa 
   Placebo/Control 
 
     90 
     35 
 
  1.5 
  0.8 
 
1.90 
(1.28-2.81) 
  
  118 
    46 
 
  2.3 
  1.1 
 
1.94 
(1.38-2.74) 
  
  174 
    80 
 
  3.8 
  2.3 
 
1.58 
(1.21-2.07) 
  
    63 
    19 
 
  5.7 
  2.3 
 
2.46 
(1.46-4.14) 
    * Odds ratio of treatment effect between GP IIb/IIIa and Placebo/Control, GP IIb/IIIa denotes platelet glycoprotein IIb/IIIa receptor blockers; †Death within 30 days; ‡ Non-fatal
myocardial infarction in patients who survived at least 30 days. Number of patients per age group: <60 y: GP 6496, Placebo/control 4659; 60-69 y: GP 5602, Placebo/control
4125; 70-79 y: GP 4991, Placebo/control 3477; >80 y: GP: 1207, Placebo/control: 842.  
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with the formula: [hBR(hOR-
1)+1]/[hBR(1-hBR)(hOR-1)] [23]. 
The NNH is the number of patients 
who need to be treated in order to 
cause one major bleeding. It is the 
inverse of the absolute risk increase 
(ARI). The NNT and NNH 
calculations were done overall and 
by age subgroups. 
 
Role of the funding source 
The trials included in this analysis 
were sponsored by several 
pharmaceutical companies, which 
are mentioned in the main trial 
reports [10-15], and in the 
acknowledgements. This study was 
designed, conducted, and 
interpreted independently of the 
sponsors. These had the right to 
review the manuscript, but not 
censor the findings. No separate 
industrial grant was obtained for this 
investigation. 
 
Age subgroups and predictors 
Overall, 11,155 (35%) patients were 
< 60, 9,727 (31%) were 60-69, 8,468 
(27%) were 70-79, and 2,049 (7%) 
were  80 years-old. Baseline 
characteristics across age 
subgroups are shown in Table 2. 
 
The proportion of women and of 
patients with a history of diabetes, 
MI or HF, and ST depression 
increased with age. Further, patients 
80 years had lower proportions of 
previous revascularisation 
procedures than younger patients. 
The proportion of patients older than 
70 years ranged between 30% in the 
PURSUIT and PRISM trials and 
40% in the GUSTO IV-ACS trial. 
 
Endpoints at 30 days by age 
subgroups 
The overall adjusted relative 
reduction in the odds of death or MI 
at 30 days was 9% (OR 0.91; 95% 
CI [0.85-0.99]). There was no 
difference in the relative benefit of 
GP IIb/IIIa receptor blockers across 
age subgroups (p for interaction = 
0.5) and this was true also for 
secondary efficacy endpoints (Table 
Table 4. Treatment effects on death or MI at 30 days according to age subgroups, by trial and overall.  
 
* Odds ratios of each age subgroup adjusted for trial. 
† Predictors included: age, gender, diabetes, smoking, previous MI, previous heart failure, previous CABG, previous PTCA, ST depression.  
‡ Odds ratios adjusted for predictors, and age trend. The interactions age by GP IIb/IIIa are significantly different among trials. p: p-value. 
 PRISM 
N=3,232 
PRISMPLUS 
N=1,915 
PARAGON-A 
N=2,282 
PURSUIT 
N=10,948 
PARAGON-B 
N=5,225 
GUSTO IV-ACS 
N=7,800 
TOTAL* 
N=31,402 
Age <60 years 
    OR (95% CI)    
 
 
1.13 
(0.66-1.96) 
 
0.98 
(0.54-1.78) 
 
1.65 
(0.83-3.30) 
 
0.72 
(0.59-0.88) 
 
0.90 
(0.64-1.27) 
 
1.01 
(0.65-1.55) 
 
0.86 
(0.74-0.99) 
Age 60-69 years 
    OR (95% CI) 
 
 
0.86 
(0.53-1.38) 
 
0.58 
(0.35-0.96) 
 
0.87 
(0.55-1.39) 
 
0.93 
(0.77-1.20) 
 
0.81 
(0.59-1.12) 
 
1.19 
(0.85-1.67) 
 
0.90 
(0.80-1.02) 
Age 70-79 years 
    OR (95% CI) 
 
0.63 
(0.36-1.09) 
 
1.02 
(0.61-1.70) 
 
0.83 
(0.53-1.31) 
 
0.91 
(0.76-1.11) 
 
1.11 
(0.82-1.50) 
 
1.15 
(0.88-1.50) 
 
0.97 
(0.86-1.10) 
Age ≥80 years 
    OR (95% CI) 
 
 
0.45 
(0.19-1.07) 
 
0.94 
(0.39-2.27) 
 
0.82 
(0.37-1.81) 
 
1.27 
(0.87-1.86) 
 
0.84 
(0.48-1.47) 
 
0.80 
(0.52-1.22) 
 
0.90 
(0.73-1.16) 
All subgroups, 
adjusted for 
predictors† 
 
0.80 
(0.60-1.06) 
 
0.83 
(0.62-1.11) 
 
0.95 
(0.72-1.25) 
 
0.88 
(0.79-0.98) 
 
0.92 
(0.78-1.10) 
 
1.07 
(0.90-1.27) 
 
0.91 
(0.86-0.99) 
Age by GP 
IIb/IIIa 
Interaction  
(p)‡ 
 
 
0.01 
 
 
0.77 
 
 
0.15 
 
 
0.03 
 
 
0.92 
 
 
0.52 
 
 
0.15 
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3). Interestingly, the ratio of non-fatal 
MI over death decreased with 
increasing age. The overall adjusted 
relative increase in the odds of major 
bleeding was 83% (OR 1.83 [1.5-
2.2]). This was especially high for 
patients 80 years (OR 2.5 [1.5-
4.1]), but there were no significant 
differences across ages (p for 
interaction=0.3) (Table 3). 
 
Benefit of GP IIb/IIIa receptor 
blockers per trial by age 
subgroups 
With regard to the incidence of death 
or non-fatal MI, two trials showed 
significantly different relative effects 
across age subgroups, but in 
opposite directions (Table 4). The 
PRISM trial patients had a clear 
gradient of GP IIb/IIIa receptor 
blocker effect across ages: older 
patients had larger odds reductions 
than younger ones (p for 
interaction=0.01). Conversely, 
younger PURSUIT patients had 
larger odds reductions than the older 
ones (p for interaction=0.03). The 
interactions between GP IIb/IIIa 
receptor blockers and age subgroup 
were heterogeneous across trials 
(p=0.002). 
 
Benefit and harm of GP IIb/IIIa 
receptor blocker across age 
subgroups The absolute risk of 
death or MI at 30 days correlated 
with age, varying from 8% in the 
youngest (<60 years) to 21% in the 
oldest group (80 years). Major 
bleeding at 30 days also correlated 
with age, from 0.8% in the youngest 
to 2.3% in the oldest. For the overall 
relative reduction in the odds of 
death or MI of 9%, the NNT was 
105. For the overall relative increase 
in the odds of major bleeding of 
83%, the NNH was 90. 
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Figure 1. Absolute event rate differences between treatment arms (GP IIb/IIIa vs. 
placebo/control) by age subgroups in beneficial (death or myocardial infarction) and harmful 
(major bleeding) endpoints. GP IIb/IIIa denotes platelet glycoprotein IIb/IIIa receptor blockers. 
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The oldest patients had the largest 
absolute reductions of death or MI, 
but also had larger absolute 
increases in major bleeding. Patients 
younger than 70 years had higher 
NNTs and NNHs (149 and 163 for 
those younger than 60 years, and 
105 and 110 for those between 60 
and 69 years) than those older than 
70 years (87 and 55 for those 
between 70 and 79 years, and 67 
and 56 for those older than 80 
years). Figure 1 shows the absolute 
event rate difference between GP 
IIb/IIIa receptor blocker and 
placebo/control arms across age 
subgroups. We noted a rather larger 
harm in patients 70 years and a 
somewhat variable benefit across all 
age subgroups. 
 
DISCUSSION 
In patients with ACS without ST 
elevation, the relative reduction in 
the odds of death or MI at 30 days 
with GP IIb/IIIa receptor blockers 
was largely independent of age. The 
oldest patients had about 3-fold the 
baseline risk of the youngest ones, 
not only for death or MI, but also for 
major bleeding. In the oldest 
patients, the use of GP IIb/IIIa 
receptor blockers yielded larger 
absolute reductions of death/MI, but 
also larger absolute increases in 
major bleeding rates in comparison 
with the youngest patients. 
 
This meta-analysis had more 
statistical power than individual trials 
to explore how the GP IIb/IIIa 
receptor blocker effects vary by age 
[7-9, 24]. Individual trials did not 
report these effects in detail across 
similar age subgroups [10, 11, 13-
15], and they analyzed different 
endpoints. Previous analyses of the 
age effects in single trials have 
yielded inconclusive results [25]. 
Only the PURSUIT and GUSTO IV-
ACS reported the same primary 
endpoint as we used in this paper. 
Also, these analyses did not adjust 
for important predictors of the 
primary endpoint. We found that the 
PRISM and the PURSUIT trials 
showed significant differential 
relative effects of GP IIb/IIIa receptor 
blockers across ages, but 
differences were in the opposite 
direction. We do not fully understand 
this phenomenon. We speculate that 
it could be related to the doses used 
as well as the duration of the study 
drug infusion. This might have 
resulted in different levels of platelet 
inhibition in the PRISM trial (where 
the dose was later shown to produce 
suboptimal platelet inhibition in 
young patients) as compared to the 
PURSUIT trial (where the dose was 
not adjusted for older age or modest 
renal impairment), which might have 
had different consequences in 
younger and older patients. 
 
The effects of other antithrombotics 
have been evaluated in elderly 
patients with unstable angina or 
NSTE-ACS [9]. The low molecular 
weight heparin enoxaparin, 
compared with unfractionated 
heparin, appeared to have greater 
relative and absolute benefit in 
patients aged 65 years and older, as 
compared with younger patients. 
When comparing clopidogrel plus 
aspirin to aspirin alone, there was a 
consistent 20% relative reduction in 
cardiovascular death, myocardial 
infarction, or stroke in both elderly 
and younger patients. For GP IIb/IIIa 
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receptor blockers, we found an 
equivalent relative benefit across 
age subgroups, which translated into 
a greater absolute benefit in older in 
comparison with younger patients. 
 
In order to describe the relative gain 
in primary efficacy end points by age 
subgroups, we defined a ratio of 
reduction of non-fatal MIs to 
reduction of deaths. For instance, a 
ratio higher than 1 shows a larger 
benefit in reduction of non-fatal MIs 
in comparison to reduction of 
deaths. Given that the ratio of non-
fatal MI to death decreased with 
increased age, the use of GP IIb/IIIa 
receptor blockers in the oldest likely 
aborted more deaths than non-fatal 
MIs. 
 
Most trials, meta-analyses, and 
systematic reviews have neglected 
the contribution of major bleeding 
rates in the evaluation of the net GP 
IIb/IIIa receptor blocker effectiveness 
across age subgroups in NSTE-ACS 
patients [1-4, 10-15, 26-31]. Elderly 
patients have higher absolute risks 
of major bleeding [6, 32]. Therefore, 
the interpretation of the overall GP 
IIb/IIIa receptor blocker efficacy 
needs to incorporate this harm. 
Although there was a trend for 
increasing bleeding risk with 
increasing age, this was nowhere 
close to being statistically significant, 
and it should be interpreted 
cautiously given the small number of 
patients in the highest age category. 
An appropriate dosing of GP IIb/IIIa 
receptor blockers is a requisite to 
obtain a higher benefit and a lower 
harm in elderly NSTE-ACS patients. 
The CRUSADE registry 
demonstrated that GP IIb/IIIa 
receptor blockers were underutilized 
and mis-dosed in elderly patients, 
who are at higher risk for adverse 
cardiac events [33]. An essential 
factor that increases the risk of 
major bleeding in elderly patients is 
low renal function, which is 
associated with higher serum levels 
of GP IIb/IIIa receptor blockers. 
Doses used in early trials were more 
aggressive than currently 
recommended doses, which are 
adjusted for renal dysfunction. Thus, 
elderly NSTE-ACS patients should 
receive adequate doses of GP 
IIb/IIIa receptor blockers to obtain 
the expected clinical benefit, and 
these doses should be adjusted for 
their level of renal function to avoid 
major bleeding events. 
 
A recent decision analysis evaluated 
the efficacy of an unspecified 
potential drug on survival in patients 
with MI and unstable angina [5], and 
included serious adverse events 
(fatal complications) as an element 
of the evaluation of benefit-risk 
balance by age-related baseline 
risks. The authors used a registry 
database, and a hard primary 
endpoint (mortality at 1 year). The 
estimate of effectiveness was larger 
than in our randomized data (relative 
risk reduction 25%, absolute risk 
reduction 2%), and the registry 
population was more heterogeneous 
in risk (baseline risk of 2.3% in the 
youngest vs.27% in the oldest). 
They defined a threshold beyond 
which the treatment benefit would be 
outclassed by the treatment harm, 
and found that the fatal complication 
rate would have to be sevenfold 
greater in the oldest compared with 
the youngest age group to outweigh 
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the survival benefits associated with 
treatment. These results need to be 
interpreted cautiously given that 
most major events in these patients 
do not lead to death. Moreover, 
retrospective observational data may 
sometimes inflate estimates of 
treatment efficacy [34]. 
 
Some limitations should be 
acknowledged. First, even with over 
30,000 randomised patients, subtle 
age interactions could have been 
missed, especially for rare events 
such as death. We did not see any 
age interactions for death based on 
the available data (not reported) and 
the clinical significance of subtle 
interactions is debatable. Second, 
the total number of patients in the 
80 age subgroup (n=2049) was 
small, and less than 25% of each of 
the other three groups (n>8400). 
Third, a substantial amount of 
missing values for a few important 
predictors (blood pressure, heart 
rate, CK-MB) limited some 
possibilities of adjusted analysis. 
However, the results with imputed 
data yielded similar conclusions (not 
shown). Fourth, additional research 
into the appropriate weighting of 
events is needed, that can allow a 
more direct comparison between 
benefits and harms. 
 
A series of nuances should be 
considered in interpreting these 
results. The trials included broad 
populations of patients with ACS. 
Through analysis of subgroups, it 
seems evident that higher risk 
patients, such as those with positive 
troponins, diabetes, and perhaps ST 
segment depression, achieve the 
greatest benefit. Further, it is likely 
that patients treated with the 
aggressive revascularisation 
strategy achieve more benefit than 
those treated with the conservative 
strategy. The trials themselves were 
heterogeneous, as GUSTO IV-ACS 
showed no benefit and perhaps a 
detriment of abciximab, and 
PURSUIT used a very liberal 
definition of myocardial infarction 
that minimized the differences 
between eptifibatide and placebo. 
Finally, the category of major 
bleeding overestimates risk relative 
to the risk of blood transfusion, 
which is a more direct measure of 
risk and occurs less frequently 
(Mahaffey KW et al., Circulation, in 
press). The EARLY ACS trial is 
enrolling patients without age limits, 
it is testing whether the benefit of 
antithrombotic drugs is similar 
between elderly and young patients, 
and it is also addressing each of the 
above issues [35]. Allowing for these 
caveats, our analysis provides 
estimates for NNTs and NNHs by 
age subgroups that may be used in 
clinical decision making for the use 
of GP IIb/IIIa receptor blockers in 
NSTE-ACS patients. 
 
In conclusion, the relative risk 
reduction of death or MI with GP 
IIb/IIIa receptor blocker is 
independent of age in patients with 
non-ST-elevation acute coronary 
syndromes. Larger absolute 
reductions of death or MI were 
observed in the oldest in comparison 
with the youngest patients, as well 
as larger absolute increases in major 
bleeding rates. Attention should be 
given to optimizing the benefit to 
elderly patients without increasing 
bleeding, by ensuring that doses 
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adjusted for renal function are given. 
Moreover, elderly patients should be 
monitored more intensively. 
 
ACKNOWLEDGEMENTS 
The data included in this subgroup 
meta-analysis were provided by 
Merck Inc, White House Station, NJ, 
USA (sponsor of the PRISM and 
PRISM-PLUS trials); F. Hoffman-La 
Roche, Basel, Switzerland (sponsor 
of PARAGON-A and PARAGON-B 
trials); COR Therapeutics Inc, San 
Francisco, CA, USA, and Schering-
Plough Inc, Kenilworth, NJ, USA 
(sponsors of the PURSUIT trial); and 
Centocor Inc, Malvern, PA, USA 
(sponsor of the GUSTO IV-ACS 
trial). 
 
CONFLICT OF INTEREST 
STATEMENT 
D J Moliterno is a consultant for 
Merck, Centocor, and Eli Lilly, and 
has received honoraria from the 
same, as well as from Roche. H 
White is a consultant for and has 
received honoraria from Merck. P 
Théroux was principal investigator 
and chairman of the Steering 
Committee for the PRISM-PLUS 
trial. P W Armstrong has received 
research grants and honoraria from 
Eli Lilly and Schering-Plough. R M 
Califf has worked with Centocor, 
Lilly, COR, Schering-Plough, and 
Merck. M L Simoons is a consultant 
for Merck, Centocor, and Lilly, and 
has provided paid expert testimony 
to Schering-Plough. 
FUNDING 
Dr. Adrián V. Hernández received 
support from the Netherlands 
Organization for Scientific Research 
(ZON/MW 908-02-117). 
 
 
REFERENCES 
1. Lincoff AM, Califf RM, Topol EJ. 
Platelet glycoprotein IIb/IIIa receptor 
blockade in coronary artery disease. 
J Am Coll Cardiol 2000;35:1103-15. 
2. Bhatt DL, Topol EJ. Current role 
of platelet glycoprotein IIb/IIIa 
inhibitors in acute coronary 
syndromes. JAMA 2000;284:1549-
58. 
3. Boersma E, Harrington RA, 
Moliterno DJ, et al. Platelet 
glycoprotein IIb/IIIa inhibitors in 
acute coronary syndromes: a meta-
analysis of all major randomised 
clinical trials. Lancet 2002;359:189- 
98. 
4. Schulman SP. Antiplatelet therapy 
in non-ST-segment elevation acute 
coronary syndromes. JAMA 
2004;292:1875-82. 
5. Alter DA, Manuel DG, Gunraj N, 
Anderson G, Naylor CD, Laupacis A. 
Age, risk-benefit trade-offs, and the 
projected effects of evidence-based 
therapies. Am J Med 2004;116:540-
5. 
6. Avezum A, Makdisse M, Spencer 
F, et al. Impact of age on 
management and outcome of acute 
coronary syndrome: Observations 
from the Global Registry of Acute 
Coronary Events (GRACE). Am 
Heart J 2005;149:67-73. 
7. Thompson SG, Higgins JP. Can 
meta-analysis help target 
interventions at individuals most 
likely to benefit? Lancet 
2005;365:341-6. 
8. Mak KH, Effron MB, Moliterno DJ. 
Platelet glycoprotein IIb/IIIa receptor 
antagonists and their use in elderly 
patients. Drugs Aging 2000;16:179-
87. 
9. Cannon CP. Elderly patients with 
 130 
acute coronary syndromes: higher 
risk and greater benefit from 
antiplatelet therapy and/or 
interventional therapies. Am J 
Geriatr Cardiol 2003;12:259-62. 
10. The PRISM Study Investigators. 
A comparison of aspirin plus 
tirofiban with aspirin plus heparin 
for unstable angina. N Engl J Med 
1998;338:1498-505. 
11. The PRISM-PLUS Study 
Investigators. Inhibition of the 
platelet glycoprotein IIb/IIIa receptor 
with tirofiban in unstable angina and 
non-Q-wave myocardial infarction. 
Platelet Receptor Inhibition in 
Ischemic Syndrome Management in 
Patients Limited by Unstable Signs 
and Symptoms. N Engl J Med 
1998;338:1488-97. 
12. The PARAGON Investigators. 
International, randomized, controlled 
trial of lamifiban (a platelet 
glycoprotein IIb/IIIa inhibitor), 
heparin, or both in unstable angina. 
Platelet IIb/IIIa Antagonism for the 
Reduction of Acute coronary 
syndrome events in a Global 
Organization Network. Circulation 
1998;97:2386-95. 
13. The PURSUIT Trial 
Investigators. Inhibition of platelet 
glycoprotein IIb/IIIa with eptifibatide 
in patients with acute coronary 
syndromes. N Engl J Med 
1998;339:436-43. 
14. The GUSTO IV-ACS 
Investigators. Effect of glycoprotein 
IIb/IIIa receptor blocker abciximab 
on outcome in patients with acute 
coronary syndromes without early 
coronary revascularisation: the 
GUSTO IV-ACS randomised trial. 
Lancet 2001;357:1915-24. 
15. The PARAGON-B Investigators. 
Randomized, placebo-controlled trial 
of titrated intravenous lamifiban for 
acute coronary syndromes. 
Circulation 2002;105:316-21. 
16. Patrono C, Coller B, FitzGerald 
GA, Hirsh J, Roth G. Platelet-active 
drugs: The relationships among 
dose, effectiveness, and side 
effects. The seventh ACCP 
conference on antithrombotic and 
thrombolytic therapy. Chest 
2004;126:234S-264S. 
17. Early Breast Cancer 
TrialistsCollaborative Group. 
Treatment of early breast cancer, vol 
1: worldwide evidence 1985-1990. 
Oxford: Oxford University Press, 
1990:12-8. 
18. Chan A-W, Hróbjartsson A, 
Haahr MT, Gøtzsche PC, Altman 
DG. Empirical evidence for selective 
reporting of outcomes in randomized 
trials. Comparison of protocols to 
published articles. JAMA 
2004;291:2457-65. 
19. Tengs TO, Wallace A. One 
thousand health-related quality-of-
life estimates. Med Care 
2000;38:583-637. 
20. Assmann SF, Pocock SJ, Enos 
LE, Kasten LE. Subgroup analysis 
and other (mis)uses of baseline 
data in clinical trials. Lancet 
2000;355:1064-9. 
21. DerSimonian R, Laird N. Meta-
analysis in clinical trials. Control Clin 
Trials 1986;7:177-88. 
22. Clarke M, Oxman A, eds. 
Cochrane reviewers handbook, 
version 4.2.0 (updated March 2003). 
In: The Cochrane Library, issue 4. 
Chichester: John Wiley & Sons, Ltd, 
2003. 
23. McQuay HJ, Moore RA. Using 
numerical results for systematic 
reviews in clinical practice. Ann 
Intern Med 1997;126:712-20. 
 131 
24. Brookes ST, Whitley E, Egger M, 
Davey Smith G, Mulheran PA, 
Peters TJ. Subgroup analyses in 
randomized trials: risks of subgroup-
specific analyses; power and sample 
size for the interaction test. J Clin 
Epidemiol 2004;57:229-36. 
25. Hasdai D, Holmes DR Jr, Criger 
DA, Topol EJ, Califf RM, Harrington 
RA, for the PURSUIT trial 
investigators. Age and outcome after 
acute coronary syndromes without 
persistent ST-segment elevation. 
Am Heart J 2000;139:858-66. 
26. Alexander JH, Harrington RA. 
Recent antiplatelet drug trials in 
acute coronary syndromes. Clinical 
interpretation of PRISM, PRISM-
PLUS, PARAGON A and PURSUIT. 
Drugs 1998;56:965-76. 
27. Vorchheimer DA, Badimon JJ, 
Fuster V. Platelet glycoprotein 
IIb/IIIa receptor antagonists in 
cardiovascular disease. JAMA 
1999;281:1407-14. 
28. Casserly IP, Topol EJ. 
Glycoprotein IIb/IIIa antagonists – 
from the bench to practice. Cell Moll 
Life Sci 2002;59:478-500. 
29. De Caterina R, Di Gioacchino L. 
Glycoprotein IIb-IIIa inhibitors in 
unstable coronary syndromes and 
percutaneous interventions – a 
conservative approach. Rev Port 
Cardiol 2003;22:995-1002. 
30. Januzzi JL, Cannon CP, Theroux 
P, Boden WE. Optimizing 
glycoprotein IIb/IIIa receptor 
antagonist use for the non-ST-
segment elevation acute coronary 
syndromes: risk stratification and 
therapeutic intervention. Am Heart J 
2003;146:764-74. 
31. Atwater BD, Roe MT, Mahaffey 
KW. Platelet glycoprotein IIb/IIIa 
receptor antagonists in non-ST 
segment elevation acute coronary 
syndromes. A review and guide to 
patient selection. Drugs 
2005;65:313-24. 
32. Ali Raza J, Movahed A. Use of 
cardiovascular medications in the 
elderly. Int J Cardiol 2002;85:203-
15. 
33. Hoekstra JW, Roe MT, Peterson 
ED, et al. Early glycoprotein IIb/IIIa 
inhibitor use for non-STsegment 
elevation acute coronary syndrome: 
patient selection and associated 
treatment patterns. Acad Emerg 
Med 2005;12:431-8. 
34. Ioannidis JPA, Haidich A-B, 
Papa M, et al. Comparison of 
evidence of treatment effects in 
randomized and nonrandomized 
studies. JAMA 2001;286:821-30. 
35. Giugliano RP, Newby LK, 
Harrington RA, et al. The Early 
Glycoprotein IIb/IIIa Inhibition in 
Non- ST-Segment Elevation Acute 
Coronary Syndrome (EARLY ACS) 
trial: A randomized 
placebocontrolled trial evaluating the 
clinical benefits of early front-loaded 
eptifibatide in the treatment of 
patients with non-ST-segment 
elevation acute coronary 
syndrome—Study design and 
rationale. Am Heart J 2005;149:994-
1002.
 132 
 133 
Chapter Ten 
 
Does time matter? A pooled analysis of 
randomized clinical trials comparing 
primary percutaneous coronary 
intervention and in-hospital fibrinolysis in 
acute myocardial infarction patients 
Eric Boersma* and The Primary Coronary Angioplasty vs. 
Thrombolysis (PCAT)-2 Trialists Collaborative Group 
 
AIMS Although outcomes after acute myocardial infarction (AMI) seemed to be superior with 
primary percutaneous coronary intervention (PPCI) relative to fibrinolysis (FL), the extent to 
which treatment delay modulates this treatment effect is unclear. 
METHODS AND RESULTS Twenty-five randomized trials (n = 7743) testing the efficacy of 
PPCI vs. FL were identified in journal articles and abstract listings published between 1990 and 
2002. Of these, individual patient data from 22 trials (n = 6763) were pooled, and multi-level 
logistic regression assessed the relationship among treatment, treatment delay, and 30-day 
mortality. Treatment delay was divided into presentation delay [symptom onset to 
randomization; FL: median 143 (IQR: 91–225) min; PPCI: 140 (91–220) min] and hospital-
specific PCI-related delay [median time from randomization to PPCI minus median time to FL 
per hospital; median 55 (IQR: 37–74) min]. PPCI was associated with a significant 37% 
reduction in 30-day mortality [adjusted OR, 0.63; 95% CI (0.42–0.84)]. Although, there was no 
heterogeneity in the treatment effect by presentation delay (pBreslow-Day = 0.88), the absolute 
mortality reduction by PPCI widened over time (1.3% 0–1 h to 4.2% >6 h after symptom onset). 
When the PCI-related delay was <35 min, the relative (67 vs. 28% pBreslow-Day = 0.004) and 
absolute (5.4 vs. 2.0%) mortality reduction was significantly higher than those with longer 
delays. 
CONCLUSION PPCI was associated with significantly lower 30-day mortality relative to FL, 
regardless of treatment delay. Although logistic and economic constraints challenge the 
feasibility of PPCI-for-all, the benefit of timely treatment underscores the importance of a 
comprehensive, unified approach to delivery of cardiac care in all AMI patients. 
 
Time is myocardium, a familiar 
adage in the cardiovascular 
community, is central to the 
controversy of the best modality of 
reperfusion after acute myocardial 
infarction (AMI).1,2 Although 
numerous pharmaceutical and 
mechanical treatment strategies 
have helped to further the quest for 
an absolute 1% mortality reduction 
after AMI, shortening the time to 
treatment may make this reduction 
attainable. Several studies, for 
example, have established that if 
fibrinolytic therapy is initiated within 
3 h of symptom onset, early mortality 
can be reduced by 25–30% as 
compared with conservative therapy. 
If treated later, only a 15% reduction 
may be observed.3–5 
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Obtaining and maintaining arterial 
patency, however, remains a 
formidable challenge to fibrinolytic 
therapy.3,6,7 Whereas normal 
coronary flow, as measured by 
Thrombolysis in Myocardial 
Infarction (TIMI) grade 3, is restored 
in 29–54% of patients receiving 
fibrinolysis (FL), primary 
percutaneous coronary intervention 
(PPCI) is associated with normal 
epicardial flow in more than 90% of 
patients.7,8 PPCI, however, is not 
without limitations. Although normal 
coronary flow may be achieved in 
the epicardial arteries, flow in the 
distal microvascular beds may be 
compromised in a considerable 
portion of patients by microscopic 
atherosclerotic debris which 
becomes dislodged during the 
procedure.9,10 Similarly, mechanical 
reperfusion is also associated with 
major systemic bleeding in excess of 
2% relative to pharmacologic 
strategies.11 The treatment delay 
associated with mobilizing the 
interventional team and arranging 
patient transfer to the nearest 
interventional facility also presents a 
considerable challenge to timely 
treatment, especially as most 
facilities do not operate during off-
hours. Under optimal 
circumstances, this will lead to at 
least a 30 min treatment-related 
delay as compared with in-hospital 
initiation of fibrinolytic therapy.12 
When compared with pre-hospital 
treatment with FL, this delay may 
range from 60 to 90 min. Outside 
of the clinical trial setting, fewer than 
30% of PPCI patients had a door-to-
balloon time less than 90 min 
according to findings from the 
National Registry of Myocardial 
Infarction (NRMI).13 Transfers from 
other institutions lengthened door-to-
balloon time considerably, with less 
than 5% of transfer patients 
undergoing PPCI within 90 min after 
first medical contact.14 
 
Recent evidence from several large 
trials suggests that the maximum 
benefits of either treatment strategy 
may occur at different time points 
after symptom onset. With 
transportation times of up to 2 h, the 
clinical benefits of PPCI over FL 
were not modified.15,16 In contrast, 
the PRimary Angioplasty in patients 
transferred from General community 
hospitals to specialized PTCA Units 
with or without Emergency 
thrombolysis (PRAGUE)-2 study 
observed no difference in 30-day 
mortality between PPCI and FL for 
patients presenting within 3 h,17 and 
the Comparison of Primary 
Angioplasty and Prehospital 
Thrombolysis in the Acute Phase of 
Myocardial Infarction (CAPTIM) trial 
provided evidence for a better 
outcome in patients receiving 
prehospital FL as compared with 
PPCI, provided that fibrinolytic 
therapy is initiated within 2 h after 
symptom onset.18,19 
Given these recent findings, the aim 
of the current study was to assess 
whether the clinical benefit of PPCI 
compared with in-hospital FL is 
modulated by the time to treatment 
in a pooled analysis of randomized 
clinical trials reported since 1990 
(Figure 1). 
 
METHODS 
Trial selection 
All randomized trials that enrolled at 
least 50 patients presenting with 
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AMI assigned to treatment with FL or 
PPCI were considered. Trials 
published between January 1990 
and December 2002 were identified 
by OVID MEDLINE and ISI Web of 
Science using a broad range of key 
words, including (acute) myocardial 
infarction, FL, fibrinolytic, 
thrombolysis, thrombolytic, 
streptokinase, tissue plasminogen 
activator, accelerated tissue 
plasminogen activator, t-PA, rt-
PA, primary, angioplasty, stent, 
and PCI. Non-English articles were 
not excluded. References of 
identified papers and abstract 
listings of annual meetings of the 
American Heart Association 
(Circulation), American College of 
Cardiology (Journal of the American 
College of Cardiology), and 
European Society of Cardiology 
(European Heart Journal) were also 
examined during the same period. 
Each trial identified in this search 
was critically and independently 
evaluated by three investigators (E 
Boersma, RJ Simes, and CM 
Westerhout) for patient population, 
study treatment, protocol, and 
endpoints. The primary investigators 
of these studies were contacted for 
verification and access to individual 
patient data. 
 
Twenty-five trials, which enrolled 
7743 patients, met the 
abovementioned search criteria 
(Appendix B, Table B1).15–18,20–40 
Individual patient data were 
unavailable in two trials (DeWood 
et al.,27 n = 90; Morais et al.,32 n = 
50) and the CAPTIM investigators 
judged that their protocol was 
incompatible with the other trials 
included in this pooled analysis, 
Figure 1 Flowchart of trial search and selection for the pooled analysis.
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which excluded an additional 840 
patients. Thus, individual patient 
data from 22 trials (n = 6763) were 
pooled for the primary analysis. Data 
were assessed for completeness, 
internal consistency of patient 
records, and consistency with 
published reports. Any discrepancies 
between analysis of the data 
provided and previously published 
results were queried and resolved 
with the primary investigator of the 
trial. 
 
Endpoint definition 
The primary endpoint of this pooled 
analysis was all-cause mortality at 
30 days. Individually, most trials 
were not designed (and were 
underpowered) to evaluate 
differences in mortality between the 
treatment strategies; however, 
pooling these studies provided 
sufficient power, particularly for 
subgroup analyses such as those 
involving time. Other endpoints (i.e. 
re-infarction and stroke) remained 
defined according to the original 
trial-specific criteria. 
 
Statistical analysis 
Continuous data were summarized 
and presented as median values 
with corresponding IQR, whereas 
dichotomous data were presented 
as counts and percentages. 
Differences in baseline 
characteristics between subgroups 
of patients were evaluated by 
Wilcoxon rank sum tests, Kruskal–
Wallis tests or x2 tests as 
appropriate. Time to treatment was 
categorized into presentation delay 
(i.e. time from symptom onset to 
randomization) and treatment delay 
(i.e. time from randomization to 
treatment). Patients were further 
categorized for presentation delays 
as 0–1, >1–2, >2–3, >3–6, and >6 h, 
which was determined a priori and 
based on previously published 
studies. Unlike presentation delay, 
the interval between randomization 
and treatment is influenced by 
allocated treatment, and analyses 
that are based on these 
observations after randomization in 
individual patients can result in 
biased estimates of treatment effect. 
Analyses based on observations at 
a hospital level may help to 
overcome this. Thus, the median 
time between randomization and the 
start of treatment (i.e. first injection 
of the fibrinolytic agent or the first 
balloon inflation) was calculated for 
each of the 153 hospitals. The 
hospital-specific difference between 
these median times was then 
determined, which is hereafter 
referred to as PCI-related delay, 
and assigned each patient within 
that hospital. PCI-related delay was 
then grouped into quintiles: 0–35,  
>35–50, >50–62, >62–79, and >79 
min. PCI-related delay should be 
interpreted as the additional time 
that is needed to start the PCI 
procedure after treatment with a 
fibrinolytic agent could have been 
started. 
 
All analyses were performed 
according to intention-to-treat 
principles. Trial-specific outcome 
data were pooled using the 
Cochrane–Mantel–Haenszel 
method, and OR and 95% CI for 30-
day death are reported. The 
Breslow-Day test was applied to 
examine the statistical evidence of 
heterogeneity among the trial-
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specific ORs. It should be noted that 
statistical tests for heterogeneity 
often lack power, and fail to 
elucidate differences which may be 
clinically important.41 
 
Initially, the influence of presentation 
delay, as well as PCI-related delay, 
on the treatment effect at 30 days 
(i.e. death) was examined using 
single-level logistic regression. 
However, given the hierarchical 
nature of these data (i.e. patients 
nested within hospitals), multilevel 
logistic regression was then applied 
to address random and fixed effects 
at the patient and hospital levels of 
the study. At the patient level, age, 
gender, weight, diabetes mellitus, 
previous MI, prior revascularization 
[PCI or coronary artery bypass graft 
(CABG)], anterior MI at presentation, 
heart rate, systolic blood pressure, 
presentation delay, and study 
treatment (FL or PPCI) were 
considered fixed effects, and 
statistical significance was evaluated 
using the t-ratio.42 At the hospital 
level, the average annual PCI 
volume and PCI-related delay were 
available at each of the 153 
hospitals. The annual PCI volume 
(on study only) was calculated as 
the average number of patients 
randomized to PPCI per year, which 
was then grouped into tertiles of its 
distribution (<10, 10–23, 24 
PPCI/year). At the study level, the 
likelihood of PCI within 30 days after 
initial FL, use of stents, use of 
glycoprotein (GP) IIb/IIIa inhibitors, 
type of fibrinolytic agent used 
(streptokinase, t-PA, or accelerated 
t-PA), single-centred vs. 
multicentred trial, and the year of 
publication were considered. When 
three-level models were tested, 
there was no variance at the study-
level, which provided statistical 
support that these studies could be 
pooled for analysis. In addition to 
these main effects, two interactions 
were considered: (i) study treatment 
and presentation delay (patient-level 
interaction); and (ii) study treatment 
and PCI-related delay 
(patient/hospital-level interaction). 
MLwiN and (version 1.10.0007) 
statistical software, with residual 
iterated generalized least squares 
and pseudoquasi-likelihood model 
specifications, was used for the 
multilevel modelling. 
 
Further analyses of the presentation 
delay treatment association were 
performed in a priori-selected patient 
subgroups [<65 vs. 65-years-old; 
female/male; diabetes mellitus; 
previous MI; anterior vs. non-anterior 
MI location; systolic blood pressure 
(<130 vs. 130 mmHg); heart rate 
(<70 vs. 70 bpm)], hospital-level 
average annual PCI volume and 
study-level type of fibrinolytic agent 
used. 
 
Two sensitivity analyses, using 
single-level logistic regression were 
performed: (i) impact of exclusion of 
three trials without individual patient 
data;18,27,32 and (ii) type of fibrinolytic 
agent used (i.e. streptokinase, t-PA, 
accelerated t-PA). Given the 15% 
reduction in 30-day mortality with 
accelerated tPA as compared with 
streptokinase in the GUSTO-I trial, 
the former has become the gold 
standard for pharmacological 
reperfusion therapy.3 Thus, a 
sensitivity analysis was performed to 
evaluate if results of the primary 
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analysis were consistent in the 
studies that compared PPCI with 
accelerated tPA. 
 
RESULTS 
Of 6763 patients, 3383 were 
randomized to FL and 3380 to PPCI. 
The distribution of baseline patient 
characteristics among patients 
randomized to FL and PPCI was 
well balanced, with prior CABG as 
the exception. (Table 1) Younger, 
male patients and patients with a 
history of previous MI, or PCI 
presented earlier, whereas those 
with diabetes mellitus appeared to 
have arrived later, especially after 6 
h. Patients with an anterior MI 
tended to present either very early 
(0–1 h) or very late (>6 h) after 
symptom onset. In trials with 
available data, 3.3% of patients 
randomized to FL actually receive 
PPCI, whereas 12.1% of patients 
randomized to PPCI did not receive 
the assigned treatment. 
 
Overall, the median presentation 
delay was 142 (IQR: 91–221) min, 
which did not differ significantly 
between FL [143 (91–225) min] and 
PPCI [140 (91–220) min], P = 0.30. 
Nearly 11% of the 6763 patients 
were randomized within the first hour 
after symptom onset, with the 
majority subsequently randomized 
between 1 and 3 h after symptom 
onset (Figure 2). As also shown in 
Figure 2, the time from 
randomization to the start of either 
FL or PPCI was not influenced by 
the length of time from symptom 
onset. Given the inherent logistics of 
the different modalities, the median 
time to FL was significantly shorter 
than that of the beginning of PCI 
[respectively, 19 (10–30) min vs. 76 
(61–95) min; P < 0.001], which gave 
an overall PCI-related delay of 55 
(37–74) min. 
 
Thirty-day adverse events and the 
influence of presentation delay 
Overall, 6.6% of 6763 patients died 
within 30 days of randomization 
(Table 2). According to randomized 
treatment, the 30-day death rate was 
7.9% of FL patients and 5.3% in 
those randomized to PPCI (P < 
0.001). In patients randomized to FL, 
Table 1 Baseline characteristics of the study population according to study treatment and presentation delay
FL PPCI Presentation delay
0–1 h .1–2 h .2–3 h .3–6 h .6 h
n 3383 3380 747 2000 1712 1640 664
Demographics and co-morbidities
Age (years)a 62 (53–71) 63 (53–71) 60 (52–68) 61 (53–70) 63 (54–71) 65 (55–73) 65 (54–74)c
Male (%) 73.2 72.6 76.6 74.8 73.2 69.5 70.6c
Diabetes mellitus (%) 12.4 13.5 11.1 9.8 13.1 14.7 20.0c
Previous MI (%) 13.2 12.5 14.1 13.5 12.6 11.9 12.5c
History of PCI (%) 4.0 3.6 3.5 5.1 3.3 2.9 3.6d
History of CABG (%) 2.1 1.2b 1.3 2.1 1.5 1.6 1.4
Clinical examination
Body weight (kg)a 79 (75–80) 79 (75–80) 79 (77–82) 79 (75–80) 79 (75–80) 79 (73–80) 79 (72–80)
Systolic blood
pressure (mmHg)a
133 (120–145) 133 (120–145) 133 (115–140) 133 (120–140) 133 (120–146) 133 (120–148) 133 (120–150)
Heart rate (bpm)a 76 (66–82) 76 (66–84) 76 (64–80) 76 (63–80) 76 (67–84) 76 (68–84) 76 (70–90)
Anterior MI (%) 45.8 46.5 49.4 46.2 43.1 44.6 52.4
aContinuous data are presented as median values (IQR).
bDifference between patients assigned to FL or PPCI, P, 0.05.
cDifference across subgroups according to time from symptom onset to randomization, P, 0.05.
dDifference across subgroups according to time from symptom onset to randomization, P, 0.001.
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30-day mortality increased two-fold 
as the presentation delay increased 
from less than 1 to over 6 h (P < 
0.001). A similar, yet non-significant 
trend was observed in patients 
assigned to PPCI (P = 0.06). 
 
Re-infarction occurred in 6.7% of FL 
patients and in 2.4% of PPCI 
patients during 30-day follow-up (P < 
0.001). Among FL patients, re-
infarction occurred in 10.4% of 
patients enrolled within 1 h after 
symptom onset, and in 6.3% of 
patients enrolled at more than 6 h 
after symptom onset (P = 0.007). In 
those randomized to PPCI, there 
was no difference in the re-infarction 
rate at 30 days according to 
presentation delay (P = 0.5). 
 
The combined endpoint of 30-day 
death and re-infarction occurred in 
13.5% of FL patients and in 7.3% of 
PPCI patients (P < 0.001). In both 
treatment groups, there appeared to 
be an increasing trend in 30-day 
death or re-infarction with longer 
presentation delay; however, this 
was only statistically significant in 
the FL group (P < 0.001). 
 
Treatment, time to treatment, and 
30-day mortality 
Overall, PPCI patients had a 37% 
relative lower odds of 30-day 
mortality than those randomized to 
fibrinolytic therapy after multi-level 
covariate adjustment [adjusted OR 
0.63; 95% CI (0.42–0.84); P < 
0.001]. According to presentation 
delay, the treatment effect 
consistently favoured PPCI in all the 
subgroups, and there was no 
evidence of heterogeneity 
(pBreslow-Day = 0.9) (Figure 3, left 
panel). The absolute mortality 
reduction by PPCI increased from 
1.3% in patients randomized in the 
first hour after symptom onset to 
4.2% in those randomized after 6 h. 
Consequently, with increasing delay, 
Figure 2 Distribution of patients (bars) and median (25th, 75th percentile)
time to treatment [FL (B)] or [PPCI (B)] according to presentation delay and
study treatment.
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the number needed treat to prevent 
a death, decreased from 77 to 24 
patients. 
 
According to quintiles of site-specific 
PPCI-related delay, the risk of 30-
day death was consistently reduced 
in PPCI patients, and there was 
evidence of heterogeneity across 
the quintiles (pBreslow-Day = 0.05) 
(Figure 3, right panel). In particular, 
PPCI was associated with a 67% 
reduction in the odds of 30-day 
mortality when the PPCI-related 
delay was less than or equal to 35 
min and with a 28% reduction in 
patients with a longer PPCI-related 
delay (pBreslow-Day = 0.004 for the 
comparison of the first quintile with 
quintiles 2–5). 
 
Subgroup and sensitivity 
analyses 
The relationship between relative 
treatment effect and presentation 
delay (less than or equal to/greater 
than 2 h) were examined within 
selected patient-, hospital-, and 
study-level characteristics (Figure 4). 
In general, treatment with PPCI was 
consistently favoured over FL in the 
subgroups considered, regardless of 
presentation delay. The average 
annual PCI volume did not influence 
the relative treatment benefit of 
PPCI over FL. The relative treatment 
effect appeared to decline with the 
use of accelerated t-PA and the year 
of randomization; however, these 
trends were not statistically 
significant. 
 
Ten of the 22 studies (n = 4172) 
compared PPCI with accelerated t-
PA (Appendix B, Table B1). In these 
trials, PPCI was associated with a 
29% relative reduction in mortality 
[7.4% FL vs. 5.6% PPCI; adjusted 
OR: 0.71; 95% CI (0.46–0.98)]. 
Similar to the primary analysis, there 
was no evidence of heterogeneity in 
the treatment effect according to 
presentation delay (pBreslow-Day = 
0.9; Figure 5). Also, as seen in the 
Table 2 Adverse events at 30 days according to presentation
delay
Overall Presentation delay
0–1 h .1–2 h .2–3 h .3–6 h .6 h
Fibrinolysis, n 3383 368 997 818 876 324
Death (%) 7.9 6.0 6.2 7.3 9.5 12.7b
Re-MI (%) 6.7 10.4 4.9 7.4 6.9 6.3a
Death or
re-MI (%)
13.5 14.9 10.4 13.6 15.0 17.6a
Stroke (%) 2.2 4.0 0.8 1.0 5.2 0.0
PPCI, n 3380 379 1003 894 764 340
Death (%) 5.3 4.7 4.2 5.1 5.6 8.5a
Re-MI (%) 2.4 1.6 2.9 2.3 2.0 3.0
Death or
re-MI (%)
7.3 6.1 6.8 7.4 7.2 10.3
Stroke (%) 0.5 0.0 0.8 0.0 1.0 0.0
aDifference across subgroups according to presentation delay, P , 0.05.
bDifference across subgroups according to presentation delay,
P, 0.001.
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primary analysis, the treatment 
effect in favour of PPCI was highest 
in the first quintile of PCI-related 
delay. The 95% CI, however, were 
wide and largely overlapping, 
resulting in lack of heterogeneity 
(pBreslow-Day = 0.3). 
 
Although individual patient data for 
three of the 25 trials originally 
identified were not available, tabular 
data for 980 patients were extracted 
from published reports and analysed 
for potential bias based on their 
exclusion.15,23,28 Overall, a 31% 
reduction in 30-day death was 
observed in the PPCI group [7.5% 
FL vs. 5.3% PPCI; OR: 0.69, 95% CI 
(0.58–0.83)]. The CAPTIM trial was 
of particular interest as ~55% of the 
840 patients were randomized within 
the first 2 h after symptom onset. 
Despite these additional patients, 
the relative treatment benefit was 
still in favour of PPCI, regardless of 
presentation delay (pBreslow-Day = 
0.3) (Figure 5). If only accelerated t-
PA trials were analysed, the relative 
benefit was attenuated but still 
without statistical evidence of 
heterogeneity (<2 h, OR: 0.98; 95% 
CI (0.66–1.47); 2 h, OR: 0.72; 
95% CI (0.54–0.95); pBreslow-Day = 
0.21). 
 
DISCUSSION 
Overall, PPCI was associated with a 
37% relative reduction in the odds of 
30-day mortality when compared 
with in-hospital fibrinolytic therapy, 
which was slightly attenuated to 28% 
when only accelerated t-PA trials 
were considered. Although these 
findings are not unlike those found 
in previously published meta- and 
pooled-analyses,11,12,43 this analysis 
extends beyond these by including 
individual patient data from trials 
reported since 1997 and focusing on 
the importance of time to treatment 
in the reperfusion debate. 
 
The time-sensitivity of fibrinolytic 
therapy has been well established 
by the substantial reduction in 
mortality observed when fibrinolytic 
treatment is administered within the 
golden hour.5 Yet, regardless of the 
delay in presentation of the current 
analysis, treatment with PPCI was 
uniformly associated with lower 
mortality relative to FL. These 
Figure 3 OR and 95% CI for 30-day death in patients randomized to PPCI when compared with FL according to presentation delay (left panel) and PCI-related
delay (right panel). OR were adjusted for patient-, hospital-, and study-level covariates.
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Figure 4 Subgroup analysis of selected patient-, study-, and site-level
characteristics. NNT (number needed to treat): the number of patients who
need to be treated in order to prevent a death. OR were adjusted for
patient-, hospital-, and study-level covariates. *Site volume on-study only,
classified by the number of patients randomized to percutaneous transluminal
coronary angioplasty per site per year: low,,10 patients/site/year; medium,
10–23 patients/site/year; high, 24 patients/site/year.
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findings were somewhat unexpected 
given the recently reported 
evidence. In the CAPTIM trial, for 
instance, patients randomized within 
2 h after symptom onset had a 
strong trend towards higher 30-day 
mortality with PPCI when compared 
with pre-hospital FL [5.7 vs. 2.2%; 
OR: 2.7; 95% CI (0.94–7.7); P = 
0.06].18 Although our sensitivity 
analysis including the tabulated data 
from the CAPTIM trial suggests that 
PPCI provides only a small mortality 
reduction relative to accelerated t-
PA in patients randomized within 2 
h, this estimate was not adjusted for 
potential confounders. Also, from 
statistical point of view, the estimate 
of treatment effect in this subgroup 
did not diverge from the estimate in 
patients randomized after 2 h. Upon 
more extensive analysis of the 
CAPTIM trial, several important 
details are worth noting. First, this 
trial was designed to prove the 
clinical superiority of PPCI over pre-
hospital FL. Although, 1200 patients 
were needed to demonstrate a 
foreseen 44% relative reduction in 
the composite endpoint of death, 
non-fatal myocardial re-infarction 
and non-fatal stroke, only 67% of the 
target sample size was achieved. As 
a result, only a trend towards lower 
event rates after PPCI was observed 
(6.2 vs. 8.2% events) and the 95% 
CI of expected and observed 
treatment effect were largely 
overlapping. Thus, the CAPTIM 
findings should be interpreted with 
caution and in the context of other 
pieces of evidence. Finally, over 
two-thirds of the CAPTIM patients 
allocated to pre-hospital FL 
underwent PCI within 30 days, which 
was notably a strong confounder of 
treatment effect in our pooled 
analysis. In fact, the pre-hospital FL 
treatment strategy of the CAPTIM 
trial closely approximates the 
strategy of so-called facilitated PCI 
in which patients receive adjunctive 
pharmacologic treatment during 
transfer for the intervention. Some 
evidence suggests that such 
strategy may result in even better 
patient outcome than the more 
traditional PPCI approach.44,45 On 
the other hand, preliminary analyses 
of the ASSENT-IV trial demonstrated 
a higher incidence of major adverse 
cardiac complications in patients 
allocated to the strategy of PPCI 
after pre-treatment with tenecteplase 
compared with PPCI alone.46 
Several trials such as the Combined 
Abciximab REteplase Stent Study in 
acute myocardial infarction 
(CARESS in AMI),47 and the 
Facilitated Intervention for Enhanced 
reperfusion Speed to Stop ischemic 
Events (FINESSE) trial are 
underway to further test this 
strategy. 
 
The balance of the treatment effect 
in the current analysis remained with 
PPCI when its association with PCI-
related delay was examined, 
particularly if the delay was 35 min 
or less. In 2001, Kent and 
colleagues48 presented a back-of-
the-envelope calculation for the 
benefit of PPCI over FL in relation to 
PCI-related delay. Based on a linear 
meta-regression on published 
findings from the first 10 randomized 
trials of PPCI vs. FL, they concluded 
that the absolute survival benefit of 
PPCI compared with FL decreased 
by 1.7% for every additional 10 min 
PCI-related delay, and thus, a PCI-
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related delay exceeding 50 min 
would nullify its benefits. Nallamothu 
and Bates49 recently repeated the 
analysis using published data of 
most of the trials included in our 
pooled-analysis and reached similar 
conclusions. Our analysis, however, 
yielded divergent results which may 
largely be explained by several 
methodological differences. First, 
Kent and Nallamothu presented only 
absolute treatment effects. Second, 
the estimated PCI-related delay in 
their analyses was based on a 
combination of median and mean 
values of time-from-onset-to- 
treatment, time-from-randomization-
to-treatment, and time-from-
hospitalization-to-treatment, 
depending on the available data in 
the separate clinical trial reports. 
Finally, the results of linear (meta-) 
regression are susceptible to 
extreme observations. Although 
back-of-the-envelope calculations 
based on tabulated data are 
relatively straightforward and easy to 
understand, the caveats of such 
analyses underscores the 
importance of pooling individual 
patient data for these analyses. 
 
PCI-related delay is subject to 
numerous biases related to the 
modalities themselves, which are 
distinct from those influencing 
presentation delays. These biases 
are often related to the delivery of 
these treatment strategies by the 
healthcare system; and thus, PCI 
delay was determined at the hospital 
level in the current analysis. This 
also has the advantage that PCI 
delay could be estimated in patients 
Figure 5 Sensitivity analyses of the use of accelerated t-PA and of the
inclusion of trials with tabular data. OR were adjusted for patient-, hospital-,
and study-level covariates.
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randomized to PPCI who ultimately 
did not undergo this procedure. 
However, these analyses are limited 
to the extent that they are 
inadequately powered to 
demonstrate effects of a delay in 
treatment. Hence, the observations 
in relation to presentation delay 
should be given more weight than 
those regarding PCI-related delay. 
 
One of the most salient messages of 
the current study is the importance 
of timely treatment in AMI patients. 
Although the relative mortality 
reduction by fibrinolytic therapy 
(relative to control) is often highest in 
patients treated earliest after 
symptom onset,5 our data also 
provides evidence that this is also 
the case for PPCI, as the relative 
treatment effects of PCI over FL 
were not influenced by presentation 
delay. Secondly, absolute mortality 
rates in patients undergoing PPCI 
increased with increasing 
presentation delay as well as with 
increasing PCI-related delay. 
Although we appreciate that these 
differences may be biased by 
differences in patient risk profiles, 
such as the elderly and diabetics 
who presented later after symptom 
onset, it is also important to 
emphasize that time to treatment 
remained an important outcome 
determinant after adjustment for 
baseline characteristics. This 
observation is consistent with the 
results from the large (n = 27 080) 
NRMI registry and a smaller (n = 
1791) registry from The Netherlands, 
and confirms that timely treatment 
results in improved outcomes.13,50 
 
 
Limitations 
Several limitations of this analysis 
should be addressed. First, the 
selection of trials may be prone to 
some bias. As stated earlier, all trials 
published between January 1990 
and December 2002 were 
considered in the search. Although 
some time has elapsed since then, 
to our knowledge, no additional trials 
have been reported. 
 
Another implication of including trials 
published since 1990 may be the 
challenge of generalizability to 
current practice, given the rapid 
evolution of therapies and overall 
cardiac care. Although our analysis 
revealed no variance across the 22 
trials, certain characteristics of 
recent studies deserve comment. 
Enrolment in DANAMI-2 and C-
PORT, which when combined 
contributed 30% to the total number 
of patients in this pooled analysis, 
was prematurely discontinued owing 
to better outcomes in patients 
randomized to PPCI, which were 
largely driven by high re-infarction 
rates in FL patients or exclusion of 
procedure-related re-infarctions. 
Ideally, a large randomized trial 
enrolling a broad spectrum of AMI 
patients would be preferable to 
meta-analyses. A trial with 80% 
power would need to enrol 4400 
patients (2200 patients in each study 
arm) to detect a 2% mortality 
difference.51 Enrolling large numbers 
of patients, however, has proven in 
the past to be a challenge as 
indicated by the early termination of 
such recent trials as DANAMI-2 and 
C-PORT. Thus, meta- and pooled-
analyses, such as this one, provide 
our best estimate of reperfusion 
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strategies in these patients. 
Population-based studies such as 
those from NRMI and others, 
however, will provide critical 
evidence as to how the broader AMI 
population and healthcare system 
factors will modulate the 
observations based in the clinical 
trial setting. 
 
Although the use of individual patient 
data provided greater analytic 
flexibility than traditional meta-
analyses, additional information on 
the context of treatment may have 
been helpful in further elucidating 
these research questions. 
Information on the experience (and 
personal characteristics) of the 
interventionalist (and/or intervention 
team), timing of PCI (business-
hours vs. off-hours), and 
geographic-, socio-, and economic 
related barriers to care is rarely 
collected by clinical trials, but may 
have profound implications to the 
generalizability of the findings which 
comes with confusing aggregate and 
individual effects, otherwise known 
the ecological fallacy.52 
 
Conclusions and clinical 
implications 
Regardless of the therapeutic 
strategy, the time expired since the 
beginning of the coronary occlusion 
remains central to the reperfusion 
debate. With this in mind, efforts 
should be increased to enhance 
early reperfusion and solutions 
should involve all stakeholders, from 
patients to providers to policy-
makers.2 Altering public perception 
of AMI and the importance of 
seeking early treatment is a complex 
undertaking which may be overcome 
through effective education 
programming among other 
behaviour-changing approaches.  
 
The real world poses logistical and 
economic challenges to the 
feasibility of a PPCI-for-all 
approach; however, the benefit of 
timely treatment as demonstrated in 
this study underscores the 
importance of developing a 
comprehensive and unified 
approach to improve the delivery of 
cardiac care in all AMI patients. 
Unlike the clinical trial setting, 
disparities in ambulatory care and 
pre-hospital services, and limited 
access to tertiary or regional heart 
centres, both in number of centres 
and 24-h/7-day capabilities, 
represent formidable challenges to 
translating treatment benefit into the 
general AMI patient population. For 
example population-based studies 
have revealed median treatment 
delays ranging from 42 to 93 min.53–
55 Until these gaps are narrowed, FL 
still remains a viable treatment 
strategy when timely PPCI is not 
available. One treatment does not fit 
all: time matters. 
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Chapter Eleven 
 
A comparison of pharmacologic therapy 
with/without timely coronary intervention 
vs. primary percutaneous intervention early 
after ST-elevation myocardial infarction: 
the WEST (Which Early ST-elevation 
myocardial infarction Therapy) study 
Paul W. Armstrong*, WEST Steering Committee 
AIMS Uncertainty exists as to which reperfusion strategy for ST-elevation myocardial infarction 
(MI) is optimal. We evaluated whether optimal pharmacologic therapy at the earliest point of 
care, emphasizing pre-hospital randomization and treatment was non-inferior to expeditious 
primary percutaneous coronary intervention (PCI). 
METHODS AND RESULTS Which Early ST-elevation myocardial infarction Therapy (WEST) 
was a four-city Canadian, open-label, randomized, feasibility study of 304 STEMI patients (>4 
mm ST-elevation/deviation) within 6 h of symptom onset, emphasizing pre-hospital ambulance 
treatment and participation of community and tertiary care centres. All received aspirin, 
subcutaneous enoxaparin (1 mg/kg), and were randomized to one of three groups: (A) 
tenecteplase (TNK) and usual care, (B) TNK and mandatory invasive study 24 h, including 
rescue PCI for reperfusion failure, and (C) primary PCI with 300 mg loading dose of clopidogrel. 
Time from symptom onset to treatment was rapid (to TNK for A = 113 and B =130 min and for 
PCI in C = 176 min). The primary outcome, a composite of 30-day death, re-infarction, refractory 
ischaemia, congestive heart failure, cardiogenic shock, and major ventricular arrhythmia, was 
25% (Group A), 24% (Group B), and 23% (Group C), respectively. However, there was a higher 
frequency of the combination of death and recurrent MI in Group A vs. Group C (13.0 vs. 4.0%, 
respectively, P-logrank = 0.021), yet no difference between Group B (6.7%, P-logrank = 0.378) 
and C. 
CONCLUSION These data suggest that a contemporary pharmacologic regimen rapidly 
delivered, coupled with a strategy of regimented rescue and routine coronary intervention within 
24 h of initial treatment, may not be different from timely expert PCI. 
 
Few issues in contemporary 
cardiovascular medicine have been 
subjected to more sustained and 
vigorous debate as the optimal 
approach to life-saving reperfusion 
therapy in patients with acute ST-
segment elevation myocardial 
infarction (STEMI). Once thrombotic 
occlusion of a major epicardial 
coronary artery was established as 
the cause of STEMI, parallel 
developments in pharmacological 
and mechanical reperfusion 
strategies occurred. Each has been 
shown to successfully salvage left 
ventricular (LV) myocardium, 
improve LV function, and enhance 
long-term survival. 
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The proponents of pharmacologic 
therapy for STEMI highlight its 
widespread availability to the broad 
cross-section of patients worldwide, 
the lack of dependence on operator 
experience or institutional resources, 
and the ability to rapidly apply such 
therapy in the emergency 
department or even prior to hospital 
arrival without the sometimes 
formidable logistics of transfer to an 
interventional facility.1–3 
Dissatisfaction with pharmacologic 
therapy is primarily related to: (i) 
suboptimal reperfusion rates, (ii) the 
presence of recurrent ischaemia and 
re-infarction, and (iii) the risk of 
intracranial and systemic bleeding 
complications.4 
 
Enthusiasm for primary 
percutaneous coronary intervention 
(PCI) has been fuelled in part by a 
systematic overview indicating that 
primary PCI was more effective than 
fibrinolysis in the therapy of STEMI.5 
Although a significant mortality 
difference was evident favouring 
PCI, the largest contribution of PCIs 
advantage over fibrinolysis was a 
reduction in re-infarction. In addition 
several methodological concerns 
have been raised about this report 
leading some to consider it as 
hypothesis generating rather than a 
definitive basis for a change in 
practice.1,6 
 
Given the uncertainty as to which 
strategy is optimal, and the 
appreciation of the importance of 
mechanical co-intervention for 
patients with failed fibrinolysis, we 
designed a feasibility study to 
compare outcomes in patients who 
underwent expeditious primary PCI 
with those receiving pharmacologic 
therapy at the earliest point of care, 
with an emphasis on pre-hospital 
randomization and treatment. Also, 
within the cohort receiving 
pharmacologic therapy, standard 
care was applied to half of the group 
whereas the other half underwent 
mandatory invasive management 
within 24 h of enrolment including 
protocol-specified rescue PCI. 
 
METHODS 
Patient population 
The Which Early ST-elevation MI 
Therapy (WEST) study involved four 
metropolitan Canadian communities 
(Edmonton, Halifax, Montreal, and 
Vancouver). Patients with STEMI in 
whom reperfusion therapy (primary 
PCI, fibrinolysis or transfer for 
rescue PCI) was feasible within 3 h 
of randomization were enrolled. The 
protocol emphasized expedited care 
with ECG, randomization and 
therapy undertaken pre-hospital 
where possible, and direct 
communication to PCI teams to 
enhance their state of readiness. 
 
Eligible patients were male or non-
pregnant females (18 years) with 
symptoms presumed secondary to 
STEMI lasting at least 20 min 
accompanied by ECG evidence of 
high risk. These included: 2 mm of 
ST-elevation in two or more 
contiguous precordial leads or limb 
leads; or 1 mm ST-elevation in two 
or more limb leads coupled with 1 
mm ST-depression in two or more 
contiguous precordial leads (total 
ST-deviation 4 mm) or presumed 
new left bundle branch block. 
Patients were excluded if primary 
PCI was deemed to be available 
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within 1 h of diagnosis, or if 
contraindications to fibrinolysis, prior 
coronary bypass grafting (CABG), or 
glycoprotein IIb/IIIa antagonist use 
within 7 days existed. 
 
Study design, treatments, and 
endpoints 
We intended to enrol 100 patients in 
each of the three treatment arms in 
this feasibility study. All patients 
received aspirin (160–325 mg) and 
subcutaneous enoxaparin (1 mg/kg) 
at randomization with subsequent 
use recommended every 12 h for a 
minimum of 72 h; additional 
intravenous enoxaparin (0.3–0.5 
mg/kg) was permitted during PCI in 
Group C and its use post-PCI was 
discretionary. Patients were 
randomized in open label fashion to 
one of three treatment groups. 
Group A received weight-adjusted 
tenecteplase (TNK) followed by the 
usual standard of care. Group B also 
received weight-adjusted TNK but 
underwent mandatory invasive 
management within 24 h of 
enrolment including protocol-
specified rescue PCI, if the 
admission ST-elevation failed to 
decrease by 50% at 90 min after 
TNK therapy or if haemodynamic or 
electrical instability occurred. Group 
C patients underwent primary PCI 
with a clopidogrel 300 mg loading 
dose administered along with ASA 
and enoxaparin on study entry. 
Abciximab was recommended for 
Group C and for use in all PCI 
procedures in each treatment group 
unless performed within 3 h of 
fibrinolytic therapy. Clopidogrel use 
was employed in Groups A and B 
according to ACC/AHA PCI 
guidelines. 
 
The primary efficacy endpoint of this 
study was a 30-day composite of 
death, re-infarction, refractory 
ischaemia, congestive heart failure, 
cardiogenic shock and major 
ventricular arrhythmia. The individual 
components were also examined. 
Definitions are provided in Appendix 
2. Two experienced observers 
blinded to treatment allocation 
undertook central adjudication of re-
infarction, refractory ischaemia, 
major ventricular arrhythmia, and the 
indications for rescue PCI. 
 
Secondary efficacy endpoints 
included 90- and 180 min ST-
resolution (according to the 
Schroeder method) and the infarct 
size was assessed using the 
Selvester QRS score and peak 
creatinine kinase (CK).7,8 Core 
laboratories were established where 
blinded assessments were 
undertaken for ECG, NT-pro-brain 
natriuretic peptide (NT-proBNP) and 
angiographic measurements as 
noted in Appendix 3. 
 
Safety outcomes included the 
occurrence of intracranial 
haemorrhage, disabling stroke, and 
major systemic bleeding. Finally, we 
assessed the composite of the 
primary efficacy and safety 
endpoints. 
 
The protocol was approved by each 
institutional Ethics Review Board 
and a Data and Safety Monitoring 
Board oversaw the study. WEST 
was registered at 
www.ClinicalTrials.gov (identifier 
NCT00121446) on 13 July 2005. 
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Statistical analysis 
Data were analysed according to 
intention-to-treat principles and are 
presented as proportions for 
categorical variables and as 
medians and interquartile ranges 
(IQR) for continuous variables. Data 
were compared across the treatment 
groups using chi-square tests, 
Fishers exact test, and Kruskal–
Wallis tests where appropriate. 
Repeated measures techniques 
were used to analyse the variance of 
NT-proBNP measures across the 
three collection periods (baseline, 72 
h and 30 days). 
 
The WEST study was designed to 
test the non-inferiority of Groups A 
and B relative to Group C. In the 
event of no difference in the primary 
efficacy composite endpoint 
between the two fibrinolytic arms, 
i.e. Groups A and B, we pre-
specified a comparison between 
their combined result and the 
primary PCI arm, i.e. Group C. 
Comparisons were undertaken using 
confidence intervals (CI) with the 
expectation that a relative minimally 
important difference (rMID) in the 
incidence of the primary endpoint of 
15% would be considered as 
evidence for the non-inferiority of 
pharmacologic therapy relative to 
primary PCI. 
 
Kaplan–Meier estimates were 
plotted for the primary efficacy 
endpoint and 30-day death/re-MI 
according to the treatment groups. 
Unadjusted Cox regression with 
90% CI was also used in the survival 
analysis of 30-day death and 
death/re-MI. Rates of the primary 
efficacy endpoint were also risk-
adjusted to explore the possibility of 
imbalance of baseline characteristics 
among the study treatment groups. 
Using logistic regression techniques, 
two approaches were applied to 
develop a model for the primary 
efficacy endpoint: (i) simplified 
model based on age, heart rate, 
systolic blood pressure, Killip class, 
and anterior MI (top five predictors in 
the GUSTO I 30-day mortality 
model);9 (ii) full model considering all 
clinically and statistically significant 
predictors of the outcome. The 
primary efficacy endpoints were then 
adjusted by the observed vs. 
expected ratio. 
 
Pre-specified subgroup analyses 
included pre-hospital vs. inhospital 
randomization and time from 
symptom onset to randomization 
(2 h vs. >2 h). 
 
The data were housed and analysed 
at the University of Alberta. All 
analyses were performed using 
SPSS 13.0 with the exact tests 
module (SPSS Inc., Chicago, IL, 
USA). 
 
RESULTS 
In Table 1, the baseline 
characteristics for the three 
treatment groups are shown. Key 
baseline characteristics were well 
balanced across the three treatment 
groups, although patients in Group B 
were slightly younger, had fewer 
anterior MIs and were more 
frequently in Killip Class I. As 
illustrated in Table 2 there was 
excellent adherence to protocol-
mandated pharmacotherapy, 
including near universal use of 
clopidogrel and 97% use of 
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abciximab in the 91 patients 
undergoing primary angioplasty in 
Group C. In contrast, 48% of the 91 
patients undergoing PCI within 24 h 
of randomization in Group B 
received abciximab. In Table 3, 
median times from symptom onset 
to protocol-mandated therapy and 
procedures are shown for the overall 
population, as well as for those 
patients randomized pre-hospital (n 
= 121) vs. in-hospital (n = 183). 
Once randomization occurred, study 
drugs were administered 
expeditiously and the overall median 
time from symptom onset to PCI in 
Group C was rapid at 176 min. 
Group C patients randomized pre-
hospital also received their PCI ~1 h 
earlier than those randomized in 
hospital. 
 
Of the Group B patients, 102 
underwent cardiac catheterization 
within 24 h, 89 of who received in-
hospital revascularization with one 
additional patient revascularized by 
30 days—of these eight patients 
received CABG. In Group C, 98 
patients underwent angiography, 91 
underwent in-hospital PCI, and 93 
patients had revascularization by 30 
days—of these three patients had 
CABG. Revascularization was also 
performed in-hospital in 60 Group A 
patients and by 30 days in 65 
patients. 
 
Protocol-mandated rescue 
angioplasty was undertaken in 28% 
of Group B patients. An additional 
nine patients in Group B met the 
ECG criteria for early rescue: three 
of these had early angiography 
without PCI, four had angiography 
and PCI within the 24 h post-
randomization window, and two 
patients did not undergo 
angiography. 14 patients (14%) in 
Group A underwent rescue PCI, a 
median of 197 min after 
randomization (IQR 172–280 min). 
Coronary stents were used in over 
97% of all patients undergoing PCI. 
Initial angiographic findings prior to 
PCI in Group C patients following 
ASA, enoxaparin, and 300 mg 
clopidogrel loading revealed that 
Table 1 Baseline patient characteristics according to study treatment groups (intention to treat)
Intention to treat All
Group A Group B Group C
n 100 104 100 304
Age, median (IQR) (years) 58 (51–69) 57 (50–67) 60 (49–71) 58 (50–69)
Gender (female) 25 (25.0) 19 (18.3) 18 (18.0) 62 (20.4)
Hypertension (yes) 37 (37.0) 56 (53.8)* 33 (33.0) 126 (41.4)
Diabetes mellitus, yes (total) 18 (18.0) 8 (7.7) 16 (16.0) 42 (13.8)
Family history of early CAD (yes) 39 (39.0) 44 (42.3) 34 (34.0) 117 (38.5)
History of angina (yes) 25 (25.0) 31 (29.8) 18 (18.0) 74 (24.3)
Previous MI (yes) 14 (14.0) 12 (11.5) 12 (12.0) 38 (12.5)
Previous PCI (yes) 9 (9.0) 8 (7.7) 5 (5.0) 22 (7.2)
Smoking status (current smoker) 45 (45.0) 53 (51.0) 38 (38.0) 136 (44.7)
MI location on Q-ECG (anterior) 42 (42.0) 37 (35.6) 42 (42.0) 121 (39.8)
Killip class
I 93 (93.9) 99 (97.1) 93 (95.9) 285 (95.6)
II 6 (6.1) 3 (2.9) 4 (4.1) 13 (4.4)
Systolic BP, median (IQR) (mmHg) 140 (12–160) 140 (128–160) 145 (124–160) 141 (124–160)
Diastolic BP, median (IQR) (mmHg) 83 (71–92) 85 (71–98) 80 (70–96) 83 (70–96)
Pulse, median (IQR) (bpm) 75 (65–85) 72 (62–84) 75 (62–88) 74 (63–86)
Weight, median (IQR) (kg) 78 (63–87) 84 (71–97) 80 (67–90) 80 (67–91)
Height, median (IQR) (cm) 169 (162–177) 173 (166–180) 173 (162–178) 173 (163–178)
*P ¼ 0.006.
Table 2 Summary of protocol-mandated pharmacotherapy
Group A Group B Group C All
n 100 104 100 304
ASA
Given within 12 h or at index event 99 (99.0) 104 (100) 98 (98.0) 301 (99.0)
Clopidogrel given instead of ASA 1 (1.0) 0 (0.0) 2 (2.0) 3 (1.0)
Discharged on ASA 91 (91.0) 101 (97.1) 92 (92.0) 284 (93.4)
Discontinued prematurely 7 (7.0) 4 (3.8) 4 (4.0) 15 (4.9)
Enoxaparin
Given at index event 98 (98.0) 102 (98.1) 98 (98.0) 298 (98.0)
Discontinued prematurely 35 (35.7) 39 (38.2) 13 (13.0) 87 (29.2)
Bleeding [n (%) of those discontinued prematurely] 3 (8.6) 5 (12.8) 2 (13.3) 10 (11.2)
Physician discretion 23 (65.7) 24 (61.5) 7 (53.8) 54 (62.1)
Other 9 (25.7) 10 (25.6) 3 (23.1) 22 (25.3)
TNK
Given at randomization 98 (98.0) 103 (99.0) —
Clopidogrel
Given at index event — — 97 (97.0)
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30% had TIMI 2 or 3 flow. In the 90 
patients who underwent PCI (with 
complete angiographic data), 90% 
had TIMI 3 and 7% had TIMI 2 flow 
at the conclusion of their procedure. 
In the 85 Group B patients 
undergoing PCI, 81% had TIMI 3 
and 12% had TIMI 2 flow at the 
conclusion of their procedure. 
 
In Table 4, the primary efficacy and 
safety endpoints are shown. No 
statistically significant differences 
were observed in the primary 
composite endpoint or any of its 
components. The 30-day mortality 
rate was generally low, particularly in 
Groups B and C. Group B tended to 
have lower rates of heart failure and 
cardiogenic shock, whereas the 
lowest rate of recurrent MI was in 
Group C. There were no intracranial 
haemorrhages, infrequent major 
systemic bleeding, and no significant 
safety differences between 
treatment groups. 
 
Figure 1 demonstrates the Kaplan–
Meier curves for the 30-day 
composite primary efficacy endpoint. 
Given that there was no significant 
difference in the primary efficacy 
endpoint between Groups A and B 
(25 vs. 24%) these groups were 
combined when assessing the non-
inferiority between fibrinolysis and 
primary PCI. As shown in Figure 2, 
the relative difference in the primary 
efficacy endpoint between Groups A, 
B and Group C fell within the 15% 
rMID (Figure 3), however, the 90% 
confidence limits were broad and 
hence, this finding is not definitive. 
The primary efficacy endpoint, risk-
adjusted for the only significant 
predictor i.e. age, was similar across 
the three treatment groups (Group 
A: 25.0%; Group B: 24.6%; Group C: 
22.5%). No significant mortality 
difference existed between groups 
{Group B vs. A: unadjusted hazard 
ratio (HR) 0.23 [90% CI (0.04–1.46)]; 
Group C vs. A: 0.25 (0.04–1.54); 
Group B vs. C: 0.95(0.09–9.7)}. In 
Figure 3, the composite of 30-day 
death and recurrent MI is shown. 
Patients in Group A were 
significantly more likely to 
experience a combination of death 
and recurrent MI than in Group C 
(Group C vs. A: unadjusted HR 0.29, 
90% CI(0.11–0.74); P-logrank = 
0.021) whereas there was no 
difference between Group B and C 
(Group B vs. C: 1.73 (0.62–4.8); P-
logrank = 0.378). 
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In the nearly 40% of patients 
randomized to treatment in the pre-
hospital setting, 22.3% experienced 
the primary efficacy endpoint 
compared with 25.1% in those 
randomized upon arrival to hospital 
(P = 0.587). There was no 
statistically significant difference 
across the treatment groups in either 
setting. 
 
As pre-specified, the primary 
efficacy endpoint occurred in 38 
(20.7%) of the 184 patients who 
were randomized 2 h of symptom 
onset, compared to 35 (29.4%; P = 
0.09) of the 119 patients randomized 
beyond the 2 h mark. This difference 
was especially evident within Group 
C patients where there was a two-
fold increase in rates in patients 
randomized beyond 2 h [16.4% (2 
h) vs. 34.2% (>2 h); P = 0.052]. 
 
In Table 5, the ECG data are shown. 
The baseline sum of ST-deviation 
was similar across the treatment 
groups. At 180 min after 
randomization there was a trend 
towards more patients achieving 
complete, i.e. 70% resolution in 
Group B as compared with Groups A 
and C. Discharge ECG QRS scores 
indicated a trend (P = 0.14) towards 
a higher score i.e. a greater % of LV 
infarction in Group C. Median peak 
(IQR) CK data within the three 
treatment groups revealed IU values 
of 1199(548–2351), 1590(771–
2624), and 1833(852–3649) for 
Groups A, B, and C respectively, P = 
0.045. 
 
Figure 4 illustrates the median NT-
proBNP in pg/mL acquired at 
baseline, 72 h and 30 days. No 
significant difference in baseline 
Table 3 Median (IQR) minutes from symptom (Sx) onset to treatment in all patients and according to pre-hospital vs. in-hospital
randomization
Group A Group B Group C
Overall (n ¼ 304) 100 104 100
Sx onset to randomization 105 (63–158) 114 (67–172) 100 (70–160)
Sx onset to first study
druga
113 (74–179) 130 (75–185) 112 (80–164)
Sx onset to PCI 395 (294–3711), n ¼ 58 425 (288–1331), n ¼ 81b 176 (140–280), n ¼ 91
Sx onset to rescue PCI 299 (270–325), n ¼ 14 277 (213–381), n ¼ 29 —
Sx onset to non-rescue PCI 1498 (341–5465), n ¼ 44 926 (398–1454), n ¼ 52 —
First medical contactc to first study druga 51 (37–75) 54 (38–77) 54 (36–69)
First medical contactc to PCI 350 (245–3561) 324 (218–1216) 127 (93–159)
Pre-hospital (n ¼ 121) 42 42 37
Sx onset to randomization 85 (63–147) 76 (50–114) 72 (49–98)
Sx onset to first study drug 91 (70–156) 91 (57–142) 82 (58–103)
Sx onset to PCI 364 (273–2056), n ¼ 27 371 (215–912), n ¼ 31 140 (115–171), n ¼ 33
Sx onset to rescue PCI 274 (254–351), n ¼ 8 217 (193–342), n ¼ 15 —
Sx onset to non-rescue PCI 484 (282–3076), n ¼ 19 810 (393–1343), n ¼ 16 —
First medical contactc to first study druga 46 (35–55) 44 (36–57) 41 (32–53)
First medical contactc to PCI 331 (223–1720) 245 (196–856) 104 (88–126)
In-hospital (n ¼ 183) 58 62 63
Sx onset to randomization 105 (74–160) 135 (91–178) 124 (89–185)
Sx onset to first study drug 119 (86–180) 146 (102–189) 137 (103–201)
Sx onset to PCI 1441 (303–5494), n ¼ 31 532 (338–1414), n ¼ 50 207 (167–292), n ¼ 58
Sx onset to rescue PCI 302 (293–333), n ¼ 6 343 (275–419), n ¼ 14 —
Sx onset to non-rescue PCI 3216 (376–5547), n ¼ 25 1137 (406–1474), n ¼ 36 —
First medical contactc to first study druga 61 (43–83) 67 (42–92) 61 (40–85)
First medical contactc to PCI 1396 (260–5403) 606 (259–1308) 143 (100–169)
aFirst study drug refers to TNK in Groups A and B and to enox in Group C.
bProtocol-mandated procedure.
cFirst medical contact refers to ambulance arrival or hospital arrival.
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median NT-proBNP measures was 
observed across the three treatment 
groups. In the repeated measure 
analysis, which was based on 184 
patients with complete NT-proBNP 
at all 3 collection times, there was a 
significant trend in the mean NT-
proBNP values from baseline to 30 
days (P < 0.001) such that an 
increase was observed from 
baseline to 72 h but then a decline at 
30 days. NT-proBNP values were 
significantly higher in Group C 
relative to Group A (P = 0.019) and 
to a lesser extent, Group B (P = 
0.092). 
 
DISCUSSION 
Our study of STEMI patients 
focusing on early reperfusion 
treatment provides several novel 
findings. Reperfusion therapy with a 
contemporary pharmacologic 
regimen, coupled with a strategy of 
regimented rescue and routine 
invasive evaluation within 24 h of 
treatment, provides an excellent 
standard of care that is not different 
from timely expert PCI at 
experienced centres. We found no 
difference in the primary composite 
outcome across the three treatment 
groups even after adjustment for 
minor baseline differences. 
Moreover, there were no intracranial 
haemorrhages and a small but 
comparable incidence of non-
haemorrhagic stroke and major 
bleeding. 
 
What might account for our findings 
that differ from most prior 
comparisons in larger populations? 
Our strategy of establishing the 
diagnosis of STEMI at the first 
medical contact contributed to 
expedited randomization with a 
median time of 105 min from 
symptom onset. Early diagnosis was 
followed by expedited treatment, 
followed by triage and transport in 
the pre-hospital population. This 
contributed to the remarkably short 
times to both fibrinolysis and PCI 
treatments rarely achieved in prior 
STEMI clinical trials. The 
approximate 46 min interval between 
fibrinolytic treatment in Group B and 
primary PCI delivery in Group C is 
well aligned with prior evidence 
suggesting similar outcomes from 
both reperfusion methods evaluated 
in a systematic overview of prior 
comparisons.10 Hence, the tendency 
towards more shock and CHF in 
Group C is of interest and 
reminiscent of the findings in the 
Comparison of Angioplasty and Pre-
Table 4 Efficacy and safety endpoints
Group A Group B Group C All
n 100 104 100 304
Primary efficacy endpoint at 30 days 25 (25.0) 25 (24.0) 23 (23.0) 73 (24.0)
Death 4 (4.0) 1 (1.0) 1 (1.0) 6 (2.0)
Re-MI 9 (9.0) 6 (5.8) 3 (3.0) 18 (5.9)
Heart failure 15 (15.0) 15 (14.4) 18 (18.0) 48 (15.8)
Cardiogenic shock 6 (6.0) 4 (3.8) 7 (7.0) 17 (5.6)
Refractory ischaemia 0 (0.0) 3 (2.9) 0 (0.0) 3 (0.1)
Major ventricular arrhythmias 1 (1.0) 1 (1.0) 1 (1.0) 3 (1.0)
Primary safety endpoint during index
hospitalization
Intracranial haemorrhage 0 0 0 0
Non-haemorrhagic stroke 0 1 (1.0) 1 (1.0) 2 (0.1)
Major systemic bleeding 1 (1.0) 2 (1.9) 1 (1.0) 4 (1.3)
Composite of primary efficacy and safety endpoint 26 (26.0) 26 (25.0) 24 (24.0) 76 (25.0)
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hospital Thrombolysis In Acute 
Myocardial Infarction trial (CAPTIM) 
where patients treated with 
fibrinolysis <2 hrs from symptom 
onset had lower mortality and 
cardiogenic shock than those 
randomized to PCI.11 It is also 
aligned with the reduced prevalence 
of cardiogenic shock in the pre-
hospital fibrinolysis vs. primary PCI 
group observed in the French 
nationwide USIC 2000 Registry.12 
These suggestive clinical trends are 
further supported by the higher peak 
CK data, discharge ECG QRS 
scores and elevated NT-proBNP 
values at days 3 and 30 found in 
Group C. Mandatory systematic and 
timely rescue PCI in Group B 
performed in 28% of patients may 
Figure 1 Kaplan–Meier curves of the primary efficacy endpoint according to
study treatment groups. Group A (n ¼ 100) is represented by the small dashed
line; Group B (n ¼ 104) by the solid line; Group C (n ¼ 100) by the large
dashed line.
Figure 2 Relative difference in the primary efficacy endpoint between
Groups A and B combined and Group C with 90% confidence limits and pre-
specified 15% rMID boundary.
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have further contributed to their 
favourable outcomes and is 
supported by the trend towards 
superior ST-resolution at 180 min. 
 
Our study was not powered to show 
a definitive impact on mortality or the 
combination of death and MI. 
Notwithstanding this, our findings 
are consistent with the notion that a 
strategy of early fibrinolysis coupled 
with routine early invasive 
management (or timely rescue PCI, 
if warranted) results in rates of death 
and re-infarction comparable with 
those achieved with direct PCI.11 
Whereas prior comparative studies 
frequently indicate that re-MI 
constitutes the principal efficacy 
advantage for PCI this difference is 
known to be mitigated by the use of 
enoxaparin, clopidogrel, and timely 
mechanical co-intervention.13–16 
Interestingly, patients in Group A 
with later and lower rescue rates and 
less frequent overall 
revascularization appeared to fare 
less well than direct PCI patients, 
especially relating to the composite 
of death and re-MI. This finding is 
consistent with the GRACIA-1 study 
where patients randomized six hours 
after fibrinolysis to angiography and 
intervention within 24 h vs. an 
ischaemia-guided conservative 
approach tended to have a reduced  
Figure 3 Kaplan–Meier curves of 30-day death/re-MI according to study
treatment groups. Group A (n ¼ 100) is represented by the small dashed
line, Group B (n ¼ 104) by the solid line, Group C (n ¼ 100) by the large
dashed line. Group C vs. A was statistically significant (logrank P ¼ 0.021).
Figure 4 Median NT-proBNP in pg/mL at baseline, 72 h, and 30 days accord-
ing to study treatment groups. Group A (n ¼ 72–84) is represented by the
small dashed line; Group B (n ¼ 75–83) by the solid line; Group C
(n ¼ 70–87) by the large dashed line. NT-proBNP values were significantly
higher in Group C both at 72 h (P ¼ 0.03) and 30 days (P ¼ 0.007) relative
to Group A.
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rate of death or re-infarction.17 It is 
noteworthy that coronary 
interventions in GRACIA-1 occurred 
a mean of 17 h after fibrinolysis 
whereas in ASSENT-4 PCI a 
strategy of immediate PCI (1–3 h) 
after TNK was associated with 
higher in-hospital mortality, cardiac 
ischaemic complications, and stroke 
as compared with those who 
received direct PCI alone.18 Hence, 
the optimal frequency and timing of 
co-intervention in patients receiving 
fibrinolysis remains uncertain but 
systematic adherence to STEMI 
rescue guidelines is likely a key 
factor. Our data are also well aligned 
with the recently reported REACT 
study.16 In that trial, when systematic 
rescue PCI was employed early after 
failed fibrinolysis in STEMI patients, 
their composite outcome of death, 
re-MI, cerebrovascular accident, and 
severe heart failure was significantly 
superior to those receiving repeat 
fibrinolysis or conservative therapy. 
Overall times from symptom onset to 
randomization were well balanced 
and short in our study, and the 
expected advantage of pre-hospital 
randomization was also evident. 
Hence, our strategy of pre-hospital 
randomization and treatment not 
only substantially shortened the time 
to pharmacologic therapy but also 
abbreviated the time to PCI by over 
1 h by ensuring enhanced readiness 
at the receiving PCI centres. 
 
Our choice and dosing of enoxaparin 
deserves discussion given the 
findings of ASSENT 3 and 3 
PLUS.19,20 We chose to omit the IV 
enoxaparin bolus and allow for 
supplemental IV dosing in the setting 
of PCI. Given the short time lapse 
from initial dosing of enoxaparin, the 
time to adequate anticoagulation 
was likely a more important issue in 
Group C.21 However, systematic use 
of abciximab, known to favourably 
affect PCI outcomes in such patients 
was also employed. 
 
Our study has some limitations that 
should be noted: because a 
screening log was not maintained 
and it was unblinded we cannot rule 
out bias. However the blind 
adjudication of clinical endpoints as 
Table 5 Electrocardiographic data: ST-deviation, ST-resolution, and QRS score
% of LV Group A Group B Group C
Sum of ST-deviation
n 100 104 100
Baseline 11.8 (7.5–17) 10 (6.5–15.5) 11.3 (7–16.5)
ST-resolution
90 min
n 90 97
50% resolution 62 (68.9) 59 (60.8)
70% resolution 39 (43.3) 44 (45.4)
180 min
n 79 85 79
50% resolution 58 (73.4) 71 (83.5) 62 (78.5)
70% resolution 48 (60.8) 59 (69.4) 44 (55.7)
QRS score on discharge ECG
n 85 92 79
0–1 0–3 20 (20.0) 15 (14.4) 10 (10.0)
2–4 6–12 27 (27.0) 36 (34.6) 22 (22.0)
.4 .12 38 (38.0) 41 (39.4) 49 (49.0)
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well as the core assessments of 
ECG, angiographic, NT-proBNP and 
CK data conducted without the 
knowledge of treatment assignment, 
make this unlikely. Because of the 
modest sample size, we cannot 
exclude the play of chance. For us to 
have reached a definitive non-
inferiority conclusion (based on a 
15% rMID and 90% CI with a 
composite endpoint of 24.0% in 
Group B and 23% in Group C), a 
trial would need to enrol 1625 
patients in each arm or 2578 
patients in each arm (based on a 
similar rMID and a 24.5% composite 
endpoint in a combined Group A and 
B vs. 23% in Group C). 
 
In summary, our investigation 
provides novel data supporting the 
efficacy, safety and feasibility of a 
strategic pharmacologic approach 
that combines fibrinolysis with timely 
catheter co-intervention for patients 
who can be assessed early after 
symptom onset. This strategy is 
especially relevant to both pre-
hospital and community hospital 
settings and its use in the current 
study should provide 
encouragement to regions where an 
integrated systems approach to the 
management of STEMI has not yet 
been undertaken. Although such a 
strategy requires 24-h/7 day access 
to interventional facilities, it may 
provide a more reasonable balance 
as it relates to the timing and 
frequency of their use. In the light of 
the failure of routine immediate 
intervention after fibrinolytic therapy 
recently reported in ASSENT-4 PCI 
coupled with persisting delays in 
accessing primary PCI, an approach 
focusing on pre-hospital care and 
other methods to ensure early 
treatment and timely and effective 
post-fibrinolytic rescue seems well 
positioned to provide a useful 
therapeutic option deserving of more 
definitive large-scale 
investigation.18,22 
 
Our findings may particularly assist 
informing the design of such an 
initiative. 
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APPENDIX 2 
Endpoint definitions 
(1) Refractory ischaemia: Symptoms 
of ischaemia with ST-deviation or 
definite T-wave inversion persisting 
for at least 10 min despite medical 
management while in hospital. 
(2) Recurrent MI (myocardial re-
infarction): (i) In the first 18 h after 
randomization: (a) Recurrent signs 
and symptoms of ischaemia at rest 
accompanied by new or recurrent 
ST-segment elevations of 0.1 mV 
in at least two contiguous leads 
lasting  30 min. 
(ii) After 18 h: (a) New Q-waves (by 
Minnesota Code Criteria) in two or 
more leads and/or enzyme evidence 
of re-infarction: re-evaluation of CK-
MB or troponin to above the upper 
limit of normal and increased by 
>50% over the previous value. 
(b) The total CK must either be re-
elevated to two times or more the 
upper limit of normal and increased 
by >25% or be re-elevated to >200 
U/mL over the previous value. 
(1) If re-evaluated to less than two 
times the upper limit of normal, the 
total CK must exceed the upper limit 
of normal by >50% and exceed the 
previous value by two-fold or be re-
elevated to >200 U/mL. 
(iii) Re-infarction after PTCA            
(± stenting): 
(a) CK greater than three times the 
upper limit of normal and 50% 
greater than the previous value 
and/or new Q-waves (Minnesota 
Code) in two or more contiguous 
leads. 
(iv) Re-infarction after CABG 
surgery: 
(a) CK greater than five times the 
upper limit of normal and 50% 
greater than the previous value 
and/or new Q-waves (Minnesota 
Code) in two or more contiguous 
leads. 
(3) Congestive heart failure: 
(i) Physicians decision to treat CHF 
with a diuretic, intravenous inotropic 
agent or intravenous vasodilator and 
either 
(a) the presence of pulmonary 
edema or pulmonary vascular 
congestion on chest X-ray believed 
to be of cardiac cause or 
(b) at least two of the following: 
(1) rales greater than one-third up 
the lung fields believed to be due to 
CHF. 
(2) PCWP >18 mmHg 
(3) Dyspnoea, with documented pO2 
less than 80 mmHg on room air or 
O2 saturation, 90% on room air, 
without significant lung disease. 
(4) Cardiogenic shock: The 
manifestation of vascular collapse 
and shock (SBP < 90 mmHg for at 
least 30 min or SBP > 90 mmHg 
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after inotropic or intra-aortic balloon 
support with a cardiac index <2.2 
L/min/m2 or <2.5 L/min/m2 inotropic 
or intraaortic balloon support, 
peripheral signs of hypoperfusion, 
and chest X-ray with pulmonary 
edema. 
(5) Major ventricular arrhythmias: 
Ventricular arrhythmias >6 h 
after randomization requiring 
electrical cardioversion/defibrillation. 
(6) Major bleeding: Bleeding that 
causes haemodynamic compromise 
requiring blood or fluid replacement, 
inotropic support, ventricular assist 
devices, surgical intervention, or 
CPR to maintain a sufficient cardiac 
output. 
 
APPENDIX 3 
NT-proBNP 
NT-pro-brain natriuretic samples 
were allowed to clot for 35–45 min 
and the blood centrifuged within 1 h 
of collection for 15 min at 1700 g 
and shipped in dry ice to a central 
laboratory (Montreal Heart Institute) 
where it was stored at -70•C. 
Samples were acquired at baseline, 
72 h after admission, and at 30 
days. Samples were batch-analysed 
at the end of the study by an 
electrochemiluminescence 
immunoassay with Roche Elecsys 
Instrument and Elecsys NT-proBNP 
Reagent kit (Roche Diagnostics, 
Indianapolis, USA) with an analytical 
range of 5–35000 pg/mL and 
respective intra-assay and inter-
assay variability of 8 and 4%. 
 
ECG 
ST-segment measurements were 
acquired manually with magnification 
and hand-held callipers to the 
closest 0.05 mV at the J point. Per 
cent resolution was acquired 
according to the method of 
Schroeder. QRS scoring was 
analysed using the method of 
Selvester, where each point in the 
score represents ~3% of the 
left ventricle.6,7 
 
 
Angiography 
All patients in Groups B and C had 
angiographic analysis undertaken 
in a core facility to assess culprit 
coronary artery TIMI flow. These 
assessments were performed by 
observers blinded to treatment 
assignment. 
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Summary and Conclusions 
William Shakespeare once said "If 
you can look into the seeds of time, 
and say which grain will grow and 
which will not, speak then unto me."; 
and even today, this desire to 
foresee the future continues. 
Throughout this thesis, we 
characterised various approaches to 
and purposes of risk assessment in 
ACS patients with aim of improving 
patient care and outcomes.  
Approaches to risk prediction in 
acute coronary syndromes 
A constellation of factors, both 
tangible and intangible, can guide 
the likelihood of an adverse event in 
an ACS patient.  In the first section 
of this thesis, three approaches to 
assess this risk were presented, 
ranging from multivariable logistic 
regression to methods novel to 
cardiovascular medicine, dynamic 
risk modelling and multilevel 
modelling.  Assessing the risk of 
short- and long-term adverse events 
in non-ST-elevation ACS patients led 
to several important findings: 
namely, the striking prognostic value 
of quantitative ST-segment 
depression and multiple biomarkers 
including NT-proBNP, troponin T 
and CRP (Chapter 1).  Whereas 
demographics, medical history and 
initial clinical indicators made up the 
classic risk profile of these patients, 
the GUSTO IV ACS trial was able to 
provide strong evidence for the 
value of these novel indicators. In 
addition to developing a clinical risk  
 
 
tool based on these factors, our 
understanding of the disease was  
also enhanced. In particular, CRP 
was only predictive of 1-year death, 
signally the long-term influence of 
inflammation.  
 
Chapter 2 focused on an innovative 
approach to risk assessment, 
dynamic risk modelling. This method 
extends beyond traditional baseline 
risk models by forecasting future 
events based on all data 
accumulated up until clinically 
relevant time points.  A series of 
logistic regression models were 
developed in over 6000 ST-elevation 
MI patients enrolled in the ASSENT-
3 trial to predict 30-day mortality at 
the following key “forecasting 
periods”: Baseline, 3 hours, Day 2 
and Day 5. A key feature of dynamic 
modelling is the ability to assess the 
change in prognostically relevant 
factors over time. For instance, the 
relative importance of traditional 
baseline characteristics, such as 
age, heart rate and systolic blood 
pressure was attenuated over time 
with the occurrence of complications 
such as stroke and heart failure. 
This continually updated appraisal of 
risk may help to advise medical 
decision making above and beyond 
what is known initially at hospital 
admission.  
 
The region or country in which a 
patient is treated is often cited as 
having some bearing on the 
treatment received and/or the risk of 
adverse events, yet the origins of 
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these differences are not well 
characterised.  Contextual factors 
such as provider characteristics, 
socioeconomic and cultural factors, 
health care practices and policies 
may play a role but often these data 
are not available to perform formal 
evaluations. To further elucidate the 
amount of variation in the treatment 
and outcomes in non-ST-elevation 
ACS patients due to patient- versus 
non-patient-level factors, multilevel 
modelling techniques were applied 
to the GUSTO IV ACS trial (Chapter 
3).  Across the 24 participating 
countries, there were significant 
differences in the processes of care 
(i.e., revascularisation) and 
outcomes (i.e., 30-day death/MI 
and1-year mortality). However, after 
accounting for key patient- and 
hospital-level factors, the inter-
country differences disappeared; 
and in fact, patient-level factors were 
attributable for between 96% and 
99% of the total variation in these 
outcomes. These results point to the 
potential fallacy in concluding that 
international differences exist 
without accounting for the variation 
related to lower-level factors such as 
hospital and patient characteristics. 
Although the hospital-level variation 
seemed small, it was significant. The 
collection of data at this level in 
future studies may help to further 
explain these differences. 
Unravelling the pathophysiology 
of acute coronary syndromes 
The breadth of data collected in 
large-scale clinical trials provides 
unmatched opportunity for improving 
our understanding of ACS. In 
Chapter 4, the quantitative and 
central assessment of baseline 
ECGs in the GUSTO IV ACS trial 
identified patients with 
electrocardiographic left ventricular 
hypertrophy (LVH). This condition is 
not typically considered in the risk 
profile of ACS; thus, we sought to 
evaluate its association with 
mortality and the composite of death 
or MI, as well as any possible 
modulation of the effect by gender 
and/or NT-proBNP, a marker of 
hemodynamic stress. Of 7443 non-
ST-elevation ACS patients, 8% had 
LVH, with women accounting for 
three quarters.  Long-term survival 
analysis identified women with LVH 
as a particularly high-risk subgroup, 
whom may be targeted with 
increased vigilance. 
Inflammation has been increasingly 
recognised for its role in the 
pathogenesis of coronary artery 
disease based on strong evidence 
supporting CRP and other 
inflammatory markers. Chronic 
infection with Chlamydia 
pneumoniae has in past been linked 
to the initiation of or contribution to 
plaque formation and destabilisation, 
but its relationship with adverse 
coronary events has yielded 
conflicting evidence. The findings 
from our nested case-control study 
in the GUSTO IV ACS trial did not 
support this infectious agent as an 
important risk factor in ACS 
(Chapter 5).  
 
Stroke is an infrequent complication 
occurring early after non-ST-
elevation ACS; however, the 
ensuing rates of morbidity and 
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mortality are high. Thus, 
identification of the factors 
associated with this event would be 
helpful in understanding the causes 
and mitigating these risks. Based on 
our analysis of six large-scale 
clinical trials in non-ST-elevation 
ACS patients, advanced age, prior 
stroke and elevated heart rate were 
among the strongest predictors of 
all-cause stroke within 30 days of 
randomisation (Chapter 6). The risk 
profile was not altered when 
predicting specifically non-
haemorrhagic or haemorrhagic 
strokes. Of note, the study 
treatment, GPIs were not associated 
with higher risk of stroke. While the 
identification of these three 
indicators provides some insight, 
relying on them to predict the 
incidence of stroke deserves caution 
given the modest discriminatory 
power of the model.  
 
Tailoring treatment in acute 
coronary syndromes 
One of the purposes of risk 
assessment is to tailor treatment and 
resources to patients with the best 
benefit/harm ratio. If a therapy is 
effective in reducing the relative risk 
of adverse events uniformly across a 
broad spectrum of patients, then 
those at higher absolute risk will 
have larger absolute risk reductions 
from the therapy.  A meta-analysis of 
the six large-scale clinical trials on 
the efficacy of GPIs in ACS 
addresses this concept relative to 
age (Chapter 9). While we observed 
a larger absolute risk reduction in 
death or MI with increasing age, a 
rise in the absolute risk of major 
bleeding was also revealed.  Given 
this, we recommended that elderly 
patients be closely observed to 
manage these risks. 
 
Although the optimal mechanism of 
reperfusion therapy remains under 
much debate, there is little disputing 
that shorter time to treatment results 
in improved outcomes in ST-
elevation MI patients.  Our pooled 
analysis of 22 clinical trials clearly 
demonstrated this. Moreover, 
patients who underwent primary PCI 
were significantly more likely to 
survive to 30 days compared to 
those treated with fibrinolysis, 
regardless of the treatment delay 
(Chapter 10). However, translating 
these findings to the real world is a 
difficult challenge given that this 
setting is often more complex than 
the clinical trial environment. As a 
result, tailoring treatment to fit local 
or regional settings in favour of 
minimising the time to treatment 
should be emphasised.  Novel 
therapeutic strategies, including pre-
hospital triage and treatment and 
regimens combining early 
pharmacological treatment with 
timely angiography, are under 
investigation with this consideration 
in mind (Chapter 11).  
 
CONCLUSIONS  
As demonstrated in this thesis, 
putting the future in service of the 
present can serve a multitude of 
purposes and can be accomplished 
using a variety of techniques. While 
we have made significant progress 
since the dawn of the modern 
definition of risk with Pascal and de 
Fermat, there remains great 
potential to refine risk assessment. 
Specifically, risk assessment in ACS 
will benefit from the exploration of 
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new measures, statistical techniques 
and study designs. Innovative 
approaches to measuring previously 
unknown or nebulous factors (and/or 
improving current measures) and 
addressing more complex research 
questions will lead to a more 
comprehensive understanding of risk 
in these patients.  
 
Although clinical trials are revered 
for their rich clinical data, they are 
also limited by select inclusion and 
exclusion criteria, which challenges 
the generalisability of the results. 
Registries and other population-
based cohorts, however, have the 
tremendous potential to forego this 
limitation through the enhancement 
of the data collected.  Regardless of 
the cohort under investigation, the 
serial collection of clinical indicators 
such as electrocardiograms, 
biomarkers and vital signs could 
significantly advance our 
understanding of the dynamic 
evolution of risk, and contextual data 
on institutions, countries and regions 
could help to complete the global 
picture of risk.  
 
Finally, the destination of these 
efforts should focus on the patient. 
In the past, there has been a 
challenge in balancing statistical 
theory and clinical pragmatism, 
which may have stunted the uptake 
of risk assessment at the patient 
level. This gap, however, can be 
narrowed through fostering a culture 
of guided risk assessment as well as 
taking advantage of the 
technological revolution (e.g., 
electronic medical records, handheld 
computers, etc.).  
 175 
Samenvatting en conclusies 
 
William Shakespeare zei eens "If 
you can look into the seeds of time, 
and say which grain will grow and 
which will not, speak then unto me". 
Ook vandaag nog bestaat dit 
verlangen om in de toekomst te 
kunnen kijken. In dit proefschrift 
hebben we verschillende methoden 
en toepassingen van risico-evaluatie 
in ACS patiënten geschetst, met als 
doel de patiëntenzorg en uitkomsten 
te verbeteren. 
 
Methoden van risico voorspelling 
in het acuut coronair syndroom  
Een grote diversiteit aan factoren, 
grijpbaar en ongrijpbaar, kan 
bijdragen tot de kans op 
complicaties bij een ACS patiënt. In 
het eerste deel van dit proefschrift 
zijn drie methoden van risico 
evaluatie weergegeven, variërend 
van multivariabele logistische 
regressie tot methoden die nieuw 
zijn in de cardiovasculaire 
geneeskunde: dynamische risico 
modellering en multilevel 
modellering. Evaluatie van het risico 
van complicaties op korte en lange 
termijn in patiënten met non-ST-
elevatie ACS, leidt tot diverse 
belangrijke bevindingen: opvallend 
was de prognostische waarde van 
kwantitatieve ST-segment depressie 
en diverse biomarkers, inclusief NT-
proBNP, troponine T en CRP 
(Hoofdstuk 1). Terwijl het klassieke 
risicoprofiel van deze patiënten 
bestaat uit demografische gegevens, 
medische voorgeschiedenis en 
klinische indicatoren bij aanvang van 
de opname, was de GUSTO IV ACS  
studie in staat om harde bewijzen te 
leveren voor de waarde van deze 
nieuwe indicatoren. Naast het 
ontwikkelen van een klinisch risico-
evaluatie instrument gebaseerd op 
deze factoren, verbeterde ook ons 
inzicht in de ziekte. In het bijzonder, 
CRP bleek alleen voorspellend voor 
1-jaars sterfte, een aanwijzing voor 
de lange termijn invloed van 
ontstekingsprocessen. 
 
Hoofdstuk 2 richt zich op 
dynamische risico modellering, een 
innovatieve methode van risico 
evaluatie. Deze methode gaat 
verder dan traditionele risico 
modellen door het voorspellen van 
toekomstige complicaties, gebruik 
makend van alle bevindingen tot aan 
een klinisch relevant tijdstip, dus niet 
alleen gebaseerd op 
opnamegegevens. 
 
Een serie van logistische regressie 
modellen is ontwikkeld, gebaseerd 
op meer dan 6000 patiënten met ST-
elevatie MI, geïncludeerd in de 
ASSENT-3 studie, om 30-dagen 
sterfte te voorspellen op de 
volgende belangrijke “voorspel-
momenten”: opname, 3 uur, dag 2 
en dag 5. Een cruciaal kenmerk van 
dynamische modellering, is het 
vermogen om de verandering in 
prognostisch belangrijke factoren in 
de tijd te beoordelen. Bijvoorbeeld, 
het relatieve belang van traditionele 
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opnamegegevens, zoals leeftijd, 
hartfrequentie en systolische 
bloeddruk, neemt door de tijd heen 
af door het optreden van 
complicaties zoals beroerte en 
hartfalen. De continu bijgestelde 
evaluatie van risico kan 
ondersteunend zijn bij het nemen 
van medische beslissingen, naast 
de gegevens die bekend zijn aan het 
begin van de ziekenhuisopname. 
 
Er wordt vaak gezegd dat de regio of 
het land waar de patiënt behandeld 
wordt van invloed is op de 
behandeling en/of de risicos op 
complicaties, maar de oorzaken van 
deze verschillen zijn niet duidelijk in 
kaart gebracht. Contextuele factoren 
zoals kenmerken van de 
zorgverleners, sociaal economische 
en culturele factoren, 
gezondheidszorgvoorzieningen en -
beleid kunnen een rol spelen, maar 
vaak zijn deze gegevens niet 
beschikbaar om dit formeel te 
kunnen onderzoeken. Om de 
variabiliteit in de behandeling en 
uitkomsten in patiënten met ST-
elevatie ACS ten gevolge van 
patiënt- versus niet-patiëntgebonden 
factoren verder toe te lichten, 
werden multilevel 
modelleringstechnieken toegepast 
op de GUSTO IV ACS trial 
(Hoofdstuk 3). Er waren significante 
verschillen tussen de 24 
deelnemende landen, in het 
zorgproces (bijv. bij revascularisatie) 
en de uitkomsten (bijv. 30-dagen 
sterfte / myocardinfarct en 1-jaars 
sterfte). Echter, de verschillen 
tussen de landen verdwenen, 
wanneer gecorrigeerd werd voor 
belangrijke patiënt- en ziekenhuis 
gebonden factoren; in feite kon 96% 
tot 99% van de totale variatie in 
deze uitkomsten toegeschreven 
worden aan patiëntgebonden 
factoren.  
Deze resultaten wijzen op de 
potentiële misvatting dat 
internationale verschillen bestaan 
zonder dat gecorrigeerd wordt voor 
de variatie in relatie tot factoren 
behorend tot een lager niveau, zoals 
ziekenhuis- en patiëntgebonden 
factoren. Hoewel de variatie tussen 
ziekenhuisgebonden factoren klein 
leek, was het wel significant. Het 
verzamelen van gegevens op 
ziekenhuisniveau in toekomstige 
studies kan bijdragen tot een 
verdere verklaring van deze 
verschillen. 
De verklaring van de 
pathofysiologie van het acuut 
coronair syndroom 
De hoeveelheid gegevens die 
verzameld zijn in grootschalige 
patiëntgebonden onderzoeken 
boden een uitstekende gelegenheid 
om ons inzicht in ACS te  
verbeteren. In hoofdstuk 4, konden 
met behulp van kwantitatieve en 
centrale beoordeling van opname 
ECGs in het GUSTO IV ACS 
onderzoek, patiënten worden 
geïdentificeerd met 
electrocardiografische linker 
ventrikel hypertrofie (LVH). Deze 
aandoening wordt gewoonlijk niet 
beschouwd als een onderdeel van 
het risicoprofiel van ACS, dus 
onderzochten we de associatie met 
sterfte of het samengestelde 
eindpunt van sterfte of een 
myocardinfarct, naast een mogelijke 
beïnvloeding van het effect van deze 
associatie door geslacht en/of NT-
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proBNP, een kenmerk van 
hemodynamische stress. Van de 
7443 patiënten met non-ST-elevatie 
ACS, had 8% LVH, hiervan was 
driekwart vrouw. Lange- termijn 
overlevingsanalyses lieten zien dat 
in het bijzonder vrouwen met LVH 
een hoog risico subgroep vormen, 
die bijzondere aandacht zou moeten 
krijgen. 
 
Het is steeds duidelijker geworden 
dat ontstekingsprocessen een grote 
rol  spelen in de pathogenese van 
coronaire hartziekten, gebaseerd op 
harde bewijzen in studies naar CRP 
en andere ontstekingsmarkers. 
Chronische infectie door Chlamydia 
pneumoniae is in het verleden 
geassocieerd met het ontstaan en 
de progressie van plaquevorming en 
-destabilisatie. Echter, wat betreft de 
relatie met complicaties op het 
gebied van hart- en vaatziekten 
spreekt de bewijsvoering elkaar 
tegen. Onze case-control studie, die 
ingebed was in de GUSTO IV ACS 
studie, leverde geen bewijs voor 
deze infectie marker als een 
belangrijke risico factor in ACS 
(Hoofdstuk 5). 
Een beroerte treedt slechts 
sporadisch op vlak na non-ST-
elevatie ACS, maar de complicatie 
gerelateerde ziekte- en sterftecijfers 
zijn hoog. Identificatie van de 
factoren die samenhangen met deze 
complicatie zouden dus kunnen 
bijdragen tot het begrijpen van de 
oorzaken en het verminderen van 
deze risicos. Uit onze analyse van 
zes grootschalige studies met 
patiënten met non-ST-elevatie ACS, 
bleken oudere leeftijd, een eerder 
doorgemaakte beroerte en een 
hogere hartfrequentie de beste 
voorspellers voor het optreden van 
een beroerte binnen 30 dagen na 
randomisatie (Hoofdstuk 6). 
 
Het risico profiel veranderde niet 
door het voorspellen van specifiek 
niet-bloedige of bloedige beroertes. 
Het is belangrijk om op te merken 
dat gebruik van de studiemedicatie, 
GPIs, niet was geassocieerd met 
een hoger risico op een beroerte. 
Hoewel de identificatie van deze drie 
indicatoren ons enig inzicht geeft, 
kunnen we hier niet volledig op 
bouwen om de incidentie van een 
beroerte te voorspellen, gegeven het 
bescheiden discriminatieve 
vermogen van het model. 
 
Behandeling op maat van het 
acuut coronair syndroom  
Een van de doelstellingen van risico 
evaluatie is om die behandeling en 
die middelen te geven aan 
patiënten, die de beste verhouding 
tussen voor- en nadelen oplevert. 
Als een therapie effectief is in het 
verminderen van het relatieve risico 
op complicaties, op een zelfde 
manier bij verschillende soorten 
patiënten, dan zullen patiënten met 
een hoger absoluut risico een 
grotere absolute risicoreductie 
hebben van de therapie. In een 
meta-analyse van de zes 
grootschalige patiëntgebonden 
onderzoeken naar de effectiviteit van 
GPIs bij patiënten met ACS werd dit 
concept onderzocht in relatie tot 
leeftijd. (Hoofdstuk 9). Terwijl we 
een grotere absolute risicoreductie 
in sterfte of MI observeerden met het 
toenemen van de leeftijd, was er ook 
een stijging van het absolute risico 
op belangrijke bloedingen. Daarom 
bevelen wij aan dat oudere patiënten 
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intensief geobserveerd worden om 
goed met deze risicos om te gaan. 
 
Hoewel er veel discussie blijft over 
het optimale mechanisme van 
reperfusie therapie, is er weinig 
discussie dat een kortere tijd tot de 
behandeling leidt tot verbeterde 
uitkomsten bij patiënten met ST-
elevatie MI. Onze gepoolde analyse 
van 22 klinische onderzoeken laat 
dit duidelijk zien. Bovendien hadden 
patiënten die een primaire PCI 
hadden ondergaan een significant 
betere 30-dagen overleving in 
vergelijking met degenen die 
behandeld waren met fibrinolyse, 
ongeacht de vertraging in de 
behandeling. (Hoofdstuk 10). 
Echter, vertaling van deze 
bevindingen naar de dagelijkse 
praktijk is een moeilijke opgave 
aangezien deze situatie vaak 
complexer is dan die van een 
klinisch onderzoek. Daarom zou, ten 
behoeve van het minimaliseren van 
de tijd tot de behandeling, het 
leveren van maatwerk benadrukt 
moeten worden, aangepast aan de 
locale of regionale situatie. In het 
licht van deze overwegingen worden 
momenteel nieuwe therapeutische 
strategieën onderzocht, inclusief 
prehospitale triage en -behandeling 
en methoden die vroege 
medicamenteuze behandeling met 
tijdige angiografie combineren. 
(Hoofdstuk 11).  
 
Conclusies  
Zoals aangetoond in dit proefschrift, 
kan de toekomst in dienst worden 
gesteld van het heden door gebruik 
te maken van diverse modellerings-
technieken. Hiermee kan een 
veelvoud aan doelstellingen worden 
bereikt. Terwijl we belangrijke 
vooruitgang hebben geboekt sinds 
de introductie van de moderne 
definitie van risico door Pascal en de 
Fermat, bestaat er nog steeds 
ruimte om risico evaluatie te 
verfijnen. In het bijzonder zal risico 
evaluatie in ACS kunnen profiteren 
van verder onderzoek naar nieuwe 
methoden, statistische technieken 
en studie-opzetten. Innovatieve 
benaderingen om voorheen 
onbekende of onduidelijke factoren 
te meten (en/of huidige methoden te 
verbeteren), en het aanpakken van 
meer complexe onderzoeksvragen, 
zullen leiden tot een beter inzicht in 
het risico van deze patiënten.  
 
Hoewel clinical trials worden 
gewaardeerd om hun uitgebreide 
klinische gegevens, zijn zij 
tegelijkertijd beperkt door hun 
selecte inclusie en exclusie criteria, 
hetgeen de generaliseerbaarheid 
van de resultaten beperkt. 
Patiënten-registraties en andere 
populatie-gebaseerde cohorten zijn 
niet beperkt door selectiecriteria.  
 
Ongeacht het onderzoekscohort kan 
het herhaaldelijk verzamelen van 
klinische indicatoren (zoals 
electrocardiogrammen, biomarkers 
en vitale functies) een belangrijke 
verbetering geven van ons begrip 
van de dynamische ontwikkeling van 
risico, terwijl contextuele gegevens 
van instellingen, landen en regios 
ons kunnen helpen om het algehele 
beeld van risico compleet te maken. 
 
Tenslotte, het eindresultaat van 
deze inspanningen moet zich richten 
op de patiënt. In het verleden was 
het een uitdaging om statistische 
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theorie en klinische realiteit met 
elkaar in balans te brengen, wat de 
toepassing van risico evaluatie op 
patiëntniveau belemmerd kan 
hebben. Echter, de afstand tussen 
theorie en praktijk kan verkleind 
worden door koestering van een 
cultuur van een model-begeleide 
risico evaluatie, alsmede door 
gebruik te maken van de 
technologische revolutie (bijv. 
electronische medische dossiers en 
handcomputers). 
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